Molecular Mechanisms of Natural Compounds : Compound Kushen Injection (CKI) in Cancer by Aung, Thazin Nwe
Molecular Mechanisms of Natural
Compounds : Compound Kushen
Injection (CKI) in Cancer
By
THAZIN NWE AUNG
Department of Molecular and Biomedical Science
School of Biological Sciences
A thesis presented for the degree of DOCTOR OF PHILOSOPHY
JANUARY 2019
Foreword
“The important thing is NOT TO STOP QUESTIONING.
Curiosity has its own reason for existence. One cannot help
but be in awe when he contemplates the mysteries of eternity,
of life, of the marvellous structure of reality. It is enough if one
tries merely to comprehend a little of this mystery each day.”
— Albert Einstein
"Old Man’s Advice to Youth: ’Never Lose a Holy Curiosity’."
LIFE Magazine (2 May 1955): p 64.
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Abstract
Chemotherapy is a treatment that uses cytotoxic drugs to kill rapidly dividing cancer cells.
There are many anti-cancer chemotherapeutic drugs used alone or in combination with
others to kill cancerous cells, and some of these, are of plant origin. Naturally occurring
compounds, such as Taxol, are used in chemotherapy and have very specific, unique,
molecular targets. However, according to the World Health Organization (Ekor, 2014),
approximately eighty percent of the world’s population depends on natural compounds
from traditional medicine and these compounds are widely used in complementary
medicine as anti-cancer drugs (Foster et al., 2000). Traditional Chinese medicine (TCM)
uses treatments that contain multiple natural compounds, a number of which have been
claimed to be of therapeutic benefit to cancer sufferers (Chung et al., 2015). Some TCM
preparations have shown anti-cancer, anti-migratory and anti-metastatic properties in
laboratory settings (Wang et al., 2009;Pan et al., 2011;Qu et al., 2016). Research suggests
that TCM natural compound mixtures might synergistically trigger therapeutic benefits
through the action of multiple components affecting multiple regulatory signaling targets
(Wang et al., 2008).
Compound Kushen injection (CKI) is a TCM anticancer agent which has been approved
by the Chinese State Food and Drug Administration to treat solid tumors in combination
with chemotherapy drugs in clinics for pain relief, cancer metastasis and enhancement
of the immune system since 1995, and is used to treat approximately 30,000 patients
daily. Although a large body of evidence has suggested CKI has anti-cancer properties
(Xu et al., 2011;Gao et al., 2018) the anti-cancer mechanisms attributable to specific
compounds within the mixture remain unknown. CKI contains multiple alkaloid and
flavonoid compounds and the main bioactive compounds such as matrine and oxymatrine
have shown to affect cancer cells in the lab. However, other medicinal herbs containing
these two compounds as main components have demonstrated patient toxicity. It is
therefore important to better understand the effects of CKI, particularly with respect the
contributions of individual compounds within the mixture.
In this thesis, I describe a multi-disciplinary approach including analytical chemistry,
cellular assays and transcriptome analysis to explore the effects of several major
compounds present in CKI. Through the application of a subtractive fractionation method
that removed individual compounds one, two or three at a time, I have been able to
map these compounds and their interactions to specific pathways based on altered gene
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expression profiles. This has illuminated the roles of several major compounds of CKI,
that on their own, have no, or minimal, activity in our bioassay. This approach has enabled
us to identify the interactions between compounds in a mixture as shown by the response
of cancer cell cultures. Using a systems biology approach along with cellular migration
and invasion assays, I have mapped the activity of related proteins and pathways which
may contribute to the migrastatic activity of CKI.
Altogether, this thesis presents an initial characterization of the underlying mechanistic
changes induced by CKI. First, by comparing differentially expressed genes across
treatment combinations generated using our subtractive fractionation approach, I identified
specific candidate pathways that were altered by the removal of compounds from the
mixture. Second, by using transcriptome data of a breast cancer cell line, the effects of
CKI on candidate anti-migratory pathways for six different cancer cell lines were assessed.
These experiments identified specific candidate target pathways through which CKI might
act. These approaches can be used to understand the roles and interactions of individual
compounds from any complex natural compound mixture whose biological activity cannot
be associated with purified compounds.
Keywords: Systems biology , Natural Compounds, TCM, CKI, Multi-target medicine,
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Chapter 1
Introduction: Understanding the Effectiveness of Natural
Compound Mixtures in Cancer through Their Molecular
Mode of Action
The work of this dissertation is two-fold. First, I have implemented a subtractive
fractionation method through which I explore the effect of compounds in the CKI mixture
on treated cancer cells. I have also applied cellular bioassays and transcriptomic analyses
to determine the phenotypic and gene expression changes in cells treated with drug
fractions. For the second part of the dissertation, I have performed transcriptome analysis
of CKI treated breast cancer cells to study the role of CKI and its fractions on metastatic
processes. This chapter provides an overview of the efficacy of traditional medicine natural
compounds mixtures in the context of cancer. I also discuss the biased/flawed scientific
evidence from natural products that suggests false positive therapeutic benefits during
drug screening. This chapter is in the format of the manuscript that was published in the
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Abstract: Many approaches to cancer management are often ineffective due to adverse reactions, drug
resistance, or inadequate target specificity of single anti-cancer agents. In contrast, a combinatorial
approach with the application of two or more anti-cancer agents at their respective effective dosages
can achieve a synergistic effect that boosts cytotoxicity to cancer cells. In cancer, aberrant apoptotic
pathways allow cells that should be killed to survive with genetic abnormalities, leading to cancer
progression. Mutations in apoptotic mechanism arising during the treatment of cancer through
cancer progression can consequently lead to chemoresistance. Natural compound mixtures that are
believed to have multiple specific targets with minimal acceptable side-effects are now of interest
to many researchers due to their cytotoxic and chemosensitizing activities. Synergistic interactions
within a drug mixture enhance the search for potential molecular targets in cancer cells. Nonetheless,
biased/flawed scientific evidence from natural products can suggest false positive therapeutic benefits
during drug screening. In this review, we have taken these factors into consideration when discussing
the evidence for these compounds and their synergistic therapeutic benefits in cancer. While there is
limited evidence for clinical efficacy for these mixtures, in vitro data suggest that these preparations
merit further investigation, both in vitro and in vivo.
Keywords: cancer; apoptosis; chemosensitization; microRNA; natural compound mixtures; metal
derivatized natural compounds
1. Introduction
Cancer remains one of the highest causes of death globally. Various types of chemotherapies
fail due to adverse reactions, drug resistance, and target specificity of some types of drugs. There is
now emerging interest in developing drugs that overcome the problems stated above by using natural
compounds, which may affect multiple targets with reduced side effects and which are effective
against several cancer types. Natural compounds from various sources including plants, animals,
and microorganisms offer a great opportunity for discovery of novel therapeutic candidates for the
treatment of cancer [1]. Apoptosis is a self-destructive programmed sequence of signal transduction
events that destroys cells that become a threat, or are no longer necessary to the organism [2].
When there is aberrant apoptosis, cells that should be killed instead become immortal, leading to the
pathogenesis of many diseases including cancer.
Apoptosis falls into two categories: extrinsic and intrinsic apoptosis. Extrinsic apoptosis occurs
when cell death is triggered by binding of extracellular stress ligands to transmembrane receptors such
Int. J. Mol. Sci. 2017, 18, 656; doi:10.3390/ijms18030656 www.mdpi.com/journal/ijms
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as death receptors CD95 (APO-1/Fas) and tumor necrosis factor (receptor1) [3] as well as dependence
receptors such as netrin-1 receptor UNC5H4 [4,5]. In contrast, intrinsic apoptosis occurs in the
mitochondria through heterogeneous signaling cascades dependent or independent of caspases [4].
Failure to trigger complete apoptosis in the unhealthy cell population is a cause for cells to grow out
of control, leading to cancer [6]. When apoptosis is defective in one of the main apoptotic pathways,
it increases the likelihood of the cell becoming cancerous. Various well-established treatments have
been designed to destroy cancer cells through apoptosis. Another important mechanism of cell death
in cancer cells in response to chemotherapy is autophagy, which takes places in the lysosome by
self-degrading intracellular proteins and organelles. It triggers cell death in the absence of apoptotic
regulators, but in the presence of important autophagy-regulated genes such as BECN1 [7] and ATG5 [8].
In this review, we primarily confine our discussion to apoptotic cell death and autophagic cell death
caused by natural chemotherapeutic agents in the context of cancer.
Resistance to treatments that target apoptotic cell death is indicative of treatment failure.
Anti-apoptotic mutations during cancer progression reduce chemotherapy-induced apoptosis in
spontaneous murine tumors [9] and produce multi-drug resistance [10]. Therefore, understanding
how to induce cell cytotoxicity via chemosensitization is as important as how to trigger apoptosis in
cancer cells with chemotherapies. It has been reported that natural compounds such as quercetin [11]
and tetrandrine [12], known to have anti-tumor activities, are able to not only kill cancer cells but
also restore drug sensitivity [13,14]. Moreover, there is evidence that natural compounds including
rhamnetin and cirsiliol can radiosensitize in non-small cell lung cancer (NSCLC) [15]. This suggests
that natural compounds can have therapeutic effects in cancer chemo-radiotherapy.
Effective development of an anti-cancer drug needs to consider different sets of upregulated,
downregulated, and mutated genes and their regulatory pathways in cancer cells. Computational
genomics is a powerful tool to identify differential gene expression based on cancer treatment, as it
improves our understanding of challenging mechanistic changes in cancer cells and facilitates treatment
with a wide range of molecular targets. Whole transcriptome sequencing comprehensively investigates
messenger RNA (mRNA)-Seq and small/non-coding RNA-sequencing (RNA-Seq), analyzing tens
of thousands of RNA transcripts to uncover their genetic functions. Transcriptomic results subjected
to Gene Ontology (GO) clustering and annotation identify differentially expressed genes and can
further identify candidate target pathways [16]. Here we highlight the efficacy of complex natural
compound mixtures by using molecular approaches with specific emphasis on cancer apoptosis
and chemosensitization.
2. Treatment of Cancer through Targeting Apoptosis
There are many therapies for treating cancer, including surgery, radiation therapy, hormone
therapy, chemotherapy, and targeted therapies such as immunotherapy and monoclonal antibody
therapy. Depending on the type of cancer and underlying biological conditions in the patient, therapy
consists of either a single or combination of classical treatments such as surgery, chemotherapy,
and/or radiotherapy.
Chemotherapy is a treatment that uses anti-cancer drugs to damage DNA in unhealthy and
rapidly dividing cancer cells. Chemotherapy with a defined dosage is usually used to trigger cancer
cell cytotoxicity at desirable apoptotic rates. The effectiveness of chemotherapeutic agents depends on
their type, dosage, and any adverse reactions in patients. There are several anti-cancer drugs used
alone or in combination with other agents to kill cancerous cells. Chemotherapeutic drugs that include
synthetic, semi-synthetic, and naturally occurring compounds are cytotoxic, and can destroy both
cancerous cells and rapidly dividing normal cells. These agents signal through both death receptors and
mitochondrial pathways to induce one or more of the apoptotic pathways [17]. They are characterized
based on their structure, derivation, and mechanism of action. Some affect parts of the cell cycle,
while others are not phase specific. Depending on the mechanism of action, they are categorized
into different groups including alkylating antineoplastic agents, kinase inhibitors, vinca alkaloids,
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anthracyclines, antimetabolites, aromatase inhibitors, and topoisomerase inhibitors [18]. Nonetheless,
the pharmacokinetic variability of synthetic drugs in patients often limits optimal effectiveness with
minimal toxic side effects. On the other hand, treatment of cancer by natural compounds and
their semi-synthetic analogues both in vitro and in vivo shows promising results against different
malignancies [19,20]. Natural compounds such as sesquiterpenes, flavonoids, alkaloids, diterpenoids,
saponins, and polyphenolic compounds [11,21] can be substituted for, or applied in combination with,
existing drugs.
3. Natural Compounds as Anti-Cancer Agents
Natural compounds with potent anti-cancer activities are widely available from different plant
tissues. Eighty percent of the population worldwide traditionally use natural compounds contained
in medicinal plants [22] and are largely dependent on them. Naturally occurring compounds target
tumor cells by regulating cell death pathways such as extrinsic and intrinsic apoptosis pathways
and autophagic pathways. Evidence from in vitro and in vivo studies in prostate cancer treatment
with isoflavones and phytoestrogens from soy showed NF-B deactivation, apoptosis induction,
and angiogenesis inhibition [23,24]. A collection of plant-derived natural anti-cancer compounds
can be found at Naturally Occurring Plant-based Anti-cancer Compound-Activity-Target Database
(NPACT, http://crdd.osdd.net/raghava/npact/) where approximately 1980 experimentally validated
compound-target interactions are documented [25]. Millimouno et al. also reviewed promising natural
compounds and their related natural sources, pharmacological actions, and molecular targets in
details [21].
4. Traditional Chinese Medicines (TCMs) as Anti-Cancer Agents
Due to the complex etiology and pathophysiology of cancer, it is relatively difficult to treat the
disease with just single target drugs. Moreover, regardless of the specificity and efficiency of single
target therapy, it is difficult to achieve optimal cytotoxic effects on cancer cells because of their rapid
molecular adaptations. In contrast, synergistic interactions within multi-component drug preparations
allow us to broaden the search for potential molecular targets in cancer cells. Traditional Chinese
Medicines (TCM) is formulated based on the compatibility and interrelationships between herbal
ingredients that render synergistic therapeutic benefits [26]. TCM uses a combinatorial approach
where the application of two or more agents at their respective effective concentrations achieves a
synergistic effect that boosts cytotoxicity to cancer cells and can have additional effects on the tumor
environment and the immune response to tumors. Therefore, TCM has been used as an alternative or
complementary medicine worldwide, and has long been used to treat cancer in China. Chinese herbal
medicinal products have been used for cancer prevention and treatment for many years [27], and there
is evidence to suggest that TCMs are effective against cancer recurrence and metastasis and can enhance
quality of life (QoL), and prolong survival time [27]. For instance, Bioactive polysaccharides with  -1,3,
 -1,4, and  -1,6 side branches in TCM stimulate the immune system, thereby indirectly suppressing
tumors [28]. TCM is also used to reduce the side effects of conventional chemotherapy for advanced
pancreatic cancer, advanced colorectal cancer, and breast cancer [29–31]. There are a range of TCM
extracts from Anemarrhena asphodeloides, Artemisia argyi, Commiphora myrrha, Duchesnea indica, Gleditsia
sinensis, Ligustrum lucidum, Rheum palmatum, Rubia cordifolia, Salvia chinensis, Scutellaria barbata, and
Uncaria rhychophylla that specifically inhibit cancer cell proliferation from breast, lung, pancreas, and
prostate tissues of human and mouse, but show limited inhibition against normal human mammary
epithelial cell growth [32]. Artemisinin derivatives artesunate (ART) and dihydroartemisinin have
been shown to inhibit cancer cell proliferation and suppress angiogenesis in cervical, uterus chorion,
embryo transversal cancer, and ovarian cancer [33]. Because naturally occurring compounds such
as plant extracts in TCM are highly chemically diverse, they have become highly significant in the
discovery and development of effective therapeutic anti-cancer drugs. TCM preparations can contain
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alkaloids, flavonoids, saponins, terpenes, polyphenols, fatty acids, and essential oils as bioactive
ingredients [34,35].
4.1. Natural Compounds from TCM as Cancer Therapeutics
The main components of TCM such as alkaloids, flavonoids, and saponins are used either
individually or as mixtures to treat different types of cancer. Below we list compounds contained in
various TCMs that have been found to have anti-cancer activities, including triggering apoptosis.
4.2. Alkaloids
Alkaloids are more abundantly found in broad ranges of the plant kingdom than other classes of
natural plant products [36] and are active against various cancers. Alkaloids commonly consist of a
nitrogen atom within a heterocyclic ring [37] and are of relatively low toxicity. Several alkaloids have a
wide range of significant biological functions including anti-inflammatory, anti-bacterial, anti-diabetic,
and anti-cancer activities [38–40]. Some well-developed semi-synthetic anti-cancer drugs are alkaloid
derivatives including vinblastine, vinorelbine, vincristine, and vindesine. They are the most important
active ingredients in traditional medicine and have been approved for cancer treatment in the United
States and Europe [41].
Matrine is a major quinolizindine alkaloid found in the Sophora flavescens Aiton plant [42]. Matrine
stimulates major apoptotic cascades by upregulating Fas/FasL and Bax, and downregulating Bcl-2
leading to the activation of caspase-3, -8, and -9 in MG-63, U-2OS, Saos-2, and MNNG/HOS human
osteosarcoma cells [43]. It also represses cancer metastasis via vascular endothelial growth factor
(VEGF)-Protein Kinase B (Akt)-nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B)
signaling in MDA-MB-231 breast cancer cells. The reduction of Bcl-2/Bax protein and mRNA levels by
matrine leads to an increase of cell cycle arrest in cancer cells [44]. In human medulloblastoma D341
cells, increased expression of Bcl-2 and decreased expression of Bax is triggered by matrine through
caspase-3 and -9 mediated apoptotic pathways [45]. In HepG2 cells, matrine induces tumor suppressor
transcription factor p53 through the adenosine monophosphate-activated protein kinase (AMPK)
signal transduction pathway, resulting in autophagic cell death through the p53/AMPK signaling
pathway [46]. Interestingly, this research reported that downregulation of AMPK leads to a switch
to apoptotic cell death from autophagic cell death [46]. The sequential signal transduction leading
from autophagy to apoptosis via the activation of p53 was discussed by Guillermo Mariño et al. [47].
Furthermore, metabolomics analysis of matrine treated HepG2 cells identified lipid droplet metabolites,
which are substrates for macro autophagy that may partly drive immunity and apoptosis [48]. Li et al.
also reported that matrine treatment reduced the level of glutathione (GSH), and the elevated level
of GSH is related to chemoresistance in cancer [49]. The above results provide evidence that matrine
alone can induce cell death and can be effective against various tumor types.
Oxymatrine is another major quinolizindine alkaloid found in the Sophora flavescens Aiton plant.
It is cytotoxic to SW1116 human colon cancer cells by downregulating human telomerase reverse
transcriptase (hTERT) and upregulating p53 as well as mad1 in a concentration dependent manner [50].
It also inhibits the growth of GBC-SD and SGC-996 gallbladder cancer cells via the activation of
caspase-3 together with Bax and the suppression of Bcl-2 and NF-B [51]. It is also known that a
mixture of oxymatrine and micellar nanoparticles is an effective proliferation inhibitor of SMM7721
cells [52]. Oxymatrine treatment significantly induces apoptosis by increasing Bax protein expression
and reducing Bcl-2 in human lung cancer A549 cells [53]. Proteomic analysis has shown that oxymatrine
induces apoptosis in HeLa cells by inhibiting inosine monophosphate dehydrogenase type II (IMPDH2),
mitochondrial related apoptotic protein [54]. These studies suggest that oxymatrine may be a useful
drug candidate for cancer therapy.
Another type of natural alkaloid is tetrandrine, contained in the Chinese medicinal plant
Hang-Fang-Chi, Radix Stephania tetrandra S. Moore. This compound has anti-inflammatory,
immunosuppressive, and anti-cancer activities [55]. It was reported that a derivative (H1) of tetrandrine
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has the ability to reverse multi-drug resistance [56]. It inhibits cancer cell proliferation and induces
apoptosis in human esophageal cancer cell lines ECa109, Eca109-C3, and human monoblastic leukemic
U937 cells. It is also effective in reversing multi-drug resistance in Adriamycin-resistant human breast
cancer MCF-7/Adr and human nasopharyngeal cancer KBv200 [12]. The molecular mechanisms of
action of tetrandrine in cancer cells include upregulation of Bax, Bak, Bad, and apaf-1, downregulation
of Bcl-2 and Bcl-xl, releasing cytochrome c, and activation of caspase-3 and -9 in the apoptotic
mitochondrial pathway [56]. The efficacy of tetrandrine with respect to activation of the intrinsic
apoptosis pathway highlights its potential importance as a therapeutic agent.
The semi-synthetic alkaloid analogue vinblastine is an anti-mitotic drug that was originally
isolated from the periwinkle plant Catharanthus roseus (L.) G. Don. It kills cancer cells by shortening
microtubules, disrupting microtubule function resulting in the disappearance of the mitotic spindle,
thereby inhibiting cell proliferation [57]. Low concentrations of vinblastine have been shown to slow
down or block mitosis in HeLa and BSC cells [57]. Vinblastine is highly potent in relapsed/refractory
anaplastic large-cell lymphoma (ALCL) with 65% five-year overall survival [58].
4.3. Flavonoids
Flavonoids are plant secondary metabolites, widely present in fruits and vegetables that are
consumed daily. They generally have a sixteen-carbon skeleton and the structures vary around
the heterocyclic oxygen ring [59]. Research has shown that flavonoids inhibit cell proliferation and
angiogenesis, cause cell cycle arrest, induce cell apoptosis, and reverse multi-drug resistance and/or a
combination of the aforementioned mechanisms [60].
Trifolirhizin, a pterocarpan flavonoid, is present in the Sophora flavescens Aiton plant. It was
shown that trifolirhizin reduces the expression of pro-inflammatory cytokines such as TNF-↵,
cyclooxygenase-2 (COX-2) and IL6 in experimentally lipopolysaccharide (LPS)-stimulated mouse
J774A.1 macrophage [61]. Zhou et al. also showed that it was able to inhibit the growth of human
ovarian A2780 and lung H23 cancer cells in vitro. The compound also has anti-proliferative activity in
oral carcinoma SCC2095 cells [62]. A combination of trifolirhizin together with maackiain (a constituent
of Trifolium pratense) has been shown to induce apoptosis in human leukemia HL-60cells. This mixture
of compounds resulted in the degradation of DNA into oligonucleosome-size fragments in a time- and
dose- dependent manner [63]. These results suggest that trifolirhizin may possibly be developed as an
anti-inflammatory nutraceutical for cancer prevention as well as for the mitigation of DNA damage
through apoptosis.
Curcumin is a traditional medicine and main curcuminoid of Curcuma longa and has been
implicated in the perturbation of several genetic pathways [64,65]. It was reported that it selectively
targets tumor cells rather than normal cells in vitro and activates different apoptotic pathways
including caspase, induction of death receptors and DNA fragmentation, mitochondrial activation,
autophagy pathways, inhibition of NF-B, and inhibition of COX-2 and 5 LOX [65]. In proteomic
identification of curcumin treated MCF-7 cells, 3-PGDH and ERP29 were found to be upregulated
and TDP-43, SF2/ASF, and eIF3i were downregulated, suggesting curcumin induced apoptosis in
breast cancer [64]. However, due to its lack of aqueous solubility, high concentrations are required
to demonstrate potential chemotherapeutic efficacy [66]. While many researchers are optimistic
regarding curcumin’s potential effectiveness against cancer, there is evidence to show that curcumin
has no therapeutic benefits despite many published articles and clinical trials [67]. Skepticism about
curcumin is based on both poor characterization of curcumin and pan-assay interference in many
experiments that indicated that curcumin was a promising compound for cancer treatment. Yet, in spite
of no significant effects in trials, researchers still think that because curcumin can interact with many
proteins and because of suggestive trends in trial results, there is still justification for further study [68].
Until better experiments are carried out, the anti-cancer activity of curcumin remains unconfirmed.
A flavonoid, quercetin, is abundant in daily-consumed foods such as onions (Allium cepa) with
a wide range of anecdotally reported health benefits that include anti-oxidant, anti-inflammatory,
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and anti-cancer activities in vitro and is effective against various cancer cells [69]. Quercetin mainly
targets the cell cycle at G1/S and G2/M check points by inducing the p21 CDK inhibitor while
decreasing pRb phosphorylation, thereby blocking E2F1, which is an important transcription factor of
DNA synthesis proteins [70]. Deng et al. reported that apoptosis-mediated cell death from quercetin
treatment resulted from arresting the cell cycle at G0/G1 phase in MCF-7 breast cancer cells. They also
showed that increasing concentrations of quercetin were directly proportional to the decreasing
concentrations of survivin, a member of a protein family that negatively regulates apoptosis [71].
Proteomic analysis revealed that quercetin treatment suppressed cell proliferation while arresting
mitosis leading to apoptosis by downregulating IQGAP1 and  -tubulin and their interactions with
other proteins in HepG2 cells [72]. Despite the abundance of quercetin, it has not been investigated in
cancer clinical trials.
4.4. Saponins
Saponins are found not only in a wide range of plants but also in animals, and have different
carbon backbones that classify them as either steroids or triterpenes. They are secondary metabolites
with potent biological functions. These compounds are active against several tumors not only as
single compounds but also in combination with conventional therapies by causing cell cycle arrest and
triggering apoptosis [73].
Chikusetsusaponin IVa butyl ester (CS-IVa-Be) is an apoptotic triterpenoid saponin extracted from
Acanthopanas gracilistylus herb. The extract from this Chinese medicinal herb has been found to cause
cell cycle arrest at G0/G1 stage in a variety of cancer cell lines including MT-2, Raji, HL-60, TMK-1, and
HSC-2 [74]. The compound induces apoptosis in MDA-MB-231 cells by inhibiting IL-6 family induced
STAT3 activity through the IL-6/JAK/STAT3 signaling pathway. It also sensitizes the Tumor necrosis
factor (TNF)-related apoptosis-inducing ligand (TRAIL), a specific inducer of cancer cell apoptosis,
in TRAIL resistant MDA-MB-231 cells by upregulating death receptor 5 (DR5) [75]. Because of this,
CS-IVa-Be induces apoptosis upon treatment with TRAIL in TRAIL resistant MDA-MB-231 cells.
Polyphyllin D is a promising anti-proliferative steroidal saponin extracted from the traditional
Chinese medicinal plant Paris polyphylla. The cytotoxic activity of polyphyllin D was observed via
induction of DNA fragmentation and dissipation of mitochondrial membrane potential D m, resulting
in mitochondrial dysfunction and loss of membrane integrity in MCF-7 and MDA-MB-231 cells [76].
A 50% reduction in tumor growth from 10 consecutive days of polyphyllin D administration in mice
was also documented.
Diosgenin is effective against HCT-116 human colon cancer cells by reducing both mRNA
and protein expression of 3-hydroxy-3-methylglutaryl CoA reductase, resulting in apoptosis [77].
It truncated the poly (ADP-ribose) polymerase protein from 116-kDa to an 85 kDA fragment, which
leads to the induction of apoptosis. This indicates that Diosgenin is a potent apoptosis inducer in
HCT-116 cancer cells. Diosgenin arrested the cell cycle at sub-G1 phase, suppressed FAS expression,
and inhibited mammalian target of rapamycin (mTOR) phosphorylation in HER2 overexpressing
human AU565 breast cancer cells, inhibiting cell proliferation [78].
Another apoptotic triterpenoid saponin is Macranthoside B (MB), extracted from
Lonicera macranthoids. It is strongly effective in various tumors via mitochondrially mediated
apoptosis resulting from an increased Bax/Bcl-2 ratio [79]. Furthermore, MB induced apoptosis via
autophagy through the ROS/AMPK/mTOR pathway, while elevating reactive oxygen species (ROS)
together with 50 AMPK, and reducing mTOR in human ovarian cancer A2780 cells [80].
With respect to the cytotoxic properties of saponins, a wide range of these compounds has been
tested, with some shown to be potent apoptotic inducers. Yet the potential of this class of compounds
remains to be fully explored, and they may also be effective in combination with other agents to
synergistically enhance their therapeutic effect in cancer.
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4.5. Drugs Based on Mixtures of Compounds
Compound Kushen Injection (CKI), approved by the State Food and Drug Administration
of China, has been used to treat different types of cancer, including liver, gastric, and non-small
cell lung carcinoma in combination with Western anti-cancer agents [81]. It contains alkaloids,
flavonoids, saccharides, and organic acids [82] and is extracted from two medical herbs including Radix
Sophorae flavescentis and Rhizoma Smilacis Glabrae [83]. It modulates immunity, decreases inflammation,
relieves cancer pain, and, most importantly, has anti-neoplastic activity [83]. For example, CKI
downregulates  -catenin through the Wnt signaling pathway, which in turn targets the oncogenes
c-MYC and CyclinD1 [84], leading to suppression of MCF-7 cancer stem cell-like side population (SP)
cells [85]. A systematic review and meta-analysis reported that CKI could reduce adverse effects in
cancer patients and improved total pain relief and QoL [86]. Transcriptome analysis of CKI treated
MCF-7 cells by Qu et al. revealed that the mixture inhibited cell proliferation and induced apoptosis in
a concentration-dependent manner by primarily targeting the cell cycle in MCF-7 cells [87]. Qu et al.
also showed that long non-coding RNA (lncRNA) H19 was dramatically downregulated in MCF-7
cells treated with CKI [87]. H19 is overexpressed in several cancer types and is associated with tumor
metastasis, for example, where lncRNA H19 suppresses miR-630, perturbing the inhibition of EZH2 in
nasopharyngeal carcinoma [88]. The primary effect of CKI on cancer cells is through the cell cycle, but
it also affects many other pathways and it may be useful as both an anticancer and anti-inflammatory
agent. It was claimed that CKI is effective in inhibiting metastasis and reversing multi-drug resistance
(MDR) as well [83]. Yet, there is currently no research evidence supporting the effectiveness of CKI
on reversing MDR in English-language journals. Therefore, in vivo and clinical relevance of the drug
should be researched to establish the effective usage of CKI with respect to chemosensitizing activities.
Anti-tumor B (ATB), known as Zeng Sheng Ping, is also an herbal medicine which is formulated
from six different medicinal plants, and its main constituents are flavones, alkaloids, phytosterols,
sapogenins, triterpenes, and triterpenoids [89]. ATB decreased lung tumor load by approximately
60% in both wild-type and Ink4a/Arf tumor suppressor gene-deficient mice and 90% in p53
transgenic mice [89]. The drug markedly reduced cell proliferation by inhibiting the mitogen-activated
protein kinase (MAPK) pathway while increasing apoptosis by reducing Bcl-2 in oral cancer in
hamsters [90]. Lim et al. also showed that the Notch2 receptor, which is an important signaling
regulator of brain tumors, and its downstream effector gene Hes1 were downregulated by ATB [91].
ATB induced apoptosis in both U87 glioblastoma and DAOY medulloblastoma cells [91], suggesting
that ATB might be effective against multiple tumors. Based on the results from animal models,
ATB has shown chemo-preventive activities in hamsters and mice with carcinogen-induced oral
cancers [92]. Microarrays, combined with GenMAPP analysis of mouse lung tumor models, showed
that multiple genes affected by herbal medicine ATB are members of different genetic pathways such as
ubiquitin-proteasome, Notch, Ras-MAPK, and G13 pathways [89], which are important in mitogenesis,
neoplastic transformation [93] and apoptosis [94]. This gene expression microarray study showed
that ATB is a potential tumor suppressor capable of targeting cell proliferation, differentiation, and
apoptosis [89].
The proteomic profile of MCF-7 cells treated with Zilongjin, an herbal antitumor medicine, showed
the downregulation of HSP27, a blocker of apoptosis [95]. Zilongjin also suppressed the expression of
eIF3I and eIF1AY proteins, which are important regulators of translation initiation [95]. Collectively,
the proteomic approach can identify translational perturbations in cancer cells and protein-wide
changes from these perturbations in response to stimuli. Microarray based gene expression analysis
of four different lung cancer cell lines treated by Zilongjin showed that 170 genes were upregulated
and 313 were downregulated by the drug. Of these 483 genes, eleven genes including HELLS, JUN,
XIAP, MCM6, CDKN2C, CCNE2, HN1L, TFDP2, CCNG2, GADD45A, and CDKN1A were found to be
involved in cancer-related pathways such as apoptosis, cell cycle, and MAPK cascade [96].
Taken together, the findings based on the molecular and ‘–omics approaches’ suggest that natural
compound mixtures have multiple targets in cancer cells. Combined compounds from two or more
10
Int. J. Mol. Sci. 2017, 18, 656 8 of 20
sources are potential resources for the development of multi-targeted anti-cancer therapeutics and
have a broader range of molecular targets in cancer cells. It is important to bear in mind that the clinical
effectiveness of some of these combined drugs have only been reported in non-English language
papers and these often lack compelling clinical data. Therefore, more work is needed to evaluate
natural compound mixtures as cancer treatments. Figure 1 shows the molecular targets of two groups
of single compounds, alkaloids and flavonoids, compared to a compound mixture, CKI, that contains
both groups of natural compounds in an in vitro setting. Summaries of therapeutic effects from single
or mixtures of natural compounds and their possible cellular mechanisms are shown in Table 1.
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Table 1. Reported therapeutic effects by single or mixtures of natural compounds in different stages of
cellular mechanisms.
Ref. Herbal Medicines Types of Cancer Cell Lines/Model Mechanisms of Actions
[97] Curcumin Colorectal Colorectal cancerstem cells (CCSCs) Apoptosis
[98] Ginsenoside Rg3 Liver Tumor bearing rats Apoptosis, Immune responses
[99] Curcumin Breast MCF-7 Anti-inflammation
[100] Matrine Lung HepG2 Proliferation and metastasischemosensitization
[72] Quercetin Lung HepG2 Apoptosis
[95] Zilongjin Breast MCF-7 Inhibits malignant proliferation, apoptosis
[101] Triterpenes fromGanoderma lucidum Cervical HeLa
Cell death, oxidative stress, calcium
signaling, and ER stress
[64] Curcumin Breast MCF-7 Apoptosis
[102] Triterpenes fromPatrinia heterophylla Leukemia K562
Energy metabolism, oxidative stress, signal
transduction, differential induction, protein
biosynthesis, and apoptosis
[54] Oxymatrine Cervical HeLa Inhibits proliferation, apoptosis
[103] Sanguinarine fromPapaveraceae family Pancreatic
BxPC-3, MIA
PaCa-2
Decreases cellular hypoxia and cell
proliferation, induces apoptosis leading to
cancer cells inhibition
[89] Zeng Sheng Ping(Antitumor B) Lung Mouse lung
Ubiquitin-proteasome, Notch, Ras-MAPK,
G13 pathway, cell proliferation,
differentiation, and apoptosis
[104] Aidi injection Breast MCF-7 Inhibits proliferation, apoptosis
[96] Zilongjin Lung A549, H446, H460,and H520
Cell cycle regulation, MAPK cascade,
and apoptosis
[87] Compound KushenInjection Breast MCF-7
Cell cycle regulation, cell growth
related pathway
5. Alternative Approach of Triggering Apoptosis Using Metal-Derivatized Natural Compounds
Structurally modified anti-cancer compounds can be highly effective in treating cancer due to
their controlling chemo-, site- selectivity in cells. The heavy metal-based compound, cisplatin, has a
broad spectrum of cytotoxicity that makes it among the most popular and effective chemotherapy
drugs. Cisplatin and compounds of this type are used to treat approximately 50%–70% of all
cancer patients [105]. Although metal-based anti-cancer drugs show significant effectiveness against
cancer, they can also have severe adverse effects. Moreover, different mechanisms are used by
cancer cells to resist cytotoxic drugs, complicating the development of novel potent anti-cancer
drugs. Natural compounds have been shown to have low adverse reactions in normal cells of
cancer patients, and natural compound-metal complexes have been confirmed as potential (pro)
drugs [106]. The alkaloid liriodenine has anti-tumor activity and when combined with platinum (II) and
ruthenium (II), the liriodenine-metal complexes covalently bind to DNA and enhance the cytotoxicity
of liriodenine. When Gallium (III) and Tin (IV) are combined with matrine, these combinations
further modulate cell cycle arrest at the G2/M phase, and Gold (III)-matrine complexes inhibit
topoisomerase I [106], thereby causing DNA replication processes in cancer cells to malfunction.
The actions of these different metal-based compounds vary depending on cell type. For instance,
Gallium III-matrine and Gold III-matrine compounds have significant anti-proliferative activities in
SW480 cells, HeLa cells, HepG2 cells, and MCF-7 cells, respectively [106]. It is worth noting that the
efficacy of synthetic metal-natural compounds in vitro greatly exceeds those of cisplatin and matrine
alone. These results indicate that metal-based cytotoxic natural compounds may hold promise as
anti-cancer therapeutics, based on their multi-targeting effects on cancer cell regulatory networks.
A summary of therapeutic effects by metal-derivatized natural compounds and their mechanisms of
actions compared to their original forms and/or existing metal-based anticancer drugs are shown in
Table 2.
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Table 2. Mechanisms of action of metal-derivatized natural compounds compared to their original
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6. Chemoresistance in Cancer and Chemosensitization by Natural Compounds
The main reason for cancer treatment failure by chemotherapy is the emergence of drug-resistance
during cancer progression. Collectively, MDR occurs when ABC transporters become overexpressed.
Out of 48 human ABC transporters, the mechanisms of actions of P-gp, MDR1, ABCB1, MRP1/ABCC1,
and ABCG2 have been widely reported clinically [113]. However, additional ABC transporters have
been explored as targets for cancer therapeutics in drug discovery. For instance, four ABC transporter
genes (ABCA4, ABCC3, ABCC5, and ABCC8) were upregulated in resistant MCF-7/AdVp3000
cells, whereas complete or partial downregulation of these genes was observed in the revertant
MCF-7/AdVpRev cells [114]. Overexpression of drug resistance associated genes ABCA4 [113,114]
and ABCA12 [115,116] were observed in human pancreatic cancers and MCF-7 breast cancer cell lines,
respectively. Therefore, it might be productive to scrutinize the mechanisms of actions of less commonly
studied ABC transporters from drug resistant cancer cell lines when treated with natural compounds.
To overcome drug resistance, natural compounds such as sesquiterpenes, flavonoids, alkaloids,
diterpenoids, saponins, and polyphenolic compounds [11,21] are substituted or applied in combination
with existing drugs. These compounds are known to have anti-tumor activities and can not only
kill cancer cells but also restore drug sensitivity. For example, tetrandrine (bioactive alkaloid)
modulates P-gp-mediated drug efflux in vitro and has anti-neoplastic activity when given together
with doxorubicin to mice bearing resistant MCF-1/DOX cells in vivo [13,14]. Another natural
product is Quercetin (a flavonoid [11]), which blocks MDR1 transcription, thereby suppressing P-gp
expression [117] and restoring daunorubicin chemosensitivity in HL-60/DOX and K562/DOX cell
lines [118,119].
A different flavonoid, curcumin, inhibits the main ABC transporters such as P-gp, MRP1,
and ABCG2, and increases vincristine chemosensitivity in SGC7901/VCR cell lines [120,121].
20(S)-Ginsenoside Rg3 (saponins) chemosensitizes vincristine, doxorubicin, etoposide, and colchicine
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resistant KBV20 cell lines in a time- and dose-dependent manner [11]. Oxymatrine chemosensitizes
cisplatin resistant HeLa/DDP cells by suppressing inosine monophosphate dehydrogenase type II
(IMPDH2) levels and inducing apoptosis through the mitochondrial pathway [54]. CKI may also act
as a stimulator of drug resistance reversal and chemosensitization in cancer. Transcriptome analysis
from Qu et al. revealed that two drug resistant ABC transporter genes, ABCA12 and ABCA4, were
significantly downregulated in CKI treated MCF-7 cells [87]. These results support the assertion that
natural compounds can reverse or alter chemoresistance.
7. Apoptosis in MDR Cells through Modulation of MicroRNA (miRNA) Networks by
Natural Compounds
The compelling link between possible successful cancer chemotherapy and triggering apoptosis
by chemosensitization is connected in this review by the involvement of microRNAs. miRNAs are
highly conserved small non-coding RNA molecules that directly interact with their target mRNA,
causing either mRNA transcriptional degradation or translational repression that results in the
reduction of gene expression [122]. miRNAs have emerged as both potential therapeutic agents
and biomarkers [123]. Some have oncogenic properties while others act as tumor suppressors.
Miller et al. reported that eight upregulated miRNAs and seven downregulated miRNAs were found
in tamoxifen resistant human breast cancer MCF-7 cells [124]. Moreover, increased expression of
miR-415 is correlated with the decreased expression of MDR1 genes and seems to elevate sensitivity to
doxorubicin in DOX-resistant breast cancer cells [125]. In tumors, epithelial-to-mesenchymal transition
(EMT) plays an important role of tumor invasion/migration and metastasis [126]. ZEB1 and ZEB2
repress E-cadherin expression [127,128] and downregulation of E-cadherin allows epithelial cells to
undergo EMT, which contributes resistance to EGFR-directed therapy in cancer. Members of the
miR-200 family, particularly miR-200c and miR-200b, target ZEB1 and ZEB2 and control EMT to
sensitize EGFR therapy [129].
Growing evidence indicates that natural compounds are important regulators of miRNA mediated
genetic pathways in cancer. For example, matrine significantly reduces the overexpression of
miRNA-21 and stimulates apoptosis in HepG2 and Hep3B cells [130]. Matrine also downregulated
14 miRNAs and upregulated their target genes in the MAPK signaling pathway in SGC7901
human gastric cancer cells [131]. Another natural compound, oxymatrine, acts on human ovarian
cancer OVCAR3 cells by upregulating miR-29b, which downregulates the expression level of
matrix metalloproteinase-2 and induces apoptosis [132]. In the microarray analysis of MCF-7 cells,
upregulation of 45 miRNAs was shown after treatment with TCM Aidi injection. Of these, miRNA-126
was found to be a suppressor of proliferation of MCF-7 cells [104]. Research showed that inhibition
of miRNA-25 by a natural phenol, isoliquiritigenin, leads to autophagy in MCF-7/ADR cells via
increased expression of autophagy regulator ULK1 [133]. In the transcriptome of CKI treated MCF-7
cells, the upregulation of hsa-miR-6879 and downregulation of its target drug resistant gene ABCA12
were observed [87]. However, the prediction of the role of pre-miR-6879 in terms of the regulation of
ABC transporters still needs to be experimentally confirmed. The link between natural compounds
inducing miRNA mediated drug resistance reversal and chemosensitization, leading to cancer cells
autophagy and apoptosis, supports the investigation of natural compounds in drug resistant cancer
chemosensitization therapy. Whilst it is known that miRNAs are important in phytochemically
mediated cancer cell death, little is known about full or partial reversal of MDR via the regulation of
miRNAs by natural compounds. Hence, there is a gap between the use of natural compounds that
regulate miRNA and MDR that is not well understood. A model of the regulatory interactions between
drugs, miRNA, and target genes in the context of autophagy, drug resistance reversal, and apoptosis is
shown in Figure 2.
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Figure 2. Three panels (A–C) show the influence of natural compounds on gene expression in terms of
MDR regulation. (A) Treatment of Isoliquiritigenin blocks binding of autophagy-related miR-25 to the 30
UTR region of ULK-1, LC3-II, and BECN-1 in killing drug-resistant breast cancer cells [133]; (B) Matrine
and indirubin-30-monoxime (IRO) reverse chemoresistance of paclitaxel (TAX) by downregulating the
expression of Sox-2, Survivin, and Oct-4 proteins i human squam us cell carcinoma [134]; (C) CKI
suppresses the expression of the drug r sistant related genes ABCA12 and ABCA4 in cancer cell
apoptosis. The involvement f miRNAs in th regulation of the e gen s with respect to drug resi tance
ha not yet been confirm d [87].
8. Conclusions
Despite significant progress in the fields of cancer diagnosis and che otherapy, cancer re ains
one of the greatest causes of death worldwide. Novel approaches to cancer management often fail due
to frequent genetic alterations and mutations in cancer genomes. Because of the high frequency of side
effects caused by chemotherapy, etastatic cancers still need new, more effective chemotherapeutics.
There is emerging interest in developing drugs to tackle these problems by using natural compounds,
which may affect multiple targets with lower side effects and be effective against several cancer types.
Despite attempts in chemotherapy using natural compounds, many questions remain regarding their
efficacy and potential modes of action. From the medicinal chemistry point of view, an important fact
when applying the natural compounds to consider is the impurities of the extracted herbal medicine
that have their own biological activity which may provide false positive signal of the molecules during
drug screening. In addition, flawed scientific evidence from natural product mixtures can suggest
false positive therapeutic benefits. Therefore, careful examination to approve the molecular target
engagement while researching drug discovery is necessary. The best possible drug combinations are
based on the understanding of the cancer-specific context of mutated oncogenes, tumor suppressor
genes, and their regulatory pathways. To evaluate novel treatment approaches involving the use of
mixtures of natural compounds, we must understand how coding and non-coding RNAs, oncogenes,
downregulated tumor suppressor genes, and mutated genes, as well as their signal transduction
pathways, respond to these drugs. Systems biology can help characterize the roles of functionally
cryptic elements such as long and short ncRNAs in cancer. We have reviewed the effectiveness of
natural compounds in cancer cells in terms of triggering apoptosis and chemosensitization through the
application of molecular genetic and “-omics” approaches. There is evidence to suggest that natural
compounds might be effective and less toxic in some circumstances. Furthermore, metal-derivatized
natural compounds can also trigger apoptosis and natural compound-metal complexes have been
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confirmed as potential (pro) drugs [106]. This suggests that natural compounds and their derivatives
merit further investigation as anti-cancer therapeutics.
The effect of multi-drug resistance during cancer progression is another important hurdle for
chemotherapy. In resistance to chemotherapy-induced cancer cell death, genetic alterations in the
drug-induced apoptotic program also cause MDR to biochemically unrelated drugs [135]. This is
illustrated by the relationship between chemoresistance and targeted upregulation of apoptosis
regulator bcl-2 by multiple DNA damaging stimuli [135]. Therefore, it is important to study
the role of natural compounds in chemosensitization, since this may create new avenues for
novel drug development in cancer treatment. The investigation of natural compound mixtures
as apoptosis-inducing and chemosensitizing cancer therapeutics will improve our understanding of
the molecular changes in cancer cells and should provide clues about how the disease can be controlled.
Our current knowledge of natural compounds’ effects on cancer is mainly from cell-based experiments
and partly from in vivo experiments. To date, the clinical effectiveness of some of these combined
drugs has not been robustly demonstrated. As a result, additional research using in vivo systems and
better clinical trials is needed to determine the safety and clinical usefulness of these drugs.
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Chapter 2
Fractional deletion of Compound Kushen Injection, a
natural compound mixture, indicates cytokine signaling
pathways are critical for its perturbation of the cell cycle
CKI is a mixture of compounds containing several major and minor components.
Accumulating evidence suggests that CKI has anti-cancer activity. However, the exact
molecular mechanism by which each or a group of single compounds exerts its anti-cancer
activity remains poorly understood. The work for this chapter addressed this question
by using analytical chemistry coupled with cellular and molecular assays. Results here
indicate that the experimental approach for this work has enabled the association of
specific compounds with alterations in specific pathway gene expression. This novel
approach of depleting components from a mixture and observing the effects using both
phenotypic and gene expression studies is likely to be a powerful tool for future research
on the mechanism of action of complex mixtures of compounds. This chapter is in the
format of the manuscript submitted to Protein and Cell. Specific Aim1: To fractionate
and reconstitute CKI in order to examine the functions and interactions of reconstituted
compounds in MDA-MB-231 breast cancer cell line. Specific Aim2: To determine how
specific compounds are responsible for specific aspects of CKI’s effects on cancer cell
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We have used computational and experimental biology approaches to identify candidate 
mechanisms of action of a traditional Chinese medicine; Compound Kushen Injection (CKI), 
in a breast cancer cell line in which CKI has been shown to cause apoptosis. Because CKI is a 
complex mixture of plant secondary metabolites, we used a high-performance liquid 
chromatography (HPLC) fractionation and reconstitution approach to define chemical fractions 
required for CKI to induce apoptosis in MDA-MB-231 cells. Our initial fractionation separated 
major from minor compounds, and showed that the major compounds accounted for little of 
the activity of CKI. By systematically perturbing the major compounds in CKI we found that 
removal of no single major compound could alter the effect of CKI on cell viability and 
apoptosis. However, simultaneous removal of two major compounds identified oxymatrine and 
oxysophocarpine as critical compounds with respect to CKI activity. We then used RNA 
sequencing and transcriptome analysis to correlate compound removal with gene expression 
and phenotype data. We determined that many compounds in CKI are required for its 
effectiveness in triggering apoptosis but that significant modulation of its activity is conferred 
by a small number of compounds. In conclusion, CKI may be typical of many plant based 
extracts that contain many compounds in that no single compound is responsible for all of the 
bioactivity of the mixture and that many compounds interact in a complex fashion to influence 






Natural compounds are chemically diverse and have long served as resources for the 
identification of drugs (Harvey et al., 2015). However, the standard approach of fractionating 
natural product extracts to identify a single compound’s biological activity can fail because the 
original activity of the mixture is not present in single compounds after fractionation. This 
failure to identify single compounds implies that some natural product mixtures derive their 
activity from the interaction of several bioactive compounds within the mixture. Characterising 
the mode of action of natural product mixtures has remained a difficult task as the 
combinatorial complexity of such mixtures makes it unfeasible to screen all combinations of 
the compounds in the mixture.  
We introduce here a “subtractive fractionation approach” using high performance liquid 
chromatography (HPLC) that can pinpoint significant interacting compounds within a mixture 
when coupled with a suitable bioassay. We combined this approach with RNA sequencing 
(RNAseq) characterisation of our bioassay, correlating the removal of interacting compounds 
with concomitant alterations in gene expression. This allows us to identify specific 
combinations of compounds associated with specific pathways and regulatory interactions. In 
this report, we have applied this approach for the first time to a particular Traditional Chinese 
Medicine formulation: CKI, which is used to treat approximately 30,000 cancer patients/day 
in China in conjunction with Western chemotherapy. 
CKI is composed primarily of alkaloids and flavonoids extracted from two herbal medicinal 
plants: Kushen (Sophora flavescens) and Baituling (Heterosmilax chinensis). Twenty-one 
chromatographic peaks have been identified from CKI with eight compounds being recognized 
as major components on the basis of their abundance (Ma et al., 2014). The extract containing 
the most abundant compounds in CKI is derived from Kushen herb which has a long history in 
the treatment of patients suffering immune function disorders (Xu et al., 2005; Cheng et al., 
2006). The main component of CKI, macrozamin, is a derivative of baituling which has been 
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a suggested therapeutic agent for the treatment of inflammatory disease (Jiang et al., 1997). 
Gao and colleagues showed that treatment with each of four of the main compounds of CKI 
(oxymatrine, matrine, sophoridine and Nmethycytisine) at 4 mg/ml significantly decreased cell 
viability (Gao et al., 2018). However, these concentrations are relatively high when compared 
to the contributing concentration of these four main compounds in CKI (Ma et al., 2014). The 
two main components of CKI, matrine and oxymatrine,  may have significant anti-cancer 
activities in various types of solid tumors including breast cancer, non small lung cancer, 
cervical cancer, prostate cancer, synovial sarcoma, and hepatocellular carcinoma (Yu et al., 
2009; Li et al., 2015; Wu et al., 2015; Cai et al., 2016; Wu et al., 2016; Aung et al., 2017; Gao 
et al., 2018; Zhou et al., 2018). In contrast, toxicity of medicinal herbs containing matrine and 
oxymatrine as main components has also been reported (Wang and Yang, 2003). 
Administration of matrine 150 mg/kg and oxymatrine 360 mg/kg significantly increased 
cytochrome P450 family protein CYPB1/2 in rats demonstrating a potential therapeutic 
drawback of these two compounds (Yuan et al., 2010). Overall, understanding the effects of 
CKI based on the effects of single compounds present in CKI has been at best, partially 
successful.  
Alternatively, by removing one, two or three compounds, we have been able to map the effects 
of these compounds and  their interactions to effects on specific pathways based on altered 
gene expression profiles in a cell-based assay. This has illuminated the roles of several major 
compounds of CKI, which on their own have little or no activity in our bioassay. This approach 
can be used to dissect the roles and interactions of individual compounds from complex natural 






Subtractive fractionation overview 
Well resolved chromatographic separation of CKI was used to collect all of the major 
components of CKI as individual fractions (Fig. 1A).  We then reconstituted all of the separated 
fractions except for those we wished to subtract. We tested the reconstituted combination of 
compounds/peaks to see if removal of a single (N-1) or multiple compounds, (N-2 or N-3, 
where N represents the total number of compounds in CKI), or removal of all major peaks 
(minor, MN) or depletion of all minor peaks (major, MJ)  significantly altered the effect of CKI 
in our cell based assays. Our cell based assays (Qu et al., 2016) measured MDA-MB-231 
(human breast adenocarcinoma) cell viability, cell cycle phase and cell apoptosis. A summary 
of the subtractive fractions used in the cell based assays is shown in Table 1. We then carried 
out RNA isolation of cells treated with CKI, individual compounds or CKI deletions for 
RNAseq. Differentially expressed (DE) genes in these samples allowed the association of 
specific compounds with cell phenotype and underlying alterations in gene regulation. By 
comparing DE genes across treatment combinations we identified specific candidate pathways 
that were altered by removal of single or multiple compounds, as detailed below. 
 
HPLC fractions and content identification using LC-MS/MS  
HPLC fractionation and reconstitution was used to generate a number of  N-1, N-2, N-3, MJ 
and MN mixtures, (Fig. 1A, 1B, 1C and Sup. Fig. 1) with specific combinations and their 
components shown in Table 1. The concentrations of known compounds in CKI and 
reconstituted subtractive fractions were determined from standard curves (Sup. Data. 1) for 
nine available reference compounds, using cytisine as an internal standard (Table 2). The 
combined concentration of 9 reference compounds from CKI was approximately 10.8 mg/ml, 
whereas subtractive fractions N-OmtOspc and N-MacOmtOspc had concentrations of 
reference compounds of 3.8 mg/ml and 2.1 mg/ml which were equivalent to the concentrations 
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of these compounds in unfractionated CKI. The depleted OmtOspc and MacOmtOspc were not 
observed in the N-OmtOspc and N-MacOmtOspc respectively. These collectively suggested 
any effects observed after the treatments of N-OmtOspc and N-MacOmtOspc were not 
influenced by the concentrations. A total of 9 (N-1), 4 (N-3) and 9 (N-2) combinations, along 
with MJ and MN deletions were tested in our cell based assays (Table 1).  
 
Phenotypic changes associated with compound deletion 
Fractionation and full reconstitution caused no changes in cell viability compared to original 
CKI (see methods) at either 24- or 48-hours in MDA-MB-231 cells. Both reconstituted CKI 
and CKI caused significantly reduced viability compared to untreated (UT) cells (Sup. Fig. 
2A). The MJ subtractive fraction contained a total of 9 compounds including eight 
previously identified MJ peaks (Ma et al., 2014) and adenine (unpublished data from Ma Yue) 
(Fig. 1A) and the MN fraction contained the remaining peaks (Fig. 1C). MJ had no effect 
on cell viability, while MN reduced cell viability to the same extent as CKI (Fig. 2A). The 
9 major compounds were individually depleted from CKI and tested as 9 (N-1) subtractive 
fractions, with no significant alterations in cell viability compared to CKI (Fig. 2B). We 
then assessed the interaction effects of single MJ compounds by adding them back to the 
MN subtractive fraction. No change in cell viability compared to MN was observed (Sup. 
Fig. 2B). Sets of 3 compounds from the 9 major/standard compounds of CKI were depleted 
to generate 3 (N-3) subtractive fractions. The nine reference compounds were allocated into 
three groups, one of which contained structurally similar compounds (Omt, Ospc, Spc) and 
two other groups ([Mac, Ade, Tri] and [Nme, Mt, Spr]) that contained structurally different 
compounds. Of these three fractions, N-OmtOspcSpc decreased cell viability significantly 
(P < 0.05) more than CKI after 48 hours (Fig. 2C) while none of the sets of three compounds 
on their own had any effect on cell viability (Sup. Fig. 2). We then generated 9 (N-2) 
subtractive fractions based on the N-3 subtractive fractions (Table 1). Out of 9 (N-2) 
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subtractive fractions (Sup. Fig. 2), only N-OmtOspc significantly decreased proliferation 
compared to CKI (P < 0.05) (Fig. 2C).  We then depleted macrozamin, the only major 
compound derived from Baituling, together with OmtOspc as N-3 (N-MacOmtOspc) in order 
to determine if there was an additional effect when compared to CKI. N-OmtOspc and N-
MacOmtOspc both decreased cell proliferation to the same extent (Fig. 2C and 2D).  
While no change in cell viability was found across all N-1 treatments, cell cycle analysis was 
performed to identify more subtle differences. There was no statistically significant difference 
in phases of the cell cycle of MDA-MB-231 cells for many of the N-1 treatments compared to 
CKI except for a statistically significant change in G1 phase by N-Omt after 48 hours (Fig. 
3A). On the other hand, N-OmtOspc treatment significantly altered the cell cycle for MDA-
MB-231 cells and induced significant higher apoptosis from 0.25 mg/ml through 2 mg/ml 
treatments as compared to CKI at both timepoints (Fig. 3B and Sup. Fig. 3). N-MacOmtOspc 
treatment also significantly altered the cell cycle at both timepoints with generally similar 
effects to N-OmtOspc (Fig. 3C).  
Annexin V/PI apoptosis assays were performed using subtractive fractions on MDA-MB-231, 
HEK-293 (human embryonic kidney cells) and HFF (primary human foreskin fibroblasts) cell 
lines. While CKI at 2 mg/ml caused increased apoptosis in MDA-MB-231 cells at both 24- and 
48-hour after treatment, N-OmtOspc and N-MacOmtOspc subtractive fractions at 
concentrations equivalent to CKI 2 mg/ml significantly increased the percentage of apoptotic 
cells at 24-hour with increasing apoptosis at the 48-hour timepoint, indicating that N-OmtOspc 
and N-MacOmtOspc  significantly enhanced apoptosis compared to CKI (Fig. 4A, 4E and Sup. 
Fig. 3A). Although CKI did not generally cause apoptosis in HEK-293 or HFF cells, N-
OmtOspc and N-MacOmtOspc subtractive fractions significantly induced apoptosis (P*** < 
0.001) at 24-hour and 48-hour (P**** <  0.0001) in both HEK-293 and HFF cells. CKI only 
induced apoptosis of HEK-293 (P* < 0.05) at 48-hour and showed no significant apoptotic 
induction in HFF (Fig. 4B, 4C and Sup. Fig. 3B and 3C). These results indicated that the N-
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OmtOspc and N-MacOmtOspc subtractive fractions induced apoptosis not only in cancerous 
cells but also in non-cancerous cell lines. In contrast to this, no significant apoptosis was 
triggered by CKI on HFF cells. A small but significant apoptotic induction was observed for 
HEK-293. 
Because of the significant decreased viability accompanied by increased apoptosis triggered 
by subtractive fractions, cytotoxicity tests were carried out for all three cell lines using CKI (2 
mg/ml) and N-OmtOspc and N-MacOmtOspc subtractive fractions at concentrations 
equivalent to CKI 2 mg/ml. N-OmtOspc and N-MacOmtOspc at equivalent concentration to 
CKI 2 mg/ml were significantly cytotoxic to both non-cancerous cell lines (Fig. 4D). 
Overall, these results indicated that removal of combinations of specific compounds from CKI 
had unpredictable effects on the ability of CKI to kill cells. While removal of all major 
compounds from CKI caused no loss of activity and removal of all minor compounds caused 
total loss of activity, removal of selected major compounds (N-OmtOspc) paradoxically caused 
major, significant increases in the ability of CKI to reduce viability and killed cells.   
 
Differential gene expression 
In order to understand the interactions of the components in CKI as a result of depletion, we 
carried out RNAseq of MDA-MB-231 cells treated with CKI and subtractive fractions. Four 
out of nine (N-1) subtractive fractions, four, namely N-Omt, N-Mac, N-Tri and N-Nme, were 
selected due to their structural differences to determine their effects on transcript levels. N-
OmtOspc and N-MacOmtOspc, OmtOspc, MacOmtOspc and CKI treated cells were 
sequenced at 24 and 48-hour timepoints.  
After normalization, clear clustering of the replicates was observed (Fig. 5A and Sup. Fig. 4, 
5, 6 and 7), indicating that all 4 (N-1) treatments show comparable downstream gene 
expression patterns. Likewise, OmtOspc and MacOmtOspc groups and N-OmtOspc and N-
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MacOmtOspc groups showed similar changes in gene expression, except for one replicate (N-
MacOmtOspc, 24-hour) that clustered with UT, OmtOspc and MacOmtOspc.  
The number of DE genes associated with each treatment was calculated using pairwise 
comparative analysis. CKI treatment was used as a baseline to compare all other treatments in 
order to emphasize the effect of depleted compounds and CKI treatment was compared to UT. 
There were thousands of upregulated and downregulated genes at 24 and 48 hours in most 
pairwise comparisons (Fig. 5B). However DE genes between OmtOspc and MacOmtOspc 
treatments were not observed and there were almost no DE genes between N-Mac, N-Nme and 
N-Tri treatments (Fig. 5B) indicating that these three subtractive fractions had very similar 
effects on gene expression.  
When we compared the DE genes found between treatments, there were a large number of DE 
genes (~71.3 %) shared between all four (N-1) treatments (Sup. Fig. 8 and 9 and Sup. Table. 
1).  A similar number of shared DE genes (~24.6 %) between four (N-1), OmtOspc and 
MacOmtOspc and between four (N-1), N-OmtOspc and N- MacOmtOspc as compared to CKI 
at 48-hours indicated that gene expression patterns from N-1 treatments were mostly different 
from N-OmtOspc, N- MacOmtOspc, OmtOspc and MacOmtOspc treated cells. 55 % of the 
DE genes between UT,  OmtOspc and MacOmtOspc were shared. When the four (N-1) 
treatments were compared to CKI treatment, 42.8 % of DE genes were shared, and when N-
OmtOspc and N- MacOmtOspc treatments were compared to CKI, 50.1 % DE genes were 
shared, indicating that N-OmtOspc and N-MacOmtOspc treatments appeared to be more 
similar to CKI than N-1 treatments.  
The overall levels of similarity in DE genes were as follows: 1) All N-1 treatments had 
approximately 70 % similar gene expression patterns, 2) OmtOspc and MacOmtOspc 
treatments were approximately 50 % similar to UT and 33 % similar to N-1 treatments, 3) 
downstream gene expression patterns between N-1, N-OmtOspc and N-MacOmtOspc were 
approximately 37 % similar. 
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Gene ontology and pathway annotation of DE genes 
DE genes were analysed for over-representation in our data sets with respect to biological 
function using Gene Ontology (GO) annotation. We looked for shared DE genes between 
treatments and identified over-represented genes in these shared genes. The only common 
function enriched across all comparisons was for "cell cycle checkpoint" (Fig. 6A). This 
confirmed earlier results (Qu et al., 2016) and was consistent with the phenotype data for CKI. 
 
Subtracted fractionation altered pathways 
We also performed pathway based analysis to look for pathway level perturbation by 
comparing DE genes within Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways 
between treatments.  We used Signaling Pathway Impact Analysis (SPIA) to identify pathways 
with statistically significant perturbation values expected to alter pathway flux. We identified 
86 pathways (Sup. Fig. 11) with statistically significant (P < 0.05) perturbations of gene 
expression and of these, 15 pathways were most obviously linked to our phenotypes of cell 
viability, cell cycle and apoptosis (Fig. 6B). By comparing the pathway gene expression global 
perturbation scores (pG) between treatments three specific observations could be made: 1) N-
1 fractional deletions vs CKI had significant effects on flux in some pathways without 
phenotypic effects, 2) N−OmtOspc vs CKI which had a pronounced phenotypic effect at both 
24- and 48-hours, had a significant effect on reducing estimated pathway flux for Cytokine-
Cytokine Receptor, Cell Cycle and TGF-Beta signaling pathways, 3) comparison of N-1 
fractional deletions vs fractional deletions of N−OmtOspc/N−MacOmtOspc showed consistent 
pathway perturbations for Cytokine-Cytokine Receptor and p53 signaling pathways. On this 
basis, we inferred that different major compounds could be deleted with very similar effects, 
indicating that they may have similar targets. In contrast, deleting Omt and Ospc 
simultaneously caused a significant shift in phenotype and was accompanied by specific 
perturbations in pathways that regulate inflammation, cell cycle and apoptosis. The combined 
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deletion of Omt and Ospc had a synergistic effect on viability, cell-cycle and apoptosis and a 
synergistic effect on gene expression, consistent with the observed changes in pathway specific 
perturbation of gene expression. Because this double compound deletion potentiated the cell 
killing effect of CKI we hypothesised that the compounds in CKI have multiple targets leading 
to a phenotypic effect that reflects the integration of stimulation and inhibition across all those 
targets.  Removal of Omt and Ospc alter the balance of stimulation and inhibition leading to 
an integrated effect for the remaining compounds in the mixture that caused more cell death 
than CKI.    
 
More detailed examination of some of these interactions within significantly perturbed 
pathways highlighted the gene-specific changes in expression for some key regulators of 
inflammation and the cell-cycle.  Most effects on gene expression from deletion of single vs 
two compounds were similar, suggesting that the enhanced cell killing by N-OmtOspc was due 
to additive effects of the compound deletions. However, by comparing differences in pairwise 
comparisons between treatments at the gene level within the Cytokine-Cytokine Receptor 
Interaction and Cell Cycle pathways we identified a subset of genes that had opposite changes 
in gene expression when comparing single compound deletions to N-OmtOspc deletion. In the 
Cytokine-Cytokine Receptor Interaction pathway (Fig. 7), these genes are IL1-R1 (Interleukin-
1 Receptor), IL-27RA (Interleukin-27 Receptor alphasubunit), TNFRSF1B (Tumor Necrosis 
Factor Receptor Superfamily Member 1B), TNFRSF14 (Tumor Necrosis Factor Receptor 
Superfamily, Member 14) and OSMR (Oncostatin M Receptor/IL-31 Receptor Subunit Beta) 
and they all transduce inflammatory ligand signals to the NFkB pathway and/or the apoptosis 
pathway. In the Cell-Cycle pathway (Fig. 8), these genes are CDKN1C (Cyclin-Dependent 
Kinase Inhibitor 1C (P57, Kip2)), CDC25B (Cell Division Cycle 25B), ATR (ATR 
Serine/Threonine Kinase), CDKN1B (Cyclin-Dependent Kinase Inhibitor 1B (P27, Kip1)), 
CDKN2D (Cyclin-Dependent Kinase Inhibitor 2D (P19, Inhibits CDK4)), TGFB1 
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(Transforming Growth Factor Beta 1), FZR1 (Fizzy And Cell Division Cycle 20 Related 1), 
CDC20 (Cell Division Cycle 20), CDC27 (Cell Division Cycle 27), ORC2 (Origin Recognition 
Complex Subunit 2), ANAPC4 (Anaphase Promoting Complex Subunit 4), ZBTB17 (Zinc 
Finger And BTB Domain Containing 17) and , ABL1 (ABL Proto-Oncogene 1, Non-Receptor 
Tyrosine Kinase). The opposite changes in gene expression stimulated by N-OmtOspc 
compared to N-1 subfractions provide support for the idea that multiple major compounds can 
have similar effects on specific genes but that the combination of Omt and Ospc can have 
synergistic and opposite effects on those same genes. This means that multiple compounds 
with overlapping targets (based on their structural similarities) can either reinforce a single 
outcome or exhibit unpredictable and opposite effects when combined.   
 
Overall our results support the concept of multi-compound/multi-target interactions for plant 
extract based drugs that contain many plant secondary metabolites.  Biological effects of 
complex plant extracts may result from interactions of multiple compounds, with negligible 
effects from single compounds alone.  This has implications for how we assess the functional 





Previous studies have demonstrated that CKI can alter the cell cycle, induce apoptosis and 
reduce proliferation in various cancer cell lines (Xu et al., 2011; Qu et al., 2016; Gao et al., 
2018). CKI also killed leukaemia cells via the Prdxs/ROS/Trx1 signalling pathway in an acute 
myeloid leukaemia patient-derived xenograft model and caused cell cycle arrest in U937 
leukaemia derived cells (Jin et al., 2018).  Cell cycle arrest by CKI at checkpoints is correlated 
with the induction of double strand breaks by CKI treatment (Cui et al., 2018). In contrast to 
our experiments reported above, oxymatrine was previously shown to arrest the cell cycle and 
induce apoptosis in human glioblastoma cells through EGFR/PI3K/Akt/mTOR signaling 
pathway (Dai et al., 2018)  and inhibit the proliferation of laryngeal squamous cell carcinoma 
Hep-2 cells (Ying et al., 2015). As shown in this report, oxymatrine or oxysophocarpine or 
combined OmtOspc treatment caused no significant change in cell viability, the cell cycle or 
apoptosis, in agreement with prior work that showed oxymatrine and oxysophocarpine exerting 
no significant effect on apoptosis, cell cycle or cell proliferation in HCT116 human colon 
cancer cells (Zhang et al., 2014).  
 
The paradoxical result that removal of OmtOspc caused a striking increase in apoptosis is most 
simply explained by a model based on integrating effects of multiple compounds on many 
targets. The interactions between compounds in the mixture can be synergistic and antagonistic 
such that if two compounds are removed that have a synergistic effect that is antagonistic to 
the remainder of the mixture, the resulting depleted mixture will be dis-inhibited compared to 
CKI. This is illustrated by our studies and others that show single compounds alone had no or 
little effect compared to CKI. For instance, while CKI treatment resulted in increased DNA 
double strand breaks and affected the cell cycle resulting in decreased cancer cell proliferation, 
oxymatrine alone exhibited only a small effect in the same assay (Cui et al., 2018). Gao and 
colleagues also reported that oxysophocarpine at 4 mg/ml had no effect, oxymatrine at 4 mg/ml 
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(*P < 0.05) and CKI at 2 mg/ml (***P < 0.001) significantly reduced the proliferation of 
hepatocellular carcinoma SMMC-7721 cells in vitro (Gao et al., 2018). Although significant 
inhibition of proliferation by oxymatrine occurred, the concentration used in this experiment 
was ~ 8x times higher than that of oxymatrine in 2 mg/ml of CKI. These studies agree with our 
experimental outcomes that oxymatrine and oxysophocarpine individually had no or little 
effect compared to CKI treatment.  
 
At the level of gene expression in our study, gene ontology analysis indicated that genes for 
“cell cycle checkpoint” were significantly enriched in cells treated with all fractionated 
mixtures or mixtures of Omt and Ospc. Consistent with other studies, our results also 
demonstrated that these compounds had little or no phenotypic effect on their own, but that 
when both were deleted, the remaining compounds unexpectedly had significantly greater 
effects on phenotype and gene expression. When examined in the context of specific pathways, 
treatment with OmtOspc or N-OmtOspc which had strikingly different effects on phenotype, 
had similar effects on the perturbation of the “Cytokine-Cytokine Receptor Interaction” 
pathway, the most commonly perturbed pathway seen in our analysis, that interestingly did not 
show up when comparing CKI to UT. This is consistent with previous work showing that CKI 
induced cytokines IL4 and IL10 in cancer patients with acute leukaemia (Tu et al., 2016).  In 
contrast to this observation, IL4 and IL10 levels were significantly decreased in transgenic 
mice treated with oxymatrine at a dose of 200 mg/kg (Dong et al., 2002). In our experiment, 
we also observed that while CKI and many of the depleted fractions had significant effect on 
the genes in the “Cytokine-Cytokine Receptor Interaction” pathway, OmtOspc and 
MacOmtOspc had little effect on the genes in that pathway. The observation that many genes 
in the “Cytokine-Cytokine Receptor Interaction” pathway were not affected by OmtOspc and 
MacOmtOspc compared to deletion fractions confirmed that removal of compounds rather than 
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treatment with single or a few compounds can be more informative of the role and significance 
of individual compounds as part of mixtures/extracts.  
 
In summary, Our approach allowed the identification of both synergistic and antagonistic 
interactions within the drug mixture. Viewed as a network where the compounds and the targets 
are nodes and the interactions between compounds and targets, and between targets are edges, 
it is clear that the edges (interactions) determine the overall effect of the compound mixture.  
By removing one or two compounds from a mixture, we can potentially perturb the target 
network(s) to either reduce the effect of the mixture for some outcome or potentiate it for 
another. We believe this approach may be of general use for the study of herbal 
medicines/extracts, avoiding failures that stem from exclusive reliance on the identification of 




Materials and Methods  
Cell lines  
MDA-MB-231 cells were purchased from the American Type Culture Collection (ATCC, VA, 
USA). HEK-293 and HFF were kindly provided by Prof. Andrea Yool (Medical School, 
University of Adelaide). Cells were cultured in Dulbecco's Modified Eagle's Medium (Thermo 
Fisher Scientific) with 10 % Fetal bovine serum (Thermo Fisher Scientific) at 370C with 5 % 
CO2.  
 
Compound fractionation by HPLC 
CKI (Batch No: 20170322, total alkaloid concentration of 26.5 mg/ml) was provided by 
Zhendong Pharmaceutical Co.Ltd (China). CKI (N) was processed to deplete Single (N-1), 
double (N-2) and triple (N-3) compounds using HPLC by standardizing using nine compounds, 
namely Oxymatrine (Omt), Oxysophocarpine (Ospc), N-methylcytisine (Nme), Matrine (Mt), 
Sophocarpine (Spc), Trifolirhizin (Tri), Adenine (Ade), Sophoridine (Spr) (Beina 
Biotechnology Institute Co., Ltd, China), and macrozamin (Zhendong Pharmaceutical Co.Ltd, 
China) which were previously reported to be found in published and unpublished data (Ma et 
al., 2014). HPLC fractionation separated Minor (MN) and Major (MJ) peaks  to determine the 
principle and secondary components.  The MJ mixture contained the nine standard compounds 
mentioned above and MN contained the remaining CKI components. In addition, nine N-1 
fractional deletions, nine N-2 fractional deletions and three N-3 fractional deletions were 
produced.  
HPLC separation was achieved using an Shimadzu HPLC instrument (Japan) equipped with 
a photodiode-array UV-Vis detector with preparative C18 column (5 µm, 250 x 10 mm) (CA, 
USA). The following mobile phase was used to fractionate the CKI mixture: 0.01 M 
ammonium acetate (adjusted to pH 8.0, solvent A) and acetonitrile + 0.09 % trifluroacetic acid 
(solvent B). The flow rate was 2 ml/min and linear gradient was adopted as follows; 0 min, 100 
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% A; 60 min, 65 % A, 70 min, 100 % A. The chromatogram was recorded from 200 nm to 
280 nm, with monitoring at 215 nm. Samples were frozen and lyophilised using a Christ Alpha 
1-2 LD lyophilizer (Martin Christ Gefriertrocknungsanlagen GmbH, Germany). Several cycles 
of lyophilisation and resuspension were used to remove all remaining HPLC solvents and final 
reconstitution was carried out using MilliQ H2O buffered with 10 mM HEPES (Gibco, Life 
technologies, USA) and adjusted to pH 6.8-7.0. Lyophilised samples were resuspended to 
create an equivalent dilution for compounds in the sample compared to CKI.  
 
Identification of reconstituted mixtures by Liquid Chromatography/Mass Spectrometry 
(LC-MS/MS)  
Agilent 6230 TOF mass spectrometer was used to determine the concentration of the known 
compounds from the CKI and reconstituted N-OmtOspc and N-MacOmtOspc mixtures. 10 µl 
sample was injected with the flow rate of 0.8 ml/min, a gradient program of 0 min, 100 % A; 
40 % B; 25 min, 60 % B, 35 min, and solvents MilliQ H2O + 0.1 % formic acid (solvent A) 
and acetonitrile + 0.1 % formic acid (solvent B). The column used was C18 (5 µm, 150 x 4.6 
mm, Diamosnsil, Dkimatech, China). The recovered contents of the samples were measured 
by spike-in compound cytosine. Gas phase ions were generated with an electrospray source, 
with key instrument parameters: gas temperature, 325; sheath gas temperature, 350; vCap, 
3500; fragmentor, 175;  acquisition range (m/z) 60-17000. Calibration curves for 9 standard 
compounds containing various concentrations were shown in Supplementary Data.  
 
Cell viability Assay 
2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) and N-
methyl dibenzopyrazine methyl sulfate (PMS) (50 : 1, Sigma-Aldrich, St. Louis, MO, USA) 
assay was used to assess cell viability as described in Qu et al (Qu et al., 2016). Briefly, 8,000 
cells in 50 µl of medium were plated in 96 wells trays overnight prior to drug treatments in 
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triplicate. Cells were subsequently treated with 50 µl of drug mixtures to provide final 
concentrations of 0.25, 0.5, 1 and 2 mg/ml  of total alkaloids in 100 µl. Cell viability was then 
measured at 24-and 48-hours after drug treatment by the addition of 50 µl of  XTT:PMS 
mixture (50 : 1 ratio). An equal volume of medium and treating agents plus XTT:PMS was 
used to subtract the background optical density. The absorbance of each well was recorded 
using a Biotrack II microplate reader at 492 nm.  
 
Annexin V/PI apoptosis assay 
Apoptosis resulting from treatment was determined using an Annexin V-FITC apoptosis 
detection kit (Thermofisher Scientific) according to the manufacturer’s protocol. Briefly, 4x105 
cells were seeded in 6-well plates in triplicate overnight prior to treatment. On the following 
day, cells were treated with the agents as described for 24-and 48-hours. Data were acquired 
with a BD LSR Fortessa X20 (BD Bio Sciences, NJ, USA) flow cytometer, and FlowJo 
software (TreeStar Inc., OR, USA) was used to analyse the acquired data and produce percent 
apoptosis values. 
 
Cell cycle assay 
Cell culture and drug treatments were performed as described above for cell cycle analysis. A 
Propidium Iodide (PI) staining protocol (Riccardi and Nicoletti, 2006) was used to detect the 
changes in cell cycle as a result of treatment after 24- and 48-hours. The characteristics of 
stained cells were measured using a BD LSR Fortessa flow cytometer, and acquired data were 
analysed using FlowJo software. 
 
Cytotoxicity assay 
Cells were seeded in 96-well plates at a density of 2.5 x 103 cells per well in triplicate. CKI 
and fractionated mixtures at final concentrations of 1 mg/ml and 2 mg/ml were added to each 
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well and after 24-hours of incubation and viable cells were measured using the Alamar Blue 
assay (Thermo Fisher Scientific). 5 µM of Mercuric chloride (Sigma-Aldrich) was used as a 
positive control and wells without cells were set as a negative control in the same plate. 
  
Sample preparation and RNA sequencing 
Cells were plated in 6 well plates with a density of 2x105 cells/ml overnight prior to drug 
treatments. On the following day, CKI (at a final concentration of 2 mg/ml) and fractionated 
mixtures (equivalent dilutions of CKI) were added. Total RNA was isolated by using an RNA 
extraction kit (Thermo Fisher Scientific) according to the manufacturer’s instructions and RNA 
samples were quantified and quality determined using a Bioanalyzer at the Cancer Genome 
Facility of the Australian Cancer Research Foundatin (Australia). RNA samples with RNA 
integrity number (RINs) > 7.0 were sent to be sequenced at Novogene (China). Briefly, after 
QC procedures were performed, mRNA was isolated using oligo(dT) beads and randomly 
fragmented by adding fragmentation buffer, followed by cDNA synthesis primed with random 
hexamers. Next, a custom second-strand synthesis buffer (Illumina) , dNTPs, RNase H and 
DNA polymerase I were added for second-strand synthesis. After end repair, barcode ligation 
and sequencing adaptor ligation, the double-stranded cDNA library was size selected and PCR 
amplified. Sequencing was carried out on an Illumina HiSeq platform PE150 with paired-end 
150 bp reads.  
 
Transcriptome data processing 
FastQC (v0.11.4, Babraham Bioinformatics) was used to check the quality of raw reads before 
proceeding with downstream analysis. Trim_galore (v0.3.7, Babraham Bioinformatics) with 
the parameters: --stringency 5 --paired --fastqc_args was used to trim adaptors and low-quality 
sequences. STAR (v2.5.3a) was then applied to align the trimmed reads to the reference 
genome (hg19, UCSC) with the parameters: --outSAMstrandField intronMotif --
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outSAMattributes All --outFilterMismatchNmax 10 --seedSearchStartLmax 30 --outSAMtype 
BAM SortedByCoordinate (Dobin et al., 2013).  Then, subread (v1.5.2) was used to generate 
read counts data with the following parameters featureCounts -p -t exon -g gene_id (Liao et 
al., 2013). Significantly differentially expressed genes between treatments were analysed and 
selected using edgeR (v3.22.3) with false discovery rate (FDR) < 0.05 (Robinson et al., 2010).  
Removal of unwanted variance (RUVs) package in R was applied to two different batches of 
transcriptome datasets to eliminate batch variance (Risso et al., 2014). APE was used to cluster 
the treatments (Paradis et al., 2004)  followed by RUVs. Gene Ontology (GO) 
overrepresentation analyses were performed using clusterProfiler with the parameter ont = 
"BP"(Biological Process), pAdjustMethod = "BH", pvalueCutoff  = 0.01, and qvalueCutoff  = 
0.05 (Yu et al., 2012). Signalling Pathway Impact Analysis (SPIA) was carried out to identify 
the commonly perturbed pathways within the treatments using the SPIA R package (Tarca et 
al., 2008). Significantly perturbed pathways were visualized using Pathview package in R (Luo 
and Brouwer, 2013).  
 
Statistical analysis 
Statistical analyses were carried out using GraphPad Prism 8.0 (GraphPad Software Inc., CA, 
USA). Student's t‐test or ANOVA (one‐way or two‐way) was used when there were two or 
three groups to compare respectively. Post hoc "Bonferroni's multiple comparisons test" was 
performed when ANOVA results were significant. Statistically significant results were 
represented as p < 0.05 (*) or p < 0.01 (**) p < 0.001 (***), or p < 0.0001 (****); ns (not 
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Fig. 1: Fractionation of CKI. (A) Diagram illustrating the process of subtractive fractionation, 
reconstitution, and screening of fractionated compounds using three cell-based assays. (B) 
HPLC profile of the 9 purified and reconstituted major peaks (MJ) demonstrating nine major 
compounds. (C) HPLC profile of reconstituted fractions not containing the 9 major compounds 
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Fig. 2: XTT cell viability assays of subtractive fractions in MDA-MB-231 cells at 24- and 48-
hour timepoints treated with 2 mg/ml of CKI and 2 mg/ml equivalent concentrations of all 
other treating agents. (A) Suppression of cell viability from the following fractions: UT 
(untreated), MJ, MN, MJ+MN (combination of MJ and MN) and Syn_CKI (synthetic CKI 
generated using nine major compounds). (B) Effect of 9 (N-1) subtractive fractions compared 
to CKI. (C) Effect of N-OmtOspc subtractive fraction and OmtOspc compared to CKI. (D) 
Effect of N-MacOmtOspc subtractive fraction and MacOmtOspc, compared to CKI. 
Statistically significant results relative to CKI treatment shown as p < 0.05 (*) or ns (not 




Fig. 3: Cell cycle assay of subtractive fractions at 24- and 48-hour timepoint treatments. (A) 
Effect of 9 (N-1) subtractive fractions on cell cycle in MDA-MB-231 cells as determined by 
PI staining assay. (B) Effect of N-OmtOspc subtractive fraction and OmtOspc on cell cycle in 
MDA-MB-231 cells as determined by PI staining assay. (C) Effect of N-MacOmtOspc 
subtractive fraction and MOO on cell cycle in MDA-MB-231 cells as determined by PI staining 
assay. (D) The representative histograms of cell cycle analysis by the treatments as compared 
to UT. Statistically significant results shown as p < 0.05 (*) or p < 0.01 (**) p < 0.001 (***), 




Fig. 4: Apoptosis and cytotoxicity assays of subtractive fractions at 24- and 48-hour timepoint 
treatments. Apoptotic effect of N-OmtOspc, N-MacOmtOspc subtractive fractions, OmtOspc 
and MacOmtOspc in (A) MDA-MB-231 cells, (B) HEK-293 cells, and (C) HFF cells as 
determined by AnnexinV/PI assay. (D) Cytotoxic effect of CKI, N-OmtOspc and N-
MacOmtOspc subtractive fractions was determined using Alamar Blue cytotoxicity assay. 
Statistically significant results shown as p < 0.05 (*) or p < 0.01 (**) p < 0.001 (***), or p < 




Fig. 5: Gene expression clustering and summary of differential gene expression (A) Clustering 
of treated samples based on gene expression, calculated as transcripts per million using Ward’s 
hierarchical cluster analysis (Ward.D2) method. Number of DE genes (FDR < 0.05 according 
to edgeR) associated with each treatment was calculated using pair-wise comparison at (B) 24 
hours and (C) 48 hours timepoint. Treatments were compared column versus row. Up-regulated 




Fig. 6: Over-representation analysis of GO functional annotation and KEGG pathway 
perturbation analysis. (A) Over-represented GO terms (Biological Process, BP=3) for DE 
genes identified from comparison of subtractive fraction treated cells against CKI treatment in 
order to show the relative change from depleting compounds. Gene ratio of each term 
calculated from Cluster Profiler was plotted based on the adjusted p-values. Top 5 most 
significant categories of GO terms were plotted by default. Colour gradient of adjusted p-values 
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ranging from red to blue in order of increasing p-values (high to low significance). Number of 
identified genes in each treatment (numbers in parentheses) were shown in the bottom and the 
sizes of the dots correspond to the ratio of gens out of all significant DE gene from each 
treatment involved in the particular terms. (B) Identification of significantly perturbed 
pathways using SPIA (pG < 0.05) analysis. Eighty-six significantly perturbed pathways from 
twenty-two comparisons were found (Sup. Fig. 10). Only 15 pathways most obviously linked 
to our phenotypes of cell viability, cell cycle and apoptosis were shown here. Positive (overall 
increase in gene expression for pathway) and negative (overall decrease in gene expression for 
pathway) perturbation accumulation values of the pathways were shown in red and blue 




Fig. 7: Differential gene expression profiles of all treatments for Cytokine-Cytokine Receptor 
pathway. The left panel shows comparison of subtractive fraction treated cells against CKI 
treatment and the right panel shows comparison of single compound subtractive fraction treated 
cells against the treatments for two and three compound subtractive fractions. Asterisks in 




Fig. 8: Differential gene expression profiles of all treatments for Cell Cycle pathway. The left 
panel shows comparison of subtractive fraction treated cells against CKI treatment and the 
right panel shows comparison of single compound subtractive fraction treated cells against the 
treatments for two and three compound subtractive fractions. Asterisks in green show a subset 
of genes that have opposite changes in gene expression across treatments.  
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Table 1: Summarized results of HPLC fractionation and treatments using three cell-based assays. N represents the number 
of all compounds contained in CKI. Significant results of CKI treatment were calculated based on UT whereas those of 
other treatments were calculated based on CKI treatments. Statistically significant results were represented as P < 0.05 (*) 
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N-1 
N-Mac      
N-Ade      
N-Tri      
N-Nme      
N-Spr      
N-Mt      
N-Omt      
N-Ospc      
N-Spc      
N-3 
N-MacAdeTri      
N-MtNmeSpr      
N-OmtOspcSpc      
N-MacOmtOspc * **** **** **** ** 
N-2 
N-MacAde      
N-MacTri      
N-AdeTri      
N-MtNme      
N-MtSpr      
N-NmeSpr      
N-OmtOspc * **** **** **** ** 
N-OmtSpc      




MacAdeTri      
MtNmeSpr      
OmtOspcSpc      




MacAde      
MacTri      
AdeTri      
MtNme      
MtSpr      
NmeSpr      
OmtOspc      
OmtSpc      
OspcSpc      
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Table 2: Concentration of 9 major compounds in CKI (N) (Batch No:20170322), remaining major compounds in N-
































































Macrozamin y = 6E-05x + 6E-05 0.996 1.1   ± 0.03 4.4 
Adenine y = 0.021x + 0.0074 0.994 0.09 ± 0.09 0.4 
N-methylcytisine y = 0.0937x + 0.042 0.9895 0.17 ± 0.02 0.7 
Sophoridine y = 0.1443x + 0.2679 0.987 0.4   ± 0.08 1.6 
Matrine y = 0.0132x + 0.7512 0.993 1.26 ± 0.06 5.04 
Sophocarpine y = 0.0343x + 0.3974 0.994 0.54 ± 0.02 2.2 
Oxysophocarpine y = 0.0371x - 0.0108 0.999 1.1   ± 0.1 4.4 
Oxymatrine y = 0.0132x + 0.6226 0.992 6.1   ± 0.09 24.4 
Trifolirhizin y = 0.0026x - 0.0002 0.990 0.08 ± 0.002 0.3 
Total 10.8 43.4 
N-OmtOspc 
Macrozamin y = 6E-05x + 6E-05 0.996 1.1   ± 0.04 4.4 
Adenine y = 0.021x + 0.0074 0.994 0.3   ± 0.5 1.2 
N-methylcytisine y = 0.0937x + 0.042 0.9895 0.03 ± 0.03 0.1 
Sophoridine y = 0.1443x + 0.2679 0.987 0.3   ± 0.07 1.2 
Matrine y = 0.0132x + 0.7512 0.993 1.7   ± 0.1 6.8 
Sophocarpine y = 0.0343x + 0.3974 0.994 0.3   ± 0.01 1.2 
Trifolirhizin y = 0.0026x - 0.0002 0.990 0.07 ± 0.01 0.3 
Total 3.8 15.2 
N-
MacOmtOspc 
Adenine y = 0.021x + 0.0074 0.994 0.06   ± 0.09 0.2 
N-methylcytisine y = 0.0937x + 0.042 0.9895 0.02   ± 0.01 0.1 
Sophoridine y = 0.1443x + 0.2679 0.987 0.04   ± 0.02 0.2 
Matrine y = 0.0132x + 0.7512 0.993 1.7     ± 0.06 6.8 
Sophocarpine y = 0.0343x + 0.3974 0.994 0.2     ± 0.02 0.8 
Trifolirhizin y = 0.0026x - 0.0002 0.990 0.08   ± 0.003 0.3 
Total 2.1 8.4 
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Chapter 3
Compound Kushen Injection, a natural compound
mixture, and its identified chemical components
differentially slow migration and invasion in colon, brain
and breast cancer cell lines
As a result of previous work that showed that CKI significantly disrupted the cell cycle
and induced apoptosis in breast cancer cells, I hypothesized that CKI might also cause
a previously unrecognized inhibition of cancer cell migration and invasion. Effects of
CKI on migration were tested using the complete mixture, fractionated subsets, and single
identified chemical components in various cell lines. Fractionation and reconstitution
experiments showed that multiple compounds in CKI are required to inhibit cell migration.
Transcriptomic analyses of the cancer cells after CKI-treatment indicated down-regulation
of gene expression for actin cytoskeleton and focal adhesion pathways, consistent with the
observed impairment of cell migration by CKI. Work here identifies the pharmacological
complexity of CKI as an important feature of its effectiveness in blocking migration and
invasion of cancer cells. This chapter is in the format of the manuscript that was submitted
to Molecular Cancer. Specific Aim1: To fractionate and reconstitute CKI in order to
determine the effects on cell migration of reconstituted mixtures as compared to complete
CKI in various cancer and non-cancer cell lines. Specific Aim2: To identify the molecular
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Metastatic secondary tumors are a major cause of cancer-related deaths worldwide. Traditional 29 
Chinese medicines (TCM) are promising sources of new agents with anti-30 
metastatic activities.  Compound Kushen Injection (CKI), extracted from two traditional 31 
medicinal plants, Kushen (Sophora flavescens) and Baituling (Heterosmilax chinensis), 32 
contains a mixture of alkaloids and flavonoids.  Prior work has shown that CKI disrupts the 33 
cell cycle and induces apoptosis in breast cancer MCF7 cells, but effects on cancer cell 34 
migration and invasion remained unknown.  35 
Methods 36 
We tested effects of CKI, fractionated subsets, and single identified chemical components on 37 
migration in colon (HT-29, SW-480, DLD-1), brain (U-87 MG, U-251 MG), and breast (MDA-38 
MB-231) cancer cell lines. Cell lines from human embryonic kidney (HEK-293) and Human 39 
Foreskin Fibroblasts (HFF) were used as non-cancerous controls.  40 
Results  41 
Circular wound closure, transwell invasion, and live cell imaging assays showed that CKI 42 
significantly reduced migration and invasion in all eight cell lines. The greatest inhibition of 43 
migration (as measured by wound closure rates) was seen in HT-29 and MDA-MB-231 cells, 44 
and the smallest effect in HEK-293. Fractionation of CKI and selective reconstitution showed 45 
that multiple compounds in combination were required to inhibit cell migration. Live cell 46 
imaging confirmed that CKI was highly effective in reducing migration of HT-29 colon and 47 
MDA-MB-231 breast cancer cells, and was moderately effective on brain cancer cells, as 48 
compared with no effect on non-cancerous HEK-293. CKI robustly blocked cell invasion 49 
through extracellular matrix across all cell types. Apoptosis measured by an annexinV/PI assay 50 
was significantly increased by CKI treatment in MDA-MB-231 cells but not in the non-51 
cancerous cells.  Cytotoxicity measured by Alamar Blue assay showed CKI had no effect on 52 
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cell viability for any cell lines.  Transcriptomic analyses comparing MDA-MB-231 with and 53 
without CKI-treatment indicated that actin cytoskeletal and focal adhesion gene expression 54 
were down-regulated, consistent with the observed impairment of cell migration by CKI.  55 
Conclusions 56 
Work here identifies the pharmacological complexity of CKI as an important feature of its 57 
effectiveness in blocking migration and invasion of cancer cells. 58 
 59 
Keywords: Traditional Chinese Medicine (TCM), Compound Kushen Injection (CKI), Cell 60 





Cancer progression results from uncontrolled migration of cells away from the primary tumor, 64 
intravasation into lymphatic or vascular circulation, invasion into secondary tissues and the 65 
formation of metastasized tumors [1, 2] which are the main cause of cancer-related deaths [3-66 
5]. Migrating cells generate a driving force for cell motility based on the extension of filipodia 67 
and lamellipodia using actin polymerization at the leading edges of the cell  [6]. New 68 
approaches for enhancing cancer treatment by impairing cell migration and metastasis might 69 
offer promise for curing patients with malignancies. Combinations of anticancer therapeutic 70 
regimens that not only reduce cell proliferation but also limit metastasis would be advantageous 71 
[7-9].  72 
Herbal medicines are used in complementary and traditional medicines  [10-12].  TCM relies 73 
on natural product extracts containing complex mixtures of components,  suggested to deliver 74 
therapeutic benefit to individuals suffering from non-small cell lung cancer, liver, breast, and 75 
colorectal cancers [12-14]. The inherent complexity of TCM suggests principle components 76 
might act in concert with adjuvant components, explaining an apparent synergy in therapeutic 77 
benefits seen from the whole extract as compared to individual compounds [15]. Modulation 78 
of multiple regulatory signaling targets has been proposed as essential for the anti-proliferative, 79 
anti-migratory and anti-metastatic properties of TCMs [16, 17].  80 
Compound Kushen Injection (CKI) has been used in combination with chemotherapies such 81 
as oxaliplatin and 5-fluorouracil in China since 1995 for the treatment of  gastric, liver and 82 
non-small cell lung carcinomas [18]. Composed of alkaloids, flavonoids, organic acids 83 
and saccharides [19], CKI has been reported to boost immunity, decrease inflammation, and  84 
decrease metastasis [20], for example by repressing RNA markers associated with tumor 85 
metastasis  in MCF-7 cells [17, 18], and impairing migration in hepatocellular carcinoma cells 86 
[21].  The challenge for defining mechanisms of action of TCMs such as CKI is to understand 87 
the differential activities of chemical components not only singly but in combination, 88 
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recognizing the likely involvement of multiple gene expression and signaling pathways in the 89 
beneficial outcomes [22].  90 
Work here is the first to show that CKI and defined chemical fractions slow cancer cell 91 
migration and invasion, and to use systems biology to identify sets of genes linked to cell 92 
migration that are regulated by CKI treatment. Differential expression of genes in the actin 93 
cytoskeleton and focal adhesion pathways supports the idea that the therapeutic activity of CKI 94 





Cell lines  98 
MDA-MB-231, HT-29, SW-480, DLD-1, U-87 MG, U-251 MG and HEK-293 were purchased 99 
from the American Type Culture Collection (ATCC, Manassas, VA) and HFF was kindly 100 
provided by Dr. Eric Smith (Basil Hetzel Institute, The Queen Elizabeth Hospital, SA, 101 
Australia). DLD-1 cells were grown in RPMI (Roswell Park Memorial Institute) culture 102 
medium (Thermo Fisher Scientific, MA, USA) with 10 % fetal bovine serum (FBS, Thermo 103 
Fisher Scientific). All other cell lines were cultured in Dulbecco Modified Eagle Medium 104 
(DMEM, Thermo Fisher Scientific) with 10 % FBS, except for HFF (which contained 15 % 105 
FBS), at 370C in 5 % CO2.  106 
 107 
CKI preparation and other chemicals  108 
CKI (Batch No: 20170322, total alkaloid concentration of 25 mg/ml) was obtained from 109 
Zhendong Pharmaceutical Co. Ltd (Shanxi, China). High performance liquid chromatography 110 
(HPLC) fractionation and liquid chromatography-mass spectrometry (LC-MS/MS) were used 111 
to analyse single compounds and confirm their concentrations in CKI.  Fractionation of CKI 112 
was done by using Shimadzu HPLC SPC-M20A photodiode-array UV-Vis detector (Japan) 113 
equipped with a C18 column (5 µm, 250 x 10 mm; Phenomenex, CA, USA), with methods for 114 
fractionation and concentration determinations as described previously [23] (Supplementary 115 
Figs. 2 and 3).   The nine compounds comprising the major fraction (MJ): oxymatrine, 116 
oxysophocarpine, n-methylcytisine, matrine, sophocarpine, trifolirhizin, adenine, and 117 
sophoridine were purchased as isolated compounds from Beina Biotechnology Institute Co., 118 
Ltd (Shanxi, China), and macrozamin was obtained from Zhendong Pharmaceutical Co. Ltd 119 
(Beijing, China). Two-fold serial dilutions from 2 mg/ml through to 0.25 mg/ml of total 120 
alkaloids in CKI, as well as equivalent dilutions of the MJ and minor (MN) fractions were used 121 
for bioassay experiments on the cancer and non-cancerous cell lines and compared with effects 122 
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of vehicle control treatments; 0.25 % Tween 80 (Sigma-Aldrich, MO, USA) and 10 mM 123 
HEPES (Thermo Fisher Scientific) in the same cell lines.  124 
 125 
Circular wound closure assay 126 
Two-dimensional (2D) cell migration was measured using circular wound closure rates  [24]. 127 
CKI-based and vehicle control treatments were applied in low serum DMEM, with the mitotic 128 
inhibitor 5-fluoro-2'-deoxyuridine (FUDR). Initial wound areas were imaged at 0 hour (10x 129 
objective) with a Canon EOS 6D camera (Canon, Tokyo, Japan) on an Olympus inverted 130 
microscope (Olympus Corp., Tokyo, Japan); XnConvert software was used to standardize the 131 
images. NIH ImageJ software (U.S. National Institutes of Health, MD, USA) was used to 132 
quantify wound areas at 0 hour and at a second timepoint (18 to 24 hours), set for each cell line 133 
to ensure wounds were not completely closed. Experiments were independently repeated three 134 
times, with four to eight replicates. 135 
 136 
Transwell invasion assay 137 
Invasion assays were performed in 24-well transwell inserts (6.5 mm, 8 µm pore size; Corning® 138 
Transwell polycarbonate; Sigma-Aldrich). The upper surface of the filter was layered with 139 
extracellular matrix (ECM) gel from Sigma-Aldrich (at dilutions empirically optimized for 140 
each cell line; Additional file 9: TableS1), allowed to dry overnight, and rehydrated with 50 µl 141 
of serum-free media per insert for 1 hour prior to cell seeding. Cultures were grown to 40 % 142 
confluence and then starved in medium with 2 % FBS serum for 24 hours prior to seeding. 143 
Cells were detached (at ≤ 80 % confluency) and resuspended in serum-free culture media 144 
(Additional file 9: TableS1). Cells were then seeded in transwell inserts (total 150 µl of cell 145 
suspension per transwell, including 50 µl of rehydration medium added earlier) at appropriate 146 
number of cells per well in the presence of CKI, MN or MJ at 2 mg/ml, or vehicle control 147 
medium. The chemoattractant gradient was created with 700 µl of culture medium (containing 148 
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the relevant CKI-based or vehicle treatment), with 5 %, 10 %, or 15 % FBS for HEK-293, 149 
cancerous cells, or HFF, respectively. Depending on invasion characteristics, cells from each 150 
line were incubated for an optimized time period ranging from 5 to 24 hours at 37°C in 5 % 151 
CO2. Non-invasive cells were scraped from the upper surface of the filter with a cotton swab; 152 
migrated cells on the bottom surface were counted after staining with crystal violet (Sigma-153 
Aldrich). The average number of invasive cells was calculated from three randomly selected 154 
fields (x100 magnification). Cell counts were normalized to numbers in the vehicle control 155 
treatment. Three independent experiments were carried out with two replicates. 156 
 157 
Cytotoxicity assay 158 
Cell viability was measured with the Alamar Blue assay [25]  according to the manufacturer's 159 
instructions (Thermo Fisher Scientific). Cells were seeded in 96-well plates in media with 2 % 160 
FBS and FUDR. After overnight incubation, treatments were applied, and cultures were 161 
incubated for 24 hours. After application of 10 % Alamar Blue solution (30-90 minutes), 162 
fluorescence was measured by using FLUOstar Optima microplate reader. Mercuric chloride 163 
(2.5 mM) served as a positive control, inducing cytotoxic cell death. A control sample with 164 
medium and treatment agent only (no cells) was included for background color subtraction. 165 
 166 
Apoptosis assay  167 
Apoptosis assays based on annexin V and propidium iodide staining were performed as 168 
described previously [17]. Briefly, MDA-MB-231, HEK-293 and HFF cells were seeded in 6-169 
well trays and treated with 2 mg/ml of CKI. After 24 hours of treatment, cells were harvested, 170 
and levels of apoptotic cells were measured using the Annexin V-FITC detection kit (Thermo 171 
Fisher Scientific) according to the manufacturer's guidelines. Cells were acquired on a 172 
LSRFortessa X-20 (BD Biosciences, NJ, USA) and data were analyzed using FlowJo software 173 
(TreeStar Inc., OR, USA). 174 
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Live cell imaging 175 
Cells in 96 well plates were cultured to 80 % confluency, then serum-starved for 12-18 hours 176 
in optimal culture media with 2 % FBS and 400 nM FUDR. Wounds were created as circular 177 
lesions in the confluent monolayers, and treatments were added as described for the circular 178 
wound closure assay above. Plates were placed in an enclosed humidified chamber at 37°C 179 
with 5 % CO2 for 20 hours, and images were acquired at 15-minute intervals with a Nikon Ti 180 
E Live Cell Microscope (Nikon, Tokyo, Japan) using Nikon NIS-Elements software. Time-181 
lapse movies as AVI files were exported from NIS-Elements. ImageJ (U.S. National Institutes 182 
of Health) was used to convert the exported files into TIFF files and converted files were then 183 
analyzed using Fiji software [26].  184 
 185 
Immunofluorescence labelling and confocal microscopy  186 
Cells were plated in µ-Plate 8 Well dishes (Ibidi, Munich, Germany), in 2 % FBS with FUDR 187 
400 nM in optimal culture media and incubated 12-18 hours at 37°C in 5 % CO2. The following 188 
day, 2 mg/ml of CKI, MN, MJ or vehicle control treatments were applied, and cells were 189 
incubated for 24 hours. After washing with phosphate-buffered saline (PBS), cells were fixed 190 
in 4 % paraformaldehyde (at room temperature for 10-30 min), rinsed 2-3 times with PBS, and 191 
permeabilized with 200 µl of 0.1 % Triton X-100 in PBS (3-5 minutes at room temperature). 192 
After 2-3 washes with PBS, Phalloidin-iFluor 488 Reagent CytoPainter (ab176753; Abcam, 193 
MA, USA) at 200 µl per well was used to stain F-actin cytoskeleton (room temperature in the 194 
dark for 1-2 hours) and washed again 2-3 times with PBS. Cell nuclei were labelled with 195 
200 µl of 1:1000 Hoechst stain (cat # 861405; Sigma-Aldrich) for 5-10 minutes. Cells were 196 






Pathway enrichment analysis of migratory genes affected by CKI 201 
RNA-sequencing (RNA-seq) data [23] of MDA-MB-231 cells treated with CKI were used to 202 
identify cell migration genes affected by CKI. Gene Ontology (GO) enrichment analyses were 203 
carried out with R package clusterProfiler 3.8.0 [27]. The following parameters for GO 204 
enrichment analysis were used: biological process at the third level; right-sided hypergeometric 205 
test; and Benjamini-Hochberg method to correct p values. Pvalue cutoff 0.05 and false 206 
discovery rate 0.1 values were used to identify significantly over-represented GO terms. 207 
Pathways that were significantly perturbed by CKI treatment were identified with Signaling 208 
Pathway Impact Analysis (SPIA) [28], and visualized using the pathview package in R [29]. 209 
KEGG (Kyoto Encyclopedia of Genes and Genomes) functional analysis was performed with 210 
R package clusterProfiler 3.8.0 [27] and OmicCircos v 1.18.0 [30]. Venn diagrams were 211 
generated using an online tool (http://bioinformatics.psb.ugent.be/webtools/Venn/). 212 
 213 
Intracellular protein staining and quantification by flow cytometry  214 
Cells cultured in 6-well trays were treated with CKI, MN or MJ as described above, harvested 215 
after 24 hours, fixed and permeabilized using Nuclear Factor Fixation and Permeabilization 216 
Buffer Set (Biolegend, CA, USA) according to the manufacturer’s instructions. 2×105 cells 217 
were labelled with rabbit anti-Cyclin D1 (CCND1) (92G2, Cell Signaling Technologies, MA 218 
USA), rabbit anti-b-actin (ACTB) (D6A8, Cell Signaling Technologies), rabbit anti-protein 219 
kinase B (AKT1, 2, 3) (Ab32505, Abcam) or rabbit IgG isotype control (Cell Signaling 220 
Technologies), and these antibodies were detected with anti-rabbit IgG-PE (Cell Signaling 221 
Technologies). For detection of b-catenin, rabbit anti-b-catenin (CTNNB1)-Alexa Fluor 647 222 
and isotype control for CTNNB1 rabbit IgG-Alexa Fluor 647 (Abcam) were used. The cells 223 
were then sorted, and the data were acquired on a BD LSRFortessa X-20. Sorting parameters 224 
were set to gate and exclude small particles such as cell debris and large duplex cells. The data 225 
were analysed using FlowJo software.   226 
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Statistical tests 227 
Statistical analyses were carried out using GraphPad Prism 8 software (San Diego, CA, USA) 228 
with one-way ANOVA. Statistically significant results were represented as p < 0.05 (*) or p < 229 
0.01 (**) p < 0.001 (***), or p < 0.0001 (****); ns (not significant). All data are shown as 230 
mean ± standard deviation (SD); n values for independent samples are indicated in italics above 231 




Results  234 
Functional annotation of MDA-MB-231 transcriptome treated by CKI 235 
Transcriptome [23] analyses were performed to identify over-represented Gene Ontology (GO) 236 
terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) for all differentially expressed 237 
(DE) genes by comparing MDA-MB-231 gene expression profiles with and without CKI 238 
treatment (Fig. 1 and Additional file1: FigureS1).  Differences in gene expression levels were 239 
used to identify migration related GO terms and pathways of interest, which were classified by 240 
functional roles via GO and KEGG over-representation analyses. Enriched GO terms 241 
connected to cell migration such as “positive regulation of locomotion”, “tissue migration “and 242 
“leucocyte migration” emerged from analyses of DE genes in CKI-treated MDA-MB-231 cells 243 
(Additional file 1: FigureS1 and Additional file 6: DataS1). Integration of DE genes associated 244 
with CKI treatment into KEGG pathways showed that some of the most over-represented 245 
pathways were “focal adhesion”, “regulation of actin cytoskeleton”, “pathways in cancer”, 246 
“TGF-b signaling pathway” and “adherens junction” (Fig. 1). These results indicated that many 247 
of the genes affected by CKI treatment were involved in cell migration-related pathways.  248 
 249 
Identification of CKI components  250 
CKI was fractionated and components were selectively recombined to create MJ and MN 251 
fractions (Fig. 2) as treatments for bioassays on cultured cells. Concentrations of the nine major 252 
compounds in CKI were measured using LC-MS/MS (see Methods). The concentrations of 253 
MJ components were determined (Additional files 2 and 3: FigureS2 and S3) from calibration 254 
curves of nine standard compounds as previously described [23] and summarized in Table 255 
1. The total concentration of the nine major compounds in CKI was 9.99 mg/ml which 256 
accounted for approximately 40 % of the dry mass of CKI, and the total concentration of the 257 
nine compounds in MJ was 8.62 mg/ml, indicating that the major compounds were clearly 258 
fractionated from CKI, and that MJ and MN components were well separated.   259 
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Impairment of cell migration by CKI and fractionated mixtures  260 
Effects of CKI on two-dimensional cell migration were assessed using a circular wound healing 261 
assay (Fig. 3a). Percent wound closure after 20 hours was calculated based on the initial wound 262 
area. CKI-based treatments were tested on eight different cancer cell lines (HT-29, SW-480, 263 
DLD-1, U-87 MG, U-251 MG and MDA-MB-231) and two non-cancerous cell lines (HEK-264 
293 and HFF), at five doses ranging from 0 to 2 mg/ml (Fig. 3b). In all cell lines, net migration 265 
rates were inhibited more by CKI than by MN or MJ treatments alone, except in HEK-293 266 
which showed low sensitivity to CKI. The retention of biological activity in the fractionated 267 
MJ and MN treatments was confirmed by demonstrating reconstituted CKI (in which MN and 268 
MJ were mixed together) was equally effective as CKI for blocking cell migration (Fig. 3b). 269 
The most sensitive cell lines were breast cancer (MDA-MB-231) and colon cancer (HT-29).  270 
DLD-1 and HEK-293 cell lines were the least sensitive.  271 
 272 
In all the CKI-sensitive cell lines, the inhibition of migration by MN alone was greater than 273 
that seen with MJ alone (Fig. 3b), but neither treatment was as potent as CKI in any cell line. 274 
To determine if a single compound in MJ accounted for the enhanced inhibition seen with co-275 
application of MJ and MN, each of the isolated major compounds alone was added in turn to 1 276 
mg/ml MN, at a final concentration equal to its original concentration in 2 mg/ml CKI. Wound 277 
healing assays showed certain compounds added to MN produced a significantly greater 278 
inhibition than MN alone, but the effective compounds and levels of potency differed between 279 
cell lines (Fig. 4 and Additional file 4: FigureS4). Matrine was effective in MDA-MB-231, 280 
HT-29 and U-251 MG cell lines; sophocarpine was effective in HEK-293; trifolirhizin was 281 
effective in HT-29, SW-480 and U-251 MG; and adenine was effective in HT-29 cells, as 282 
determined by a significant decrease in migration as compared to MN alone. More than one 283 




None of the CKI-based treatments induced significant cytotoxicity at 1 or 2 mg/ml, as assessed 286 
by Alamar Blue assays (Fig. 5a, b and c). The lack of cytotoxicity suggested that the observed 287 
impairment of the two-dimensional cell migration was not an indirect consequence of reduced 288 
cell viability. However, CKI at 2 mg/ml substantially increased apoptosis in MDA-MB-231 289 
and moderately increased apoptosis in HEK-293 cells, without a significant effect on HFF (Fig. 290 
5d, e, f and g). These data extend prior work which showed CKI increased apoptosis in MCF-291 
7 breast cancer cells (Qu et al., 2016), and support the idea that multiple responses induced by 292 
CKI could contribute to its overall anti-cancer effects.  293 
 294 
To quantify the effects of CKI on two-dimensional cell motility in vitro in more detail, 295 
trajectories of individual cells were monitored in real time using live cell imaging (Fig. 6). 296 
Vehicle-treated cells were compared with those treated with 2 mg/ml CKI, or 1 mg/ml MN 297 
or MJ (doses equal to their concentration in CKI). Data were compiled for representative 298 
cells from six cancer and two non-cancerous cell lines. Positions of individual cells as a 299 
function of time over 20 hours were determined by the location of the cell nucleus (Fig. 6a).  300 
Distances moved per unit time interval showed a Gaussian distribution; the peak position 301 
illustrates the mean distance travelled per increment. Significant displacement of the curve to 302 
the left (representing a decreased mean distance travelled per time interval) was evident for 303 
CKI treatment in all cell lines as compared to vehicle-treated controls (Fig. 6b, and Additional 304 
file 5: VideoS1). Significant reductions in mean distance by either MN or MJ were observed 305 
in HT-29 and SW-480 cells. Reductions in mean distance by MN but not MJ were seen in U-306 
87 MG, MDA-MB-231 and HFF cells. U-251 MG and DLD-1 cancer cells responded only to 307 
whole CKI. The effectiveness of CKI in blocking migration depended on the simultaneous 308 
presence of multiple minor and major compounds, but the specific agents conferring anti-309 




Impairment of invasiveness by CKI treatments in cancer and non-cancer cell lines  312 
A transwell Boyden chamber assay with ECM-coated filters was used to measure the 313 
invasiveness of cells in response to a serum chemoattractant gradient in vehicle control, CKI, 314 
MN, and MJ treatment conditions (Fig. 7). CKI treatment and the combined MN+MJ treatment 315 
(i.e., reconstituted CKI) both significantly reduced invasiveness in all cell types. Smaller but 316 
significant decreases in invasiveness were seen with MN alone in all cell types except SW-480 317 
and were seen with MJ alone in all but SW-480 and MDA-MB-231 cell lines. These results 318 
suggested that a combination of major and minor components of CKI was required for maximal 319 
inhibition of invasiveness through extracellular matrix barriers.  320 
 321 
Transcriptome analysis of MDA-MB-231 cells treated with CKI 322 
Functional enrichment analysis was used to narrow the field of candidate mechanisms 323 
potentially associated with the anti-migratory effects of CKI. Perturbations of KEGG Pathways 324 
that were significantly over-represented in DE genes affected by CKI treatment were further 325 
analysed using SPIA (Fig. 8a and Additional file 7: DataS2). “Melanogenesis”, “TGF-b 326 
signaling pathway”, “focal adhesion”, “regulation of actin cytoskeleton”, “ErbB signaling 327 
pathway”, and “GnRH signaling pathway” were significantly perturbed based on 'global 328 
perturbation values' (pG<0.05), consistent with the results of the KEGG analysis. Together, 329 
these analyses provided evidence that CKI was likely to impair cell migration by altering both 330 
adhesion and motility (Fig. 8b and c). To explore this idea, genes from two strongly affected 331 
pathways (“focal adhesion” and “actin cytoskeleton”) were characterised by comparing three 332 
independent gene datasets: (i) a set containing 135 Tumor Alterations Relevant for Genomics 333 
driven Therapy (TARGET) genes; (ii) a set containing 140 migration related genes collected 334 
from published articles; and (iii) a set containing 1381 genes from KEGG pathways. We 335 
identified 14 clinically relevant DE genes, which were:  CTNNB1, CDH1, AKT1, AKT2, AKT3, 336 
CCND1, MAPK1, JAK2, APC, CDK4, RB1, PIK3CA, and PTEN, all of which have been shown 337 
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to affect cell migration (Fig. 8d, Additional file 8: DataS3 and Additional file 10: TableS2), 338 
suggesting that the slowing of cell migration could be clinically relevant to CKI treatment 339 
outcomes.  340 
 341 
CKI interrupts F-actin polymerization  342 
The results of functional enrichment analysis highlighted the actin cytoskeleton and focal 343 
adhesion pathways as potential targets of CKI. As a result, we decided to examine the effect of 344 
CKI on F-actin polymerization, filopodia formation and lamellipodia extension using 345 
confocal microscopy in all eight cell lines (Fig. 9). Cells in all lines treated with CKI, MN 346 
and MJ (at doses equal to those in 2 mg/ml CKI) at 24 hours were smaller and lacked cellular 347 
processes such as lamellipodia as compared to vehicle control treated. Abundant 348 
lamellipodia seen in the control treatment were visibly diminished in the treatment groups. 349 
Comparing responses within the treatment groups, CKI disrupted the lamellipodia 350 
extensions more than was seen with MN or MJ alone. The impairment of F-actin 351 
polymerization was consistent with the idea that MN and MJ fractions both contribute slowing 352 
cell migration. 353 
 354 
CKI and fractionated mixtures perturb the actin cytoskeleton 355 
To validate the gene expression changes at the protein level, we performed flow cytometry 356 
analyses of four proteins; CTNNB1, AKT (1, 2, 3), CCND1, and ACTB, selected for their 357 
significant contributions in actin cytoskeleton and focal adhesion pathways in MDA-MB-231 358 
and HEK-293 cell lines. Results shown in Fig. 10 indicated that CKI, MN and MJ significantly 359 
downregulated the protein expression, confirming the gene expression data. While there was 360 
prominent down-regulation of CTNNB1 expression in MDA-MB-231 by all treatments, AKT 361 
(1, 2, 3) was downregulated by CKI and MN but not MJ treatments. In HFF cells, all treatments 362 
downregulated ACTB and CCND1 significantly; CKI and MN significantly reduced AKT (1, 363 
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2, 3) expression whereas MJ caused significant increase. In contrast, in the HFF cell line, 364 
CTNNB1 protein expression was significantly increased by CKI and MN, but significantly 365 
downregulated by MJ. In HEK cells, CKI upregulated ACTB, AKT and CCND1, whereas MN 366 
upregulated ACTB and downregulated CCND1; MJ had no significant impact on these four 367 
proteins (Fig. 10). These results showed that CKI, MN and MJ significantly downregulated the 368 
four proteins in MDA-MB-231 cells, with similar although not identical results in the two non-369 
cancer cell lines, providing additional support for the idea that CKI affects cancer cell migration 370 





Natural compounds with anti-cancer activities have been suggested to include potential anti-374 
metastatic agents  [17, 21, 31, 32]. Clinical chemotherapeutics for cancers are targeted mainly 375 
to killing rapidly dividing cells [33], but  cause serious side effects including 376 
immunosuppression, hair loss and infertility, without eliminating risks of secondary neoplasms 377 
[34]. Non-toxic treatments to reduce metastasis as adjuncts to primary cancer therapies are 378 
greatly needed. CKI increased apoptotic activity in breast cancer MCF-7 and hepatocellular 379 
carcinoma HCC cell lines [17, 21]. Results here showed that CKI also significantly slowed cell 380 
migration and invasion, an outcome consistent with its beneficial clinical effects. The 381 
complexity of TCM presents a challenge for identifying single active compounds. By 382 
separating components of CKI into major and minor groups, and by adding novel screens for 383 
migration and invasion into the analyses of CKI biological activity, we have shown that co-384 
application of multiple compounds was far more effective in blocking cell migration than 385 
single agents alone, and that different compounds (serendipitously combined in CKI) are 386 
required for activity across diverse cell types.   387 
 388 
Components of CKI have both anti-proliferation and anti-migration activities which differ 389 
between cell lines, suggesting that refinement of the TCM composition could enable 390 
customized management for different cancer types. A subset of the major compounds in CKI 391 
have been investigated previously.  For example, oxymatrine impaired angiogenesis in mouse 392 
breast cancer in vitro and in vivo, by altering NF-κB pathway and VEGF signaling [35]. 393 
Matrine inhibited migration and proliferation of mouse lung adenocarcinoma in vitro and 394 
slowed xenograft growth  in vivo, by reducing expression of a calcium-dependent chloride 395 
channel shown to be upregulated in multiple cancer types [36, 37]. Consistent with these 396 
findings, we found matrine added to the CKI minor fraction further impaired cancer cell 397 
migration (Fig. 4); however, in contrast, addition of oxymatrine to the CKI minor fraction did 398 
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not affect the control of migration in any of the cell lines we tested. Oxysophocarpine slowed 399 
metastasis of oral squamous cell carcinoma in vitro and in vivo, by altering transcription factor 400 
Nrf2 and stress protein signaling pathways [38]. In contrast, our results showed 401 
oxysophocarpine partially reversed the inhibition of migration observed with the CKI minor 402 
fraction.  Work here showed that the major components trifolirhizin and adenine, not 403 
previously characterized, when added to CKI minor fraction further slowed cell migration, 404 
suggesting these agents merit further study as potential therapeutics, singly and in combination.  405 
Not all components of CKI enhance its anti-cancer activities; for example, depletion of three 406 
compounds (oxymatrine, oxysophocarpine and macrozamin) increased the anti-proliferative 407 
activity of CKI [23]. 408 
 409 
Rational analysis of the differential effects of agents in a TCM mixture can benefit from 410 
quantitative systems biology approaches. Transcriptomics has proven valuable for identifying 411 
altered patterns of global gene expression in response to complex agents such as CKI [18]. Our 412 
pathway analysis of the transcriptome of CKI-treated MDA-MB-231 cells revealed a strong 413 
association with genes linked to “TGF-b signaling”, “focal adhesion”, “GnRH signaling”, and 414 
“regulation of actin cytoskeleton”. These pathways are linked with migratory phenotype, actin 415 
polymerization and lamellipodia protrusion [39]  [40] [41]. Focal adhesion sites are points of 416 
contact with extracellular matrix, anchoring actin filaments via protein complexes with 417 
transmembrane integrin  receptors [42]. Matrine has been reported to disrupt actin filament 418 
organization in DLD-1 colorectal adenocarcinoma cells [43]. Work here is the first to show 419 
that treatment with whole CKI significantly perturbed “focal adhesion” and “regulation of actin 420 
cytoskeleton” pathways, and to confirm predictions of the transcriptomic results by showing 421 




Two striking outcomes of our pathway analyses were the significant negative perturbation 424 
of the cytokine Transforming growth factor beta (TGF-b) and positive perturbation of 425 
Gonadotropin-releasing hormone (GnRH) signaling pathways by CKI treatment. 426 
Multifunctional TGF-b promotes the process of epithelial-mesenchymal transition, which 427 
facilitates cell migration, invasion and metastasis  [44, 45]. Reduced TGF-b signaling would 428 
be consistent with our findings of impaired invasion and migration with CKI treatment. 429 
Conversely, GnRH activity has been associated with attenuating migration of DU145 human 430 
prostatic carcinoma cells by remodelling the actin cytoskeleton [46]. Increased GnRH 431 
signaling would be consistent with beneficial effects of CKI treatment. Further work is 432 
needed to fully understand the mechanisms of action of CKI on cell migration and invasion, 433 
the signaling pathways involved, the synergistic effects of combined therapeutic agents, and 434 
the translational potential by extending these analyses to metastatic cancer cells in vivo.  435 
 436 
Conclusions 437 
The primary outcome of this study is the demonstration that cancer cell migration and invasion 438 
rates are significantly reduced by CKI, suggesting that therapeutic activity of CKI in human 439 
cancer patients may arise in part from downregulation of a panel of key molecular targets 440 
necessary for adhesion and motility in metastasis. The secondary outcome of this study is that 441 
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Fig. 1:  Summary of the KEGG analyses of over-represented pathways for differentially 627 
expressed genes after CKI treatment in MDA-MB-231 cells. From outer to inner, the first circle 628 
indicates the pathways; the second shows the genes involved; and the third summarizes 629 
significant changes in expression for transcript levels that were upregulated (red) or 630 





Fig. 2: HPLC profiles of the components present in (a) CKI, (b) MJ and (c) MN fractions.  634 
Samples (50 µl at 1 mg/ml) were run through a C18 semi-preparative column.  Numbers 635 
indicate the nine major compounds; 1: macrozamin, 2: adenine, 3: n-methylcytisine, 4: 636 






Fig. 3: Dose-dependent inhibition of cell migration by CKI, MJ and MN fractions in eight cell 641 
lines, measured by wound closure assays. (a) Wound areas were imaged at 0 hour (initial) and 642 
after 20 hours of treatment. (b) Graphs show percent inhibition of cell migration standardized 643 
to the initial wound area, as a function of dose for treatments with CKI (blue), MJ (green), MN 644 





Fig. 4: Combinatorial analysis of effects on wound closure for the MN fraction tested in 648 
combination with each of nine individual major compounds of CKI, summarized as a heatmap. 649 
Data were normalized to values for percentage of migration blocked with MN alone at 0.5 650 
mg/ml. Boxes display the net effects of added single major compounds, as no change (white), 651 
increased percentage block (red), or reduced percentage of migration blocked (blue). 652 
Statistically significant differences are shown as p < 0.05 (*), p < 0.01 (**), and p < 0.001 653 
(***).  No symbol in a box indicates the response was not significantly different from that with 654 





Fig. 5: Assessment of the effects of CKI and fractions on cell viability and incidence of 658 
apoptosis. Viability was measured by Alamar Blue assay in eight cell lines treated with (a) 659 
CKI, (b) MN or (c) MJ fractions (at doses present in 2 mg/ml CKI). Cell viability responses 660 
standardized as a percentage to mean values for vehicle control were not significantly different 661 
(ns) in any condition, based on repeated experiments with 8 replicates total. Apoptosis was 662 
compared in three cell lines with and without CKI treatment, for (d) MDA-MB-231, (e) HEK-663 
293, and (f) HFF cells, analyzed by flow cytometry (see Methods for details).  Pseudo-color 664 
plots illustrate the percentages of cells in the late (quadrant Q2) and early (Q3) stages of 665 
apoptosis. (g) Histogram summarizing compiled data (mean ± SD) depicting percentage 666 




Fig. 6: Live-cell imaging of individual cell migration trajectories, with and without the 669 
treatments in eight cell lines. Six representative cells located near wound boundaries were 670 
selected at time zero and tracked by time-lapse imaging at 10-minute intervals for 20 hours by 671 
the positions of cell nuclei. (a) Trajectory plots of individual cells, starting at the graph origin 672 
at time 0, were assigned in quadrants based on treatment groups: VC (vehicle control, blue), 673 
CKI (red), MN (green), and MJ (violet). X and Y axis values are in µm. (b) Frequency 674 
histograms of distances moved by individual cells per 10-minute interval over 20 hours. 675 
Colours indicate treatment groups, as above. Total cumulative distances moved per cell are 676 
collated in box plots (insets). Boxes enclose 50 % of values; error bars show the full range; and 677 
horizontal lines are median values.  Statistically significant difference is indicated as p < 0.05 678 




Fig. 7:  Effects of CKI and fractions on cell invasiveness in eight cell lines.  Migration 681 
efficiencies of cells across an extracellular matrix barrier after treatment with CKI, minor 682 
(MN), major (MJ), or combined (MN+MJ) fractions were measured by transwell invasion 683 
assays. (a) Images show stained cells that had passed through the filter to reach the opposite 684 
side of the transwell membrane.  CKI, MN and MJ were applied at doses equal to those present 685 
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in 2 mg/ml CKI; Ctrl is vehicle control. (b) Compiled results are shown in histograms; n-values 686 
are in italics in corresponding figure key. Statistically significant differences compared to 687 




Fig. 8: Identification of significantly perturbed pathways using SPIA analysis. (a) 101 692 
significantly perturbed pathways in MDA-MB-231 treated by CKI 2 mg/ml were observed.  693 
Total perturbation values are shown on the x-axis, and pathway IDs are on the y-axis. The 694 
global perturbation P value (pG < 0.05) was used. (b) Significantly perturbed “focal adhesion” 695 
pathway in MDA-MB-231 treated by CKI 2 mg/ml. (c) Significantly perturbed “regulation of 696 
actin cytoskeleton” pathway in MDA-MB-231 treated by CKI 2 mg/ml. Up- and down-697 
regulated genes are shown in red and green respectively and genes that were not affected by 698 
CKI treatment are shown in white or grey. (d) 14 "core genes" that are found across three 699 




Fig. 9:  Patterns of distribution of polymerized F-actin after CKI-based treatments in eight cell 702 
lines, visualized by confocal microscopy. (a) F-actin was labelled with phalloidin (green), and 703 
nuclei with Hoechst (blue), for treatment groups (from left to right): vehicle control (Ctrl), CKI, 704 
minor and major fractions at doses present in 2 mg/ml CKI. Scale bars are 50 μm. (b) Areas 705 
(µm2) of F-actin staining per cell are summarized in box plots. Statistically significant results 706 















































































































































































Fig. 10: Flow cytometry analyses of four proteins: CTNNB1, AKT (1, 2, 3), CCND1, and 710 
ACTB compared in three cell lines with and without CKI-based treatments. The levels of 711 
protein expression for four genes predicted by transcriptomic analysis to be significantly down-712 
regulated were evaluated by FACS in three cell lines (a) MDA-MB-231, (b) HEK-293, and (c) 713 
HFF. Statistically significant differences compared to vehicle controls were analysed using 714 
one-way ANOVA and post hoc tests and are shown as p < 0.05 (*), p < 0.01 (**), p < 0.001 715 











Table 1: Concentration of 9 major compounds in CKI (Batch No:20151139) and MJ. Total 725 
alkaloid content in CKI (Batch No:20151139) = 25 mg/ml based on manufacturer’s assay. 726 
Regression line for the calculation of compounds has previously been described (Aung et al., 727 
2018). 728 
 729 
*Total alkaloid content in CKI (Batch No:20151139) = 25 mg/ml based on manufacturer’s 730 
assay. Regression line for the calculation of compounds have been previously described 731 




Mixtures Compounds concentration (mg/mL) %Contribution 
CKI 
Macrozamin 1.1 ± 0.07 4.4 
Adenine 0.04 ± 0.03 1.6 
N-methylcytisine 0.2 ± 0.04 0.8 
Sophoridine 0.3 ± 0.19 1.2 
Matrine 1.7 ± 0.17 6.8 
Sophocarpine 0.5 ± 0.03 2 
Oxysophocarpine 1.2 ± 0.18 4.8 
Oxymatrine 5.6 ± 0.66 22.4 
Trifolirhizin 0.12 ± 0.01 0.4 
Total 11.1 44.4 
MJ 
Macrozamin 1.2 ± 0.17 4.8 
Adenine 0.2 ± 0.01 0.8 
N-methylcytisine 0.2 ± 0.04 0.8 
Sophoridine 0.4 ± 0.12 1.4 
Matrine 1.5 ± 0.6 6 
Sophocarpine 0.3 ± 0.003 1.4 
Oxysophocarpine 1.1 ± 0.14 4.3 
Oxymatrine 5.9 ± 0.7 23.6 
Trifolirhizin 0.05 ± 0.01 0.2 
Total 10.8 43.3 
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Chapter 4
Identification of Candidate Anti-cancer Molecular
Mechanisms of Compound Kushen Injection Using
Functional Genomics
CKI has been used clinically as a complementary medicine for cancer treatment together
with chemo- and radio-therapy over 15 years. By analysing the transcriptome of MCF-7
breast cancer cells treated by CKI, we mapped the effects CKI to specific pathways such
as the cell-cycle pathway based on altered gene expression profiles in a cell-based assay.
Reconstruction of co-expression networks in this study showed that CKI downregulated
lncRNA H19, a molecule known to be upregulated in cancer. This chapter is in the format
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ABSTRACT
Compound Kushen Injection (CKI) has been clinically used in China for over 
15 years to treat various types of solid tumours. However, because such Traditional 
Chinese Medicine (TCM) preparations are complex mixtures of plant secondary 
metabolites, it is essential to explore their underlying molecular mechanisms in a 
systematic fashion. We have used the MCF-7 human breast cancer cell line as an initial 
in vitro model to identify CKI induced changes in gene expression. Cells were treated 
with CKI for 24 and 48 hours at two concentrations (1 and 2 mg/mL total alkaloids), 
and the effect of CKI on cell proliferation and apoptosis were measured using XTT 
and Annexin V/Propidium Iodide staining assays respectively. Transcriptome data of 
cells treated with CKI or 5-Fluorouracil (5-FU) for 24 and 48 hours were subsequently 
acquired using high-throughput Illumina RNA-seq technology. In this report we show 
that CKI inhibited MCF-7 cell proliferation and induced apoptosis in a dose-dependent 
fashion. We integrated and applied a series of transcriptome analysis methods, 
including gene differential expression analysis, pathway over-representation analysis, 
de novo identification of long non-coding RNAs (lncRNA) as well as co-expression 
network reconstruction, to identify candidate anti-cancer molecular mechanisms of 
CKI. Multiple pathways were perturbed and the cell cycle was identified as the potential 
primary target pathway of CKI in MCF-7 cells. CKI may also induce apoptosis in MCF-7 
cells via a p53 independent mechanism. In addition, we identified novel lncRNAs and 
showed that many of them might be expressed as a response to CKI treatment.
INTRODUCTION
The complexity of carcinogenesis at the genetic 
level has been investigated more and more deeply by 
leveraging fast-developing omics-related techniques 
in the past decades [1–3]. Novel genetic mutations and 
molecular markers are now comprehensively identified 
in cancer genome sequencing projects. More importantly, 
whole transcriptome analyses are much more widely used 
to identify novel cancer-related transcripts or regulatory 
elements, such as long non-protein-coding RNAs 
(lncRNAs) and alternative splicing, and are also used to 
characterise the underlying molecular mechanisms based 
on global gene expression changes in different types of 
cancers in vivo or in vitro [4–6]. The current challenge is 
to integrate these new techniques to discover or evaluate 
novel cancer therapies [7].
Traditional Chinese Medicines (TCMs) are 
experience-based remedies derived from hundreds or 
thousands of years of clinical use in China. Most TCMs 
are extracted from one or more medicinal herbs. The 
existence of multiple bioactive ingredients makes many 
TCMs potential novel resources for the discovery of new 
cancer drugs, such as multi-targeted cancer drugs [8]. 
Compound Kushen Injection (CKI, also known as Yanshu 
injection) is a State Administration of Chinese Medicine-
                  Research Paper
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approved TCM formula used in the clinical treatment of 
various types of cancers in China [9, 10]. It is extracted 
from the roots of two medicinal herbs, Kushen (Radix 
Sophorae Flavescentis) and Baituling (Rhizoma smilacis 
Glabrae), using modern standardised Good Manufacturing 
Processes (GMP) [11, 12]. The chemical fingerprint 
of CKI contains at least 8 different components, with 
primary compounds Matrine and Oxymatrine [12]. This 
indicates that multiple compounds in CKI may deliver an 
integrated anti-tumor effect through multiple targets and 
their associated molecular pathways.
By detecting the expression of key genes or proteins 
in single molecular pathways, the anti-tumor effects 
of Matrine or Oxymatrine, including the inhibition of 
cell proliferation and induction of apoptosis, have been 
demonstrated in various types of cancer [13–17]. The 
molecular mechanisms of CKI as a system have also 
been recently explored [11, 18]. Quantitative detection 
of expression changes of key regulators, including beta-
catenin, CyclinD1 and c-Myc, of the canonical Wnt/
beta-catenin pathway, have shown that CKI can suppress 
the stem cells in MCF-7 cells by down-regulating this 
signalling pathway [11]. In addition, other studies suggest 
that CKI can inhibit mouse sarcoma growth and reduce 
tumor-induced hyperalgesia via the AKT and TRPV1 
signalling pathways by reducing the phosphorylation of 
ERK and AKT kinases and BAD [18].
The main goal of modern pharmacology is to 
elucidate the molecular mechanisms that can be targeted 
by therapeutic compounds. Analyses using purified 
single components of TCM can be somewhat useful, 
but are limited when it comes to identifying integrated 
systemic effects resulting from a multi-compound 
formula. Furthermore, previous studies attempting to 
understand the mode of action of CKI have only focused 
on single or a few molecular pathways by assessing the 
expression of key regulators in these pathways. We have 
therefore, taken advantage of high throughput whole 
transcriptome analyses, and applied these to explore the 
system wide molecular mechanisms targeted by TCM. 
We have identified a comprehensive list of expressed 
genes perturbed by CKI, and used gene expression data 
to characterise molecular pathways potentially targeted 
by CKI in MCF-7 human breast cancer cells. Our results 
show that CKI can alter the expression of many cancer 
relevant genes and lncRNAs, correlated with the inhibition 
of cell proliferation through cell cycle arrest and the 
induction of apoptosis via p53 independent pathways.
RESULTS
CKI inhibits MCF-7 cell proliferation and 
induces cell apoptosis
To characterise the effect of CKI on proliferation 
of MCF-7 breast cancer cells, we used the XTT assay to 
measure cell viability after treating with different doses of 
CKI. The proliferation of MCF-7 cells was dramatically 
inhibited when treated with a high dose of CKI (2 mg/
mL, based on the total alkaloid concentration in CKI) 
and showed a dose-dependent effect (Figure 1A and 
Supplementary Figure 1A). An Annexin V/Propidium 
Iodide (PI) assay was used to quantify cell apoptosis 
when MCF-7 cells were treated with CKI. Percentage of 
apoptotic cells, particularly at the higher dose of CKI, was 
increased at both time points compared with untreated 
cells, indicating that apoptosis was induced in cells treated 
with CKI (Figure 1B and 1C). The caspase3/7 colorimetric 
assay also showed that there was increased caspase3/7 
activity in cells treated with CKI (Supplementary Figure 
1B). Altogether, these results showed that CKI could 
inhibit growth and induce apoptosis of MCF-7 cells in 
vitro.
Global gene expression changes in MCF-7 cells 
treated with CKI
To further investigate the underlying molecular 
mechanisms of CKI on MCF-7 cells, we performed 
high-depth next generation sequencing using an Illumina 
HiSeq 2500. In total, more than 732 million stranded 100 
basepairs (bp) paired-end reads were sequenced from 9 
groups of MCF-7 cells treated with two doses of CKI or 
one dose of chemotherapy drug 5-Fluorouracil (5-FU) for 
24 and 48 hours along with untreated cells (Supplementary 
Table 1) (GSE78512). The global gene expression profiles 
of CKI treated cells, particularly in cells treated with high 
dose CKI (2 mg/mL), were clearly different from the 
profile of 5-FU treated cells compared with untreated cells 
(Supplementary Figure 2). We then used edgeR to identify 
the statistically significant differentially expressed (DE) 
genes for the pairwise comparisons between cells treated 
with 1 mg/mL CKI, 2 mg/mL CKI and 5-FU for 24 or 48 
hours respectively (Figure 2 and Supplementary Table 2). 
Compared with untreated cells, fewer than 200 genes had 
significantly altered expression in cells treated with low 
dose CKI (1 mg/mL) for 24 or 48 hours (Figure 2A and 2B). 
However, many more DE genes (1,826 genes for 24 hours 
and 2,904 for 48 hours) were identified in cells treated with 
high dose CKI (2 mg/mL). Interestingly, when comparing 
the number of DE genes in cells treated with high dose CKI 
with low dose CKI, we observed almost twice as many 
genes down-regulated but only a small number of genes 
(828 to 791) up-regulated (Figure 2A and 2B). Furthermore, 
we compared DE genes in cells treated with high dose CKI 
and in cells treated with 5-FU (Supplementary Figure 3). 
For up-regulated genes in cells treated with high dose CKI 
for 24 hours, approximately half (396 out of 791) of these 
were also identified as DE genes, with most (384) being up-
regulated in 5-FU treated cells as well. 459 down-regulated 
genes were also shown as DE genes with most of these (424 
out of 459) also being down-regulated in cells treated with 
5- FU for 24 hours (Supplementary Figure 3A). After cells 
were treated with CKI or 5-FU for 48 hours, the number 
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of DE genes decreased dramatically in 5-FU treated cells, 
but greatly increased in cells treated with 2 mg/mL CKI 
(Supplementary Figure 3B). The common DE genes altered 
by CKI or 5-FU showed consistent expression changes at 
48 hours (Supplementary Figure 3B).
To validate the gene expression changes from 
transcriptome analysis, we performed quantitative PCR 
(qPCR) for 6 genes and acquired overall consistent results 
(Figure 2C, Supplementary Figure 4 and Supplementary 
Table 2).
Annotation of the molecular pathways altered by 
CKI in MCF-7 cells
Since CKI likely contains multiple bioactive 
ingredients, we used a number of systems biology methods 
to explore the molecular mechanisms of CKI.
The over-represented Gene Ontology (GO) terms for 
all DE genes identified in cells treated with high dose CKI 
(2 mg/mL) for 24 hour and 48 hours are shown in Figure 
3A and 3B. Based on their functional similarity, these 
GO terms were clustered into several primary categories, 
including “Regulation of biological process, cellular 
process and metabolic process”, “Cell differentiation, 
development”, “Transport, localisation”, “Chromatin 
organisation, organelle organisation”, “Cell motility and 
migration” and “Secondary metabolic processes and 
reactive oxygen species metabolic”. Interestingly, we 
found that the majority of cell growth or proliferation 
related GO terms included more down-regulated genes, 
while GO terms associated with “Secondary metabolic 
processes and reactive oxygen species metabolic” showed 
enrichment of more up-regulated genes (Figure 3A). 
In MCF-7 cells treated with CKI for 48 hours, similar 
categories of over-represented GO terms seen at 24 
hours were also observed, such as “Metabolic process”, 
“Regulation of metabolic process” and “Localization”. In 
addition, cell proliferation related terms, including “Cell 
cycle”, “Cell growth” and “Cell death” were also over-
represented in DE genes from cells treated with CKI for 
48 hours (Figure 3B). Furthermore, we compared the over-
representation of GO terms of the 200 most significantly 
Figure 1: CKI inhibits proliferation and induces apoptosis of MCF-7 cells. A. Inhibition of MCF-7 cell proliferation with CKI 
treatment. The level of viability of cells under different treatments was measured using XTT:PMS. Data are represented as mean ±SEM 
(n=6). B. and C. Induction of apoptosis in MCF-7 cells with CKI treatment. The level of apoptosis was determined by measuring the levels 
of Annexin V and PI staining: B) Percentages of Annexin V+/PI+ cells, and C) representative plots of Annexin V and PI staining. Data are 




DE genes in cells treated with CKI or 5-FU for 24 hours 
or 48 hours (Figure 3C and 3D). In cells treated with CKI 
or 5-FU for 24 hours, over-represented GO terms were 
generally divided into two clusters with respect to the 
different expression status of the genes that contributed 
to each term. Terms such as “Cellular hormone metabolic 
process” and “Pigment metabolic process” were dominated 
by up-regulated genes, which were mainly DE genes 
from CKI treated cells only. On the other hand, terms 
represented by “Chromosome segregation”, “Cell cycle”, 
Figure 2: Differential gene expression in MCF-7 cells treated with CKI or 5-FU for 24 and 48 hours. Numbers of DE genes 
(FDR < 0.05 according to edgeR) between different groups at A. 24 hours or B. 48 hours time. Comparison is based on row against column. 
Therefore, cells with a red background show numbers of up-regulated genes and cells with a blue background show numbers of down-
regulated genes. C. Validation of transcriptome sequencing. Total of 6 DE genes (TP53, CCND1, CYP1A1, BCL2, IL-20 and H19) identified 
by transcriptome sequencing were selected and were subjected to validation analysis by qPCR. Data are represented as mean ±SEM (n=9). 
Statistical analyses were performed using t-test comparing with “untreated” (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).
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“Meiotic nuclear division” and “Somatic diversification 
of immune receptors”, were mainly contributed by down-
regulated genes, particularly DE genes from 5-FU treated 
cells. After 48 hours, the same over-represented GO terms 
in cells treated with CKI or 5-FU for 24 hours were found, 
but the proportions of DE genes from cells treated with 
CKI were increased for most of these terms, particularly 
for “Chromosome segregation” related terms. In addition, 
more significantly over-represented GO terms were found 
in cells treated with CKI or 5-FU for 48 hours compared 
to those in 24 hours, such as “Regulation of viral process” 
and “Negative regulation of intracellular transport”, and 
the majority of DE genes that contributed to these terms 
were down-regulated in cells treated with CKI.
In order to further characterise the potential 
functional pathways altered by CKI, we performed over-
representation analysis of Kyoto Encyclopedia of Genes 
and Genomes (KEGG) pathways for all DE genes in 
cells treated with high dose CKI. Metabolic pathways 
represented by “Steroid hormone biosynthesis”, and 
including “Pentose and glucuronate interconversions” 
and “Drug metabolism” and so on, were over-represented 
based on DE genes in cells treated with CKI for 24 hours 
(Figure 4A). The majority of DE genes that contributed 
to these terms were up-regulated (Figure 4A). Over-
represented cell growth related pathways, such as “Cell 
cycle” and “DNA replication”, were also observed 
(Figure 4A). In addition, cancer-related pathways, such as 
“Prostate cancer”, “Bladder cancer” and “MicroRNA in 
cancer”, were also shown as over-represented pathways. 
It is also interesting to note that DE genes that contributed 
to cell growth and cancer related pathways were generally 
Figure 3: GO functional annotation of DE genes in CKI treated cells. Over-represented GO terms (Biological Process at 3rd 
level) for DE genes identified from comparison of CKI treated cells against untreated cells for A. 24 hours or B. 48 hours. Red coloured 
nodes mean more than 60% of DE genes that contributed to a term were up-regulated and green coloured nodes mean more than 60% 
of DE genes that contributed to a term were down-regulated. The colour gradient represents the proportion of up- or down- regulated 
genes between these cut offs, and the node size is proportional to the significance of over-representation. Terms with similar functional 
classifications are connected with edges and the most significant term in each cluster is shown in bold. Comparison of over-represented GO 
terms for the top 200 significant DE genes in cells treated with 2 mg/mL CKI or 5-FU for C. 24 hours or D. 48 hours. Four different colours 
were used to represent the proportion of DE genes from up- or down- regulated genes. For CKI (red = up-regulated and green = down-
regulated) or 5-FU (blue = up-regulated and yellow = down-regulated). Node size is proportional to the significance of over-representation 
and terms with similar functional classifications are connected with edges and the most significant term in each cluster is shown in bold.
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down-regulated in cells treated with CKI (Figure 4A). 
After cells were treated with CKI for 48 hours, most of 
the over-represented pathways found at 24 hours were still 
shown as significantly over-represented. However, some 
over-represented metabolic pathways and disease-related 
pathways at 48 hours were not shown as significantly 
over-represented pathways in cells treated with CKI for 
24 hours. These pathways included “Arginine and proline 
metabolism”, “Pyrimidine metabolism”, “Fructose 
and mannose metabolism”, “Parkinson’s disease” and 
“Alzheimer’s disease”. In contrast to over-represented 
metabolic or disease related pathways in cells treated with 
CKI for 24 hours, these 48-hours-only significant over-
represented metabolic or disease pathways were mostly a 
function of down-regulated DE genes (Figure 4B). Next, 
we compared the over-represented KEGG pathways based 
on the top 200 significantly DE genes in cells treated with 
CKI or 5-FU. Consistent with the results in Figure 4A and 
4B, metabolic related pathways were primarily contributed 
by CKI up-regulated genes. Cell growth and cancer related 
pathways were also over-represented, and were mostly 
contributed by down-regulated genes in cells treated with 
CKI or 5-FU (Figure 4C and 4D). More significantly over-
represented cancer-related pathways were found in cells 
treated with CKI or 5-FU after 48 hours, and DE genes in 
these pathways were mainly down-regulated (Figure 4D).
Many pathways perturbed by CKI in MCF-7 
cells were inhibited
From the above gene set enrichment analysis, we 
observed that many over-represented GO terms or KEGG 
Figure 4: KEGG functional annotation of DE genes in cells treated with CKI. Over-represented KEGG pathways for all DE 
genes identified from comparison of CKI treated cells with untreated cells for A. 24 hours or B. 48 hours. Red coloured nodes mean that more 
than 60% of DE genes that contributed to this pathway were up-regulated and green coloured nodes mean that more than 60% of DE genes 
that contributed to this pathway were down-regulated. The colour gradient represents the proportion of up- or down- regulated genes between 
these two cut offs, and node size is proportional to the significance of over-representation. Pathways with similar functional classifications 
are connected with edges and the most significant term in each cluster is shown in bold. Comparison of over-represented KEGG pathways 
for the top 200 significant DE genes in cells treated with 2 mg/mL CKI or 5-FU for C. 24 hours or D. 48 hours. Four different colours were 
used to represent the proportion of DE genes from up- or down- regulated genes. For CKI (red = up-regulated and green = down-regulated) or 
5-FU (blue = up-regulated and yellow = down-regulated). Node size represents the significance of over-representation and terms with similar 
functional classifications are connected with edges and the most significant term in each cluster is shown in bold.
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pathways were enriched in down-regulated genes from 
cells treated with CKI. We used Signalling Pathway 
Impact Analysis (SPIA) to identify significantly perturbed 
functional pathways when integrating gene expression 
information with signalling pathway topology [19]. 21 
KEGG pathways were identified as significantly perturbed 
in cells treated with high dose CKI (2 mg/mL) after 24 
hours, and the majority of these pathways (16 out of 21) 
were shown as inhibited (Supplementary Table 3). In cells 
treated with 5-FU for 24 hours, more KEGG pathways 
(75) were identified as significantly perturbed, but only 
22 of these were shown as inhibited (Supplementary 
Table 3). We then compared these significantly perturbed 
pathways in cells treated with CKI or 5-FU. Interestingly, 
all significantly altered pathways in cells treated with CKI 
were also shown as significantly perturbed in cells treated 
with 5-FU (Figure 5A). This suggests that at 24 hours, CKI 
and 5-FU perturbed some of the same pathways. However, 
the perturbation status of these common altered pathways 
in cells treated with CKI or 5-FU was quite different. The 
majority of inhibited pathways in cells treated with CKI 
were shown as activated in cells treated with 5-FU (Figure 
5A). Although the perturbation status indicated by SPIA is 
just suggestive, it still provides some clues that CKI might 
target different genes even though it might perturb the 
same pathway as 5-FU. After cells were treated with CKI 
or 5-FU for 48 hours, 11 significantly perturbed pathways 
were identified in each of treatment group, but only 3 of 
these were shown as significantly perturbed pathways in 
both cells treated with CKI or 5-FU (Figure 5B).
In order to examine the perturbation of CKI on 
KEGG pathways at the individual gene level, we mapped 
the expression status of DE genes in cells treated with 
CKI or 5-FU on the cell growth and death related pathway 
“Cell cycle” as an example (Figure 6). Consistent with 
what we observed in the above KEGG over-representation 
analyses, the majority of DE genes in the “Cell cycle” 
pathway were down-regulated both in cells treated with 
CKI or 5-FU. Many essential regulators, such as Cyclin-
dependent kinase 2 (CDK2), Transcription Factor 
Dp-1 (DP-1), Origin recognition complex (ORC) and 
Minichromosome maintenance protein complex (MCM) 
families, which are important in regulation of the G1/S 
transition [20, 21], were significantly down-regulated 
both in cells treated with CKI or 5-FU. However, some 
key regulators in this “Cell cycle” pathway had different 
expression status in cells treated with CKI or 5-FU. 
For example, CCND1, which encodes Cyclin-D1 (a 
member of the CycD protein family), was significantly 
down-regulated in cells treated with CKI compared with 
untreated cells. In contrast, CCND3, encoding Cyclin-D3 
which also belongs to the CycD protein family, was 
significantly up-regulated in cells treated with 5-FU. 
Interestingly, as an important pro-apoptosis modulator, 
the expression of p53 was opposite in cells treated with 
CKI (down-regulated) or 5-FU (up-regulated) compared 
to untreated cells. In addition, the protein levels of p53 
were significantly decreased in cells treated with CKI for 
24 hours and showed no significant change at 48 hours. In 
contrast p53 increased in cells treated with 5-FU for both 
24 and 48 hours (Figure 6C). Taken together the results 
of down-regulated p53 mRNA and protein levels (Figure 
2C and 6C) but elevated apoptosis activity (Figure 1B) 
in MCF-7 cells treated with CKI, suggest that CKI may 
induce cell apoptosis in a p53 independent fashion. In cells 
treated with CKI or 5-FU for 48 hours, essential genes 
for G1/S transition (as discussed above) were still shown 
as significantly down-regulated. In addition, more genes, 
such as Cyclin A1 (CCNA1, encoding CycA), Cyclin B1 
and B2 (CCNB1 and CCNB2, encoding CycB), Mitotic 
Arrest Deficient 1 (MAD1, encoding mad1) and Mitotic 
Arrest Deficient 2 (MAD2, encoding mad2), which are 
important regulators of G2 or M phase, were shown as 
significantly down-regulated in cells treated with CKI for 
48 hours.
The cell cycle assay using flow cytometry indicated 
that proportions of cells in G1 and S phases were 
significantly lower in MCF-7 cells treated with high dose 
CKI (2 mg/mL), while significantly higher in G2/M phase, 
indicating a cell cycle arrest at G2/M phase by CKI in MCF-
7 cells (Supplementary Figure 5). In summary, possible p53 
independent apoptosis together with perturbation of other 
cancer cell growth associated pathways, such as “Cell 
cycle”, probably contribute the anti-cancer effect of CKI.
The expression of many clinically relevant 
cancer genes was altered in MCF-7 cells treated 
with CKI
To investigate the potential molecular targets of CKI 
in MCF-7 cells, we examined the changes in expression 
of 135 genes in a curated database of Tumour Alterations 
Relevant for Genomics-driven Therapy (TARGET) from 
The Broad Institute (https://www.broadinstitute.org/
cancer/cga/target). These genes are directly linked to a 
clinical outcome when somatically altered in cancer. Many 
genes showed similar expression changes in cells treated 
with CKI or 5-FU, and this confirmed what we observed 
in the pathway analysis (see above) (Figure 7A). However, 
the expression of some genes was either of a higher 
degree or in a different direction in cells treated with CKI 
compared with cells treated with 5-FU. For example, ETS 
translocation variant 4 (ETV4), whose overexpression 
is oncogenic in prostate cells [22], was greatly down-
regulated in cells treated with CKI compared with cells 
treated with 5-FU. On the other hand, Cyclin-Dependent 
Kinase Inhibitor 1A (CDKN1A, also named as p21) was 
highly up-regulated in 5-FU treated cells but not in CKI 
treated cells. We then examined how many significantly 
DE genes in cells treated with CKI or 5-FU were also 
in this TARGET gene list. In total, 27 DE genes in cells 
treated with CKI for 24 hours were in the TARGET gene 
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list, and more up-regulated genes (18 compared to 2) in 
cells treated with 5-FU for 24 hours were in the TARGET 
gene list (Figure 7B). In cells treated with CKI or 5-FU for 
48 hours, 28 DE genes were in the TARGET list from cells 
treated with CKI, while only 6 of the DE genes from cells 
treated with 5-FU for 48 hours were in this list (Figure 
7C).
Figure 5: Perturbation of KEGG pathways in cells treated with CKI or 5-FU for A. 24 hours or B. 48 hours inferred with 
SPIA. Perturbation accumulation and significance of perturbation for each KEGG pathway were calculated based on the fold changes 
of expression of DE genes compared to untreated cells, integrated with the topology information in this pathway. Positive perturbation 
accumulation values mean this pathway is activated and vice versa. “5-FU only” or “CKI only” represent pathways that are only significantly 
perturbed in one condition not in the other.
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Reconstruction of non-coding and protein-coding 
RNA co-expression networks altered by CKI
The differential expression analysis of refGenes 
showed that lncRNA, H19, was significantly down-
regulated after cells were treated with CKI (Figure 2C and 
Supplementary Table 2). In order to better understand the 
potential expression change of lncRNAs in response to CKI 
in MCF-7 cancer cells, we carried out de novo identification 
of lncRNAs from this transcriptome dataset. In total, 2,576 
lncRNA transcripts, which are from 2,287 unique genomic 
loci, were identified (Supplementary Figure 6). We also 
found that the majority of these lncRNAs were novel by 
comparing the genomic coordinates of these lncRNAs with 
two well-annotated human lncRNA datasets (Figure 8A) 
[23, 24]. The expression of many lncRNAs was changed in 
cells treated with CKI or 5-FU (Figure 8B). The expression 
of lncRNAs in cells treated with CKI for 24 hours was 
quite different compared with cells treated with 5-FU for 
24 hours. While at 48 hours, we observed more similar 
lncRNA expression in cells treated with CKI or 5-FU 
(Figure 8B). These results indicate that some of these 
lncRNAs may play specific regulatory roles responding to 
different reagent treatments.
In order to identify potential lncRNA candidates 
that were highly relevant to CKI treatment in MCF-
7 cells, we reconstructed the co-expression networks 
for 15,115 detectable refGenes and 2,287 lncRNAs in 
9 different samples. 53 co-expression modules were 
reconstructed based on the expression profiles of refGenes 
or lncRNAs across 9 samples (Supplementary Figure 7 
and Supplementary Table 4). Upon examination of the 
eigengene expression patterns of these 53 modules, we 
found three modules with expression profiles that were 
consistent with CKI-specific modules (Figure 8C and 
Supplementary Figure 8). Centrality analysis of these 
Figure 6: Comparison of individual gene expression change in MCF-7 cells treated with CKI (2 mg/mL) or 5-FU for 
A. 24 hours or B. 48 hours in the cell cycle pathway. Significant DE genes are coloured with red (up-regulated) or green (down-regulated). 
Each coloured box is separated into two parts, the left half represents the expression change status in cells treated with CKI and the right 
half represents the expression change status in cells treated with 5-FU. White or grey colours represent gene(s) that are not significantly 
differentially expressed. C. CKI caused down-regulation (24 hours) or no significant change (48 hours) of p53 protein level. The level 
of p53 protein present in cells treated with CKI was measured by flow cytometry. For the top panel, mean fluorescent intensity (MFI) of 
cells stained with anti-p53 where MFI of isotype control was subtracted. Data are represented as mean ±SEM (n=9). Statistical analyses 
were performed using t-test comparing with “untreated” (**p<0.01, ***p<0.001, ****p<0.0001). The bottom panel shows representative 
histograms of anti-p53 staining.
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CKI-specific co-expression modules allowed us to identify 
“hub” nodes, many of which belonged to lncRNAs (Figure 
8D and Supplementary Figure 8). These results showed 
that lncRNAs may be co-regulated or involved in the 
same regulatory pathways with protein-coding genes when 
MCF-7 cells  are treated with CKI. We then performed GO 
and KEGG over-representation analysis for the protein-
coding genes in these three CKI-specific modules, and 
“Cell proliferation” was identified as the most significantly 
over-represented functional term (Table 1). Interestingly, 
we also found genes in these CKI-specific co-expression 
modules are over-represented in functions involved in 
“intracellular signal cascade” and “second-messenger-
mediated signaling” (Table 1), which might be triggered 
by the multiple molecular species present in CKI. In 
addition, we also identified three co-expression modules, 
which showed highly correlated co-expression profiles in 
both cells treated with CKI or 5-FU. We defined these as 
“CKI-5FU” modules (Supplementary Figure 9). These 
modules contained over-represented genes in “cell cycle”, 
“DNA replication” and other cell growth related pathways 
(Supplementary Table 5). This result was consistent with 
what we observed in our DE analysis (see above).
DISCUSSION
Many TCMs or other herbal medicines, such as CKI 
used in this study, are extracted from multiple medicinal 
herbs. The fact that multiple potentially bioactive 
ingredients are present in these formulas suggests that 
they have multiple targets, and therefore perturb multiple 
biological pathways. Transcriptome analysis using high-
throughput next generation sequencing technologies has 
been widely used in cancer biology for the identification 
of novel biomarkers, mutations and even novel transcripts, 
such as lncRNAs, in different cancer types [4, 5, 25, 26]. 
We have used whole transcriptome analysis to identify 
potential molecular mechanisms of CKI in vitro. We 
not only identified potential gene targets of CKI based 
Figure 7: Expression change of clinically relevant cancer genes in cells treated with CKI or 5-FU. A. Heatmap showing the 
expression fold changes of cancer relevant genes from the TARGET database. Overlap of TARGET genes with DE genes in MCF-7 cells 
treated with 2 mg/mL CKI or 5-FU for B. 24 hours or C. 48 hours.
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on differential gene expression, but also characterised 
potential biological pathways targeted by CKI. Although 
further experiments are required to validate these candidate 
targets, our results provide a very important starting point 
for subsequent experimental functional validation.
We have identified genes whose expression was 
significantly altered in MCF-7 cells treated with CKI. 
Consistent with the phenotypic analyses, the global gene 
expression changes in cells treated with CKI support a 
dose-dependent effect on MCF-7 cells, which had been 
Figure 8: Expression change of de novo identified lncRNAs and an example of a CKI-specific co-expression module. 
A. Overlap of de novo identified lncRNAs (CKI_lncRNAs) with two annotated human lncRNA datasets: “BI_lncRNAs” as annotated 
lncRNAs from the Broad Institute and “GENCODEv7_lncRNAs” as lncRNAs from GENCODE version7. B. Heatmap showing expression 
fold change of 2,287 lncRNAs in 6 treated cell samples compared to corresponding untreated cells. C. Expression pattern of transcripts in 
CKI-specific module “brown1” is shown in top panel, and barplot in bottom panel shows the eigengene values in different samples. Green 
represents “under-expressed” and red represents “over-expressed” in the heatmap. The “eigengene value” is defined as the first principal 
component of this module, so it can be considered as a representative of the gene expression profiles in this module. D. Visualization of 
CKI-specific co-expression module “brown1”. The black labels represent refGenes and gold labels represent lncRNAs. The size of the 
node/label and edge weight are proportional to between-ness betweeness centrality.
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reported in MCF-7 stem cells and other types of cancer 
cells in previous studies [10, 11]. However, we have 
generated a far more comprehensive candidate gene list 
by considering CKI as a whole rather than looking at 
the effect of individual constituents. As expected, genes, 
including Cytochrome P450 family 1 (CYP1A1), Aldo-
Keto Reductase Family 1, Member C2 (AKR1C2) and 
Member C3 (AKR1C3), which are involved in xenobiotic 
compound metabolism, were significantly up-regulated 
when cells were treated with CKI [27, 28] but not with 
5-FU. On the other hand, many genes involved in cell 
growth or used as biomarkers of carcinogenesis, such 
as CCND1 [29], were significantly down-regulated. 
Interestingly, we observed one lncRNA H19, known to 
be over-expressed in several types of cancer [30, 31], 
was dramatically down-regulated in cells treated with 
CKI. Recently, many lncRNAs have been characterised 
as important gene regulators in various types or stages of 
carcinogenesis [32]. We hypothesise that lncRNAs may 
be also involved in the gene regulatory networks altered 
by CKI in MCF-7 cells. Whether lncRNAs are primary 
targets or secondary links to regulated pathway, still 
requires further study. Compared to traditional single-gene 
analyses used to understand the molecular mechanisms of 
TCM, transcriptome screening has significant advantages 
for identifying potential target genes.
Carcinogenesis is a complex cellular process 
involving multiple genetic alterations that perturb 
different biological processes or pathways [33]. By 
screening transcriptome-wide gene expression changes 
in vitro, one can do more than the mere identification of 
molecular markers for cancer diagnosis or therapy, one 
can also provide useful evidence to better characterise 
the underlying mechanisms of drug effects on cancer 
at pathway or network levels [34, 35]. Using whole 
transcriptome analysis, we identified multiple potential 
molecular pathways altered by CKI in MCF-7 cells. 
Cell growth related pathways, such as cell cycle, cell 
division, DNA replication and so on, were significantly 
altered in MCF-7 cells treated with CKI. By integrating 
the expression data and topologic information of genes 
involved in these pathways, it appears that cell cycle arrest 
might be one of the primary anti-tumour mechanisms of 
CKI in MCF-7 cells. As expected, 5-FU also significantly 
altered these cell growth related pathways, as reported in 
previous studies [36, 37]. However, when we consider the 
expression change of individual genes in these pathways, 
we found that many different genes were significantly 
altered by CKI or 5-FU, but the overall perturbation 
status of these pathways was consistent. We also 
noticed that CKI and 5-FU had opposite effects on some 
pathways, such as the p53 signalling pathway. Although 
the expression of the key p53 gene in the p53 signalling 
pathway was significantly down-regulated in cells treated 
with CKI, we still observed changes in the expression of 
down-stream genes in the apoptosis pathway, such as Bcl-
2. Bcl-2 is an important anti-apoptotic gene [38], which 
was significantly down-regulated in CKI treated cells, 
Table 1: Significantly over-represented GO and KEGG terms in protein-coding genes from three CKI-specific co-
expression modules (count >4 and P-value < 0.05)
Category Term Count Fold enrichment P-value
GOTERM_BP_FAT GO:0008283~cell proliferation 8 3.354 0.009
GOTERM_BP_FAT
GO:0010604~positive regulation of 
macromolecule metabolic process 11 2.346 0.016
GOTERM_BP_FAT GO:0032989~cellular component morphogenesis 7 3.223 0.020
GOTERM_BP_FAT GO:0048514~blood vessel morphogenesis 5 4.332 0.027
GOTERM_BP_FAT GO:0035295~tube development 5 4.155 0.031
GOTERM_BP_FAT GO:0007242~intracellular signaling cascade 13 1.892 0.036
GOTERM_BP_FAT
GO:0019932~second-messenger-mediated 
signaling 5 3.890 0.038
GOTERM_BP_FAT
GO:0000904~cell morphogenesis involved in 
differentiation 5 3.746 0.043
GOTERM_BP_FAT GO:0000902~cell morphogenesis 6 3.081 0.043
GOTERM_BP_FAT GO:0001568~blood vessel development 5 3.731 0.043
GOTERM_BP_FAT GO:0001944~vasculature development 5 3.642 0.047
KEGG_PATHWAY hsa05200:Pathways in cancer 7 3.391 0.013
KEGG_PATHWAY hsa04020:Calcium signaling pathway 5 4.514 0.021
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indicating that MCF-7 cells still underwent apoptosis 
when treated with CKI. The down-regulation of Bcl-2 had 
been reported in other types of cancer cells treated with 
Matrine or Oxymatrine, two of the major components of 
CKI [16, 39–41]. Taking into account the results from the 
apoptosis assay, we propose that CKI may induce MCF-
7 cell apoptosis via p53 independent pathways. As CKI 
is normally clinically used in combination with other 
cancer chemotherapies, our results also provide primary 
molecular evidence for this potential simultaneous effect 
in clinical usage [11].
Advances in omics technologies have allowed the 
development of new cancer therapies [42]. Improved gene 
therapies, such as targeted cancer therapies or precision 
medicine, are attracting more and more attention as 
a result of improved abilities to characterise cancer 
mechanisms in individual patients [42, 43]. On the other 
hand, therapies involving whole body system modulation, 
such as immunotherapy [44] and multiply-targeted 
therapies [45], are also proposed as potentially effective 
or complementary weapons for cancer treatment [46]. The 
nature of many TCMs or ancient medicines that include 
multiple bioactive ingredients, suggests that they can be a 
rich resource for identifying or developing multi-targeted 
cancer drugs [47]. However, most TCMs or ancient 
medicines are experience-based medicines developed 
from a long history of clinical use and little is known of 
their molecular modes of action. Classical pharmacology 
has used a reductionist strategy of purification and testing 
of single components from TCM, but this limits our 
understanding of the potential interaction or cumulative 
effects of multiple components on a functional system. 
The application of systems biology techniques, such as 
whole transcriptome analyses, is a good starting point to 
understand the functional system effects of TCMs, as a 
basis for further improvement and optimisation of existing 
TCMs in the context of evidence based medicine.
Studies have confirmed that many lncRNAs 
play important regulatory roles in cancer [32]. Our de 
novo identification of lncRNAs showed that some of 
these may contribute to regulatory networks, and even 
be specifically or differentially expressed in MCF-7 
cancer cells treated by CKI. By integrating lncRNAs 
with protein-coding RNAs to reconstruct co-expression 
networks, we showed that this can be used as another 
powerful tool to understand global transcription changes 
potentially sensitive to TCM. We were able to confirm 
that “Cell cycle” and other cell growth related pathways 
might be the primary target pathways of CKI in MCF-
7 cell line as shown in DE analysis, but were able to do 
this in a more general sense, because we included all 
expression detectable transcripts during the reconstruction 
of co-expression networks. In addition, we also showed 
co-expression networks may be useful in identifying 
potential co-expressed “hub” transcripts, including both 
protein-coding RNAs and lncRNAs, for further functional 
experiments [48]. In conclusion, we applied and integrated 
multiple transcriptome analysis tools to describe and 
analyse the complexity of molecular mechanisms altered 
by CKI in MCF-7 breast cancer cells, and we hope that 
this can be useful to harness the “magic power” of TCM.
MATERIALS AND METHODS
Cell culture and drugs
MCF-7 cells were purchased from ATCC (HTB-
22™, VA, USA) and were cultured in DMEM medium 
(Thermo Fisher Scientific, MA, USA) supplemented with 
10% fetal bovine serum (Thermo Fisher Scientific) and 
0.01 mg/mL human recombinant insulin (Thermo Fisher 
Scientific) at 37°C with 5% CO2. CKI (total alkaloids 
concentration of 20.8 mg/mL) was obtained from 
ZhenDong pharmaceutical Co.Ltd (Shanxi, China), and 
5-FU was ordered from Sigma-Aldrich (MO, USA). For 
all in vitro experiments performed in this study, CKI was 
used at dilution of final concentration of either 1 mg/mL 
or 2 mg/mL of total alkaloids, and 5-FU was used at a final 
concentration of 10 ug/mL.
For cell culture in 6-well trays used for cell 
apoptosis assay, cell cycle assay, p53 protein staining 
assay and RNA extraction, each well was seeded with 
5×105 cells in 2 mL of medium and cultured overnight. On 
the following day, 1 mL of either medium, CKI or 5-FU 
was added to the cells. After 24 and 48 hours of treatment, 
cells were harvested and used in the above assays.
Cell viability assay
The wells of 96-well trays were seeded with 1×104 
cells in 50 μL of medium and cultured overnight. On the 
following day, 50 μL of either medium, CKI or 5-FU were 
added to the cells. Viability of the cells was measured at 0, 
24 and 48 hours after the treatment by adding XTT:PMS 
(50:1; Sigma-Aldrich). After 4-hour incubation at 37°C 
optical density (OD) of each well was read at 490 nm. The 
background OD was also measured and the average was 
subtracted from the OD readings of appropriate wells.
Apoptosis assay by annexin V/PI staining
Cells were cultured in 6-well trays and treated 
with drugs as described above. After 24 and 48 hours of 
treatment, cells were harvested and the rate of apoptosis 
was measured using Annexin V-FITC detecton kit 
(Biotool, TX, USA) according to the manufacturer’s 
instructions. The stained cells were sorted and data 
acquired on an LSRII (BD Biosciences, NJ, USA) and the 




Caspase 3/7 colorimetric assay
Caspase 3/7 activity in cells was measured with 
a Caspase-3/7 Colorimetric Assay Kit (BioVision, CA, 
USA). Cells were cultured in 6-well trays and treated 
with drugs as described above. After 24 and 48 hours 
of treatment, cells were harvested and proteins from 
cells were extracted according to the manufacturer’s 
instructions and concentrations were determined with a 
Nanodrop 2000 (Thermo Scientific). Caspase-3/7 activity 
was then measured according to the manufacturer’s 
instructions.
Cell cycle assay
Cells were cultured in 6-well trays and treated 
with drugs as described above. After 24 and 48 hours 
of treatment, cells were harvested and subjected to cell 
cycle analysis by PI staining as described previously [49] 
and the stained cells were sorted and the data acquired on 
LSRII and the data were analysed using FlowJo software.
Intranuclear/intracellular staining for p53
Cells were cultured in 6-well trays and treated 
with drugs as described above. After 24 and 48 hours 
of treatment, cells were fixed and permeabilised using 
Nuclear Factor Fixation and Permeabilization Buffer Set 
(Biolegend, CA, USA) according to the manufacturer’s 
instructions. 2×105 cells were labelled either with anti-
p53-PE or mouse IgG2b-PE (1 μg/mL; Biolegend) and the 
cells were sorted and the data were acquired on an LSRII, 
and the data were analysed using FlowJo software.
RNA extraction and sequencing
Cells were cultured in 6-well plates with a seeding 
density of 5×105 cells/well and treated with CKI or 
5-FU for 24 and 48 hours as above. Total RNA was 
isolated with the mirVana PARIS Kit (Thermo Fisher 
Scientific) according to the manufacturer’s protocol. RNA 
samples were sent to the Cancer Genome Facility of the 
Australian Cancer Research Foundation (SA, Australia) 
for sequencing. The quality of the total RNA was verified 
on a Bioanalyzer ensuring all samples had RINs >7.0. 
Starting with 1 ug of total RNA, the polyA fraction was 
enriched using a NEBNext(r) Poly(A) mRNA Magnetic 
Isolation Module. Stranded mRNA libraries for Illumina 
sequencing were prepared using the NEBNext(r) Ultra 
Directional RNA kits from New England Biolabs, Inc. 
according to the manufacturer’s protocol (Version 2.0 July 
2013). Actinomycin D was added during cDNA synthesis 
to ensure high levels of strand specificity. All libraries 
were run on a Bionanalyzer to confirm library size and 
yield. Barcoded libraries were normalized and pooled 
based on concentrations determined by qPCR with Library 
Quantification kits from KAPA Biosystems. Libraries 
were sequenced using an Illumina HiSeq 2500 across 5 
lanes with stranded paired-end 100 base pair reads. Raw 
and processed data were deposited at the Gene Expression 
Omnibus (GEO) data repository (GSE78512).
Data processing and functional annotation
Low quality and adaptor sequences in raw reads 
were trimmed using Trim_galore (v0.3.7, Babraham 
Bioinformatics) with the following parameters: 
--stringency 6 --paired. Then cleaned reads were 
aligned to the reference genome (hg19, UCSC) 
using STAR_2.4.0j with the following parameters: 
--outSAMstrandField intronMotif --outSAMattributes All 
--outFilterMismatchNmax 10 --seedSearchStartLmax 30 
[50]. Differential expression analysis was performed with 
edgeR and DE genes were selected with a False Discovery 
Rate (FDR) < 0.05 [51].
GO and KEGG over-representation analyses were 
performed using ClueGO with the following settings: 
biological process at 3rd level (for GO); right-sided 
hypergeometric test for enrichment analysis; p values were 
corrected for multiple testing according to the Benjamini-
Hochberg method. Over-represented terms/pathways were 
visualised with Cytoscape v3.2.1 [52, 53]. Signalling 
Pathway Impact Analysis (SPIA) was performed with 
SPIA package in R [19]. Gene expression status mapping 
in KEGG pathways was visualised with the R Pathview 
package [54].
Transcriptome validation with qPCR
Cells were cultured in 6-well trays and treated with 
drugs as described above. Untreated cells as well as cells 
treated for 24 and 48 hours were harvested and the cell 
pellets were snap-frozen in liquid nitrogen. Total RNA 
was extracted using PureLink RNA Mini Kit (Thermo 
Fisher Scientific) and treated with TURBO DNA-Free 
(Thermo Fisher Scientific) according to the manufacturer’s 
instructions. cDNA synthesis was performed using High 
Capacity cDNA Reverse Transcription Kit (Thermo Fisher 
Scientific) according to the manufacturer’s instructions.
qPCR reactions were set up with PowerUp SYBR 
Green Master Mix where forward and reverse primers 
were added at a final concentration of 400 nM each. 
Reactions were run on the StepOne Plus Real-Time PCR 
system and the data were analysed using its software 
v2.3 (Thermo Fisher Scientific). Relative levels of target 
mRNAs were calculated as 1/2ΔCT, where ΔCT=CT of 
target − CT of RSP13. The sequences of all primers used 
in this study are provided in Supplementary Table 6.
LncRNA identification
The flowchart for lncRNA identification is shown 
in Supplementary Figure 6. In summary, short reads 
were mapped against the genome and assembled into 
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longer transcripts, and then transcripts shorter than 200 
nucleotides (nt) were removed. Genomic coordinates 
of long transcripts were checked against refGenes 
from UCSC and classified into “refGene transcripts”, 
“intergenic transcripts”, “intronic transcripts” and 
“antisense transcripts”. The latter three classes of 
transcripts were selected to filter unannotated protein-
coding potential transcripts by following two steps: 1) 
Sequence similarity search against the Swiss-Prot protein 
database; 2) Predict Open Reading Frame(s) (ORF). In 
order to get a more reliable lncRNA dataset, we selected 
transcripts with expression higher than 1 count per million 
(CPM, normalised using the TMM method in edgeR) in at 
least 2 of 27 individual samples.
Reconstruction of co-expression networks
RefGenes were pre-filtered by expression (> 1 
CPM in at least 2 of 27 individuals). Expression matrices 
for all pre-filtered refGenes and lncRNAs were merged 
to reconstruct co-expression networks with WGCNA 
[55]. “16” was selected as the soft thresholding power 
according to the protocol of WGCNA. Co-expression 
modules were visualized with Cytoscape v3.2.1. Between-
ness centrality was used to select “hub” nodes. GO and 
KEGG over-representation analyses were performed with 
DAVID (Database For Annotation, Visualization and 
Integrated Discovery) [56].
ACKNOWLEDGMENTS
The Authors would like to thank Adriana Caon for 
technical help in cell culture and Seyyed Hani Moussavi 
Nik for technical help in RNA isolation.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
1. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis 
K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, 
Sougnez C, Onofrio R, Carter SL, Park K, et al. The 
genomic complexity of primary human prostate cancer. 
Nature. 2011; 470: 214-20. doi: 10.1038/nature09744.
2. Pleasance ED, Cheetham RK, Stephens PJ, McBride 
DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, 
Ordonez GR, Bignell GR, Ye K, Alipaz J, Bauer MJ, et 
al. A comprehensive catalogue of somatic mutations from 
a human cancer genome. Nature. 2010; 463: 191-6. doi: 
10.1038/nature08658.
3. Saadatpour A, Lai S, Guo G, Yuan GC. Single-Cell Analysis 
in Cancer Genomics. Trends Genet. 2015; 31: 576-86. doi: 
10.1016/j.tig.2015.07.003.
4. Barrett CL, DeBoever C, Jepsen K, Saenz CC, Carson 
DA, Frazer KA. Systematic transcriptome analysis reveals 
tumor-specific isoforms for ovarian cancer diagnosis and 
therapy. Proc Natl Acad Sci U S A. 2015; 112: E3050-7. 
doi: 10.1073/pnas.1508057112.
5. White NM, Cabanski CR, Silva-Fisher JM, Dang HX, 
Govindan R, Maher CA. Transcriptome sequencing 
reveals altered long intergenic non-coding RNAs in 
lung cancer. Genome Biol. 2014; 15: 429. doi: 10.1186/
s13059-014-0429-8.
6. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, 
Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso 
CS, Kominsky HD, Cao X, Jing X, Wang X, et al. 
Transcriptome sequencing across a prostate cancer cohort 
identifies PCAT-1, an unannotated lincRNA implicated in 
disease progression. Nat Biotechnol. 2011; 29: 742-9. doi: 
10.1038/nbt.1914.
7. Simon R, Roychowdhury S. Implementing personalized 
cancer genomics in clinical trials. Nat Rev Drug Discov. 
2013; 12: 358-69. doi: 10.1038/nrd3979.
8. Hsiao WL, Liu L. The role of traditional Chinese herbal 
medicines in cancer therapy--from TCM theory to 
mechanistic insights. Planta Med. 2010; 76: 1118-31. doi: 
10.1055/s-0030-1250186.
9. Sun M, Cao H, Sun L, Dong S, Bian Y, Han J, Zhang L, Ren 
S, Hu Y, Liu C, Xu L, Liu P. Antitumor activities of Kushen: 
literature review. Evid Based Complement Alternat Med. 
2012; 2012: 373219. doi: 10.1155/2012/373219.
10. Zhao Z, Fan H, Higgins T, Qi J, Haines D, Trivett A, 
Oppenheim JJ, Wei H, Li J, Lin H, Howard OM. Fufang 
Kushen injection inhibits sarcoma growth and tumor-
induced hyperalgesia via TRPV1 signaling pathways. 
Cancer Lett. 2014; 355: 232-41. doi: 10.1016/j.
canlet.2014.08.037.
11. Xu W, Lin H, Zhang Y, Chen X, Hua B, Hou W, Qi X, 
Pei Y, Zhu X, Zhao Z, Yang L. Compound Kushen 
Injection suppresses human breast cancer stem-like cells 
by down-regulating the canonical Wnt/beta-catenin 
pathway. J Exp Clin Cancer Res. 2011; 30: 103. doi: 
10.1186/1756-9966-30-103.
12. Ma Y, Gao HM, Liu J, Chen LM, Zhang QW, Wang 
ZM. Identification and Determination of the Chemical 
Constituents in a Herbal Preparation, Compound Kushen 
Injection, by Hplc and Lc-Dad-Ms/Ms. Journal of Liquid 
Chromatography & Related Technologies. 2014; 37: 207-
20. doi: 10.1080/10826076.2012.738623.
13. Yu P, Liu Q, Liu K, Yagasaki K, Wu E, Zhang G. Matrine 
suppresses breast cancer cell proliferation and invasion via 
VEGF-Akt-NF-kappaB signaling. Cytotechnology. 2009; 
59: 219-29. doi: 10.1007/s10616-009-9225-9.
14. Liu T, Song Y, Chen H, Pan S, Sun X. Matrine inhibits 
proliferation and induces apoptosis of pancreatic cancer 




15. Chen H, Zhang J, Luo J, Lai F, Wang Z, Tong H, Lu D, Bu 
H, Zhang R, Lin S. Antiangiogenic effects of oxymatrine on 
pancreatic cancer by inhibition of the NF-kappaB-mediated 
VEGF signaling pathway. Oncol Rep. 2013; 30: 589-95. 
doi: 10.3892/or.2013.2529.
16. Ling Q, Xu X, Wei X, Wang W, Zhou B, Wang B, Zheng 
S. Oxymatrine induces human pancreatic cancer PANC-1 
cells apoptosis via regulating expression of Bcl-2 and IAP 
families, and releasing of cytochrome c. J Exp Clin Cancer 
Res. 2011; 30: 66. doi: 10.1186/1756-9966-30-66.
17. Zhang Y, Piao B, Zhang Y, Hua B, Hou W, Xu W, Qi X, Zhu 
X, Pei Y, Lin H. Oxymatrine diminishes the side population 
and inhibits the expression of beta-catenin in MCF-7 breast 
cancer cells. Med Oncol. 2011; 28: S99-107. doi: 10.1007/
s12032-010-9721-y.
18. Guo YM, Huang YX, Shen HH, Sang XX, Ma X, Zhao 
YL, Xiao XH. Efficacy of Compound Kushen Injection in 
Relieving Cancer-Related Pain: A Systematic Review and 
Meta-Analysis. Evid Based Complement Alternat Med. 
2015; 2015: 840742. doi: 10.1155/2015/840742.
19. Tarca AL, Draghici S, Khatri P, Hassan SS, Mittal P, Kim 
JS, Kim CJ, Kusanovic JP, Romero R. A novel signaling 
pathway impact analysis. Bioinformatics. 2009; 25: 75-82. 
doi: 10.1093/bioinformatics/btn577.
20. Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle 
transcription during G1 and S phases. Nat Rev Mol Cell 
Biol. 2013; 14: 518-28. doi: 10.1038/nrm3629.
21. Schaarschmidt D, Ladenburger EM, Keller C, Knippers R. 
Human Mcm proteins at a replication origin during the G1 
to S phase transition. Nucleic Acids Res. 2002; 30: 4176-85.  
22. Pellecchia A, Pescucci C, De Lorenzo E, Luceri C, Passaro 
N, Sica M, Notaro R, De Angioletti M. Overexpression of 
ETV4 is oncogenic in prostate cells through promotion 
of both cell proliferation and epithelial to mesenchymal 
transition. Oncogenesis. 2012; 1: e20. doi: 10.1038/
oncsis.2012.20.
23. Cabili MN, Trapnell C, Goff L, Koziol M, Tazon-Vega B, 
Regev A, Rinn JL. Integrative annotation of human large 
intergenic noncoding RNAs reveals global properties and 
specific subclasses. Genes Dev. 2011; 25: 1915-27. doi: 
10.1101/gad.17446611.
24. Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, 
Tilgner H, Guernec G, Martin D, Merkel A, Knowles DG, 
Lagarde J, Veeravalli L, Ruan X, et al. The GENCODE v7 
catalog of human long noncoding RNAs: analysis of their 
gene structure, evolution, and expression. Genome Res. 
2012; 22: 1775-89. doi: 10.1101/gr.132159.111.
25. Lin KT, Shann YJ, Chau GY, Hsu CN, Huang CY. 
Identification of latent biomarkers in hepatocellular 
carcinoma by ultra-deep whole-transcriptome sequencing. 
Oncogene. 2014; 33: 4786-94. doi: 10.1038/onc.2013.424.
26. Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty 
PM, Gnad F, Guan Y, Gilbert HN, Stinson J, Klijn C, 
Guillory J, Bhatt D, et al. Genome and transcriptome 
sequencing of lung cancers reveal diverse mutational and 
splicing events. Genome Res. 2012; 22: 2315-27. doi: 
10.1101/gr.140988.112.
27. Walsh AA, Szklarz GD, Scott EE. Human cytochrome 
P450 1A1 structure and utility in understanding drug and 
xenobiotic metabolism. J Biol Chem. 2013; 288: 12932-43. 
doi: 10.1074/jbc.M113.452953.
28. Jin Y, Penning TM. Aldo-keto reductases and bioactivation/
detoxication. Annu Rev Pharmacol Toxicol. 2007; 47: 263-
92. doi: 10.1146/annurev.pharmtox.47.120505.105337.
29. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. 
Cyclin D1 is a nuclear protein required for cell cycle 
progression in G1. Genes Dev. 1993; 7: 812-21.  
30. Hibi K, Nakamura H, Hirai A, Fujikake Y, Kasai Y, 
Akiyama S, Ito K, Takagi H. Loss of H19 imprinting in 
esophageal cancer. Cancer Res. 1996; 56: 480-2. 
31. Adriaenssens E, Dumont L, Lottin S, Bolle D, Lepretre 
A, Delobelle A, Bouali F, Dugimont T, Coll J, Curgy JJ. 
H19 overexpression in breast adenocarcinoma stromal 
cells is associated with tumor values and steroid receptor 
status but independent of p53 and Ki-67 expression. 
Am J Pathol. 1998; 153: 1597-607. doi: 10.1016/
S0002-9440(10)65748-3.
32. Huarte M. The emerging role of lncRNAs in cancer. Nat 
Med. 2015; 21: 1253-61. doi: 10.1038/nm.3981.
33. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, 
Diaz LA, Jr., Kinzler KW. Cancer genome landscapes. 
Science. 2013; 339: 1546-58. doi: 10.1126/science.1235122.
34. Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu 
H, Degenhardt J, Mayba O, Gnad F, Liu J, Pau G, Reeder 
J, Cao Y, et al. A comprehensive transcriptional portrait of 
human cancer cell lines. Nat Biotechnol. 2015; 33: 306-12. 
doi: 10.1038/nbt.3080.
35. Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker 
RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, Holbeck 
SL, Simon RM, Doroshow JH, et al. The exomes of the 
NCI-60 panel: a genomic resource for cancer biology and 
systems pharmacology. Cancer Res. 2013; 73: 4372-82. doi: 
10.1158/0008-5472.CAN-12-3342.
36. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama 
JI, Yamamura T, Hashimoto-Tamaoki T. Dual antitumor 
effects of 5-fluorouracil on the cell cycle in colorectal 
carcinoma cells: a novel target mechanism concept for 
pharmacokinetic modulating chemotherapy. Cancer Res. 
2001; 61: 1029-37. 
37. Hernandez-Vargas H, Ballestar E, Carmona-Saez P, von 
Kobbe C, Banon-Rodriguez I, Esteller M, Moreno-Bueno 
G, Palacios J. Transcriptional profiling of MCF7 breast 
cancer cells in response to 5-Fluorouracil: relationship 
with cell cycle changes and apoptosis, and identification of 
novel targets of p53. Int J Cancer. 2006; 119: 1164-75. doi: 
10.1002/ijc.21938.
38. Czabotar PE, Lessene G, Strasser A, Adams JM. Control 
of apoptosis by the BCL-2 protein family: implications for 
125
Oncotarget66019www.impactjournals.com/oncotarget
physiology and therapy. Nat Rev Mol Cell Biol. 2014; 15: 
49-63. doi: 10.1038/nrm3722.
39. Chang C, Liu SP, Fang CH, He RS, Wang Z, Zhu YQ, Jiang 
SW. Effects of matrine on the proliferation of HT29 human 
colon cancer cells and its antitumor mechanism. Oncol Lett. 
2013; 6: 699-704. doi: 10.3892/ol.2013.1449.
40. Zhang Y, Zhang H, Yu P, Liu Q, Liu K, Duan H, Luan G, 
Yagasaki K, Zhang G. Effects of matrine against the growth 
of human lung cancer and hepatoma cells as well as lung 
cancer cell migration. Cytotechnology. 2009; 59: 191-200. 
doi: 10.1007/s10616-009-9211-2.
41. Liu J, Yao Y, Ding H, Chen R. Oxymatrine triggers 
apoptosis by regulating Bcl-2 family proteins and activating 
caspase-3/caspase-9 pathway in human leukemia HL-60 
cells. Tumour Biol. 2014; 35: 5409-15. doi: 10.1007/
s13277-014-1705-7.
42. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug 
therapy for cancer in the post-genomic era. Nat Biotechnol. 
2012; 30: 679-92. doi: 10.1038/nbt.2284.
43. Garman KS, Nevins JR, Potti A. Genomic strategies for 
personalized cancer therapy. Hum Mol Genet. 2007; 16: 
R226-32. doi: 10.1093/hmg/ddm184.
44. Mahoney KM, Rennert PD, Freeman GJ. Combination 
cancer immunotherapy and new immunomodulatory targets. 
Nat Rev Drug Discov. 2015; 14: 561-84. doi: 10.1038/
nrd4591.
45. Petrelli A, Giordano S. From single- to multi-target drugs 
in cancer therapy: when aspecificity becomes an advantage. 
Curr Med Chem. 2008; 15: 422-32. 
46. Vanneman M, Dranoff G. Combining immunotherapy and 
targeted therapies in cancer treatment. Nat Rev Cancer. 
2012; 12: 237-51. doi: 10.1038/nrc3237.
47. Wang Y, Fan X, Qu H, Gao X, Cheng Y. Strategies and 
techniques for multi-component drug design from medicinal 
herbs and traditional Chinese medicine. Curr Top Med 
Chem. 2012; 12: 1356-62. 
48. Yang Y, Han L, Yuan Y, Li J, Hei N, Liang H. Gene 
co-expression network analysis reveals common 
system-level properties of prognostic genes across 
cancer types. Nat Commun. 2014; 5: 3231. doi: 10.1038/
ncomms4231.
49. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium 
iodide staining and flow cytometry. Nat Protoc. 2006; 1: 
1458-61. doi: 10.1038/nprot.2006.238.
50. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, 
Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast 
universal RNA-seq aligner. Bioinformatics. 2013; 29: 
15-21. doi: 10.1093/bioinformatics/bts635.
51. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a 
Bioconductor package for differential expression analysis 
of digital gene expression data. Bioinformatics. 2010; 26: 
139-40. doi: 10.1093/bioinformatics/btp616.
52. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini 
M, Kirilovsky A, Fridman WH, Pages F, Trajanoski 
Z, Galon J. ClueGO: a Cytoscape plug-in to decipher 
functionally grouped gene ontology and pathway annotation 
networks. Bioinformatics. 2009; 25: 1091-3. doi: 10.1093/
bioinformatics/btp101.
53. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, 
Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a 
software environment for integrated models of biomolecular 
interaction networks. Genome Res. 2003; 13: 2498-504. 
doi: 10.1101/gr.1239303.
54. Luo W, Brouwer C. Pathview: an R/Bioconductor package 
for pathway-based data integration and visualization. 
Bioinformatics. 2013; 29: 1830-1. doi: 10.1093/
bioinformatics/btt285.
55. Langfelder P, Horvath S. WGCNA: an R 
package for weighted correlation network 
analysis. BMC Bioinformatics. 2008; 9: 559. doi: 
10.1186/1471-2105-9-559.
56. Huang da W, Sherman BT, Lempicki RA. Systematic 
and integrative analysis of large gene lists using DAVID 




The Effect of Compound Kushen Injection on Cancer
Cells: Integrated Identification of Candidate Molecular
Mechanisms
In this chapter, the transcriptome analysis of two cell lines including MDA-MB-231 and
HEPG2 were combined with the previous data from MCF-7 to compare the core and
unique set of genes with respect to the responses to CKI treatment. A set of 363 core
genes associated with cell cycle, energy metabolism, DNA replication/repair, and various
cancer pathways were identified. This chapter is in the format of a manuscript that has
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Background: Because TCM preparations are often combinations of multiple herbs 23 
containing hundreds of compounds, they have been difficult to study. Compound Kushen 24 
Injection (CKI) is a complex mixture cancer treatment used in Chinese hospitals for over 25 
twenty years.  26 
Purpose: To demonstrate that a systematic analysis of molecular changes resulting from 27 
complex mixtures of bioactives from Traditional Chinese Medicine can identify a core set of 28 
differentially expressed (DE) genes and a reproducible set of candidate pathways.  29 
Study Design: We used a cancer cell culture model to measure the effect of CKI on cell cycle 30 
phases, apoptosis and correlate those phenotypes with CKI induced changes in gene 31 
expression.  32 
Methods: We treated cancer cells with CKI in order to generate and analyse high-33 
throughput transcriptome data from two cancer cell lines. We integrated these differential 34 
gene expression results with previously reported results. 35 
Results: CKI induced cell-cycle arrest and apoptosis and altered the expression of 363 core 36 
candidate genes associated with cell cycle, apoptosis, DNA replication/repair and various 37 
cancer pathways. Of these, 7 are clinically relevant to cancer diagnosis or therapy and 14 38 
are cell cycle regulators, and most of these 21 candidates are downregulated by CKI.  39 
Comparison of our core candidate genes to a database of plant medicinal compounds and 40 
their effects on gene expression identified one-to-one, one-to-many and many-to-many 41 
regulatory relationships between compounds in CKI and DE genes. 42 
Conclusions: By identifying promising candidate pathways and genes associated with CKI 43 
based on our transcriptome-based analysis, we have shown this approach is useful for the 44 
systematic analysis of molecular changes resulting from complex mixtures of bioactives.   45 
 46 
Keywords:   47 






TCM, traditional Chinese medicine; CKI, compound Kushen injection; GO, Gene Ontology; 52 
DO, Disease Ontology; KEGG, Kyoto Encyclopedia of Gene and Genomes; PI, propidium 53 
iodide.  54 
 55 
Introduction   56 
The treatments of choice for cancer are often radiotherapy and/or chemotherapy, and 57 
while these can be effective, they can cause quite serious side-effects, including death. 58 
These side-effects have driven the search for adjuvant therapies to both mitigate side-59 
effects and/or potentiate the effectiveness of existing therapies. Traditional Chinese 60 
Medicine (TCM) is one of the options for adjuvant therapies, particularly in China, but 61 
increasingly so in the West. While clinical trial data on the effectiveness of TCM is currently 62 
limited, it remains an attractive option because of its long history and because its potential 63 
effectiveness is believed to result from the cumulative effects of multiple compounds on 64 
multiple targets (Jiang, 2005). Because TCM often has not been subjected to rigorous 65 
evidence based assessment and because it is based on an alternative theoretical system 66 
compared to Western medicine, adoption of its plant derived therapeutics has been slow. 67 
In this report, we continue to characterise the molecular effects of Compound Kushen 68 
Injection (CKI) on cancer cells.  CKI has been approved by the State Food and Drug 69 
Administration (SFDA) of China for clinical use since 1995 (Shu et al., 2014) (State medical 70 
license no. Z14021231). CKI is an herbal extract from two TCM plants, Kushen (Sophora 71 
flavescens) and Baituling (Smilax Glabra) and contains more than 200 different chemical 72 
compounds. These compounds include alkaloids and flavonoids such as matrine, oxymatrine 73 
and kurarinol that have been reported to have anti-cancer activities  (Shu et al., 2014; Wang 74 
et al., 2015; Zhang et al., 2013; Zhao et al., 2014).  Some of these activities have been shown 75 
to influence the expression of TP53, BAX, BCL2 and other key genes known to be important 76 
in cancer cell growth and survival (Liao et al., 2015; Ninomiya and Koketsu, 2013; Wu et al., 77 
2015; Zhang et al., 2001).  78 
We have previously characterised the effect of CKI on the transcriptome of MCF-7 breast 79 
carcinoma cells and in this report, we extend our previous results to two additional human 80 
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cancer cell lines (MDA-MB-231, breast carcinoma and HEPG2, hepatocellular carcinoma). 81 
Both cell lines have also been shown to undergo apoptosis in response to the ingredients of 82 
CKI (Wang et al., 2015; Wu et al., 2015; Zhang et al., 2010; Zhao et al., 2014). HEPG2 is one 83 
of the most sensitive cancer cell lines with respect to exposure to CKI (Yang et al., 2017) and 84 
CKI is often used in conjunction with Western chemotherapy drugs for the treatment of liver 85 
cancer patients in China. While the specific mechanism of action of CKI is unknown, several 86 
recent studies have reported that CKI or its primary compounds affect the 87 
regulation/expression of oncogene products including β-catenin, TP53, STAT3 and AKT (Liu 88 
et al., 2014; Ma et al., 2016; Shu et al., 2014; Wang et al., 2015; Yu et al., 2009). 89 
However, these and other reports did not evaluate the entire range of molecular changes 90 
from treatment with a multi-component mixture such as CKI (Gao et al., 2018; Hao and Xiao, 91 
2014). Whilst several research databases and tools for TCM research have been developed 92 
(Cui et al., 2014; Song et al., 2013; Wang and Chen, 2013), they are limited by the fact that 93 
most of the studies that contribute to the corpus of these databases are from different 94 
experimental systems, use single compounds or measure effects based on one or a handful 95 
of genes/gene products.  96 
In contrast to previous studies, our strategy was to carry out comprehensive transcriptome 97 
profiling and network reconstruction from cancer cells treated with CKI. Instead of focusing 98 
on specific genes or pathways in order to design experiments, we have linked phenotypic 99 
assessment and RNA-seq analysis to CKI treatment. This allows us to present an unbiased, 100 
comprehensive analysis of CKI specific responses of biological networks associated with 101 
cancer. Our results indicate that different cancer cell lines that undergo apoptosis in 102 
response to CKI treatment can exhibit different CKI induced gene expression profiles that 103 
nonetheless implicate similar core genes and pathways in multiple cell lines. 104 
The current study presents the effects of CKI on gene expression in cancer cells with an aim 105 
to identify candidate pathways and regulatory networks that may be perturbed by CKI in 106 
vivo. To this end we primarily use concentrations of CKI higher than used in vivo in order to 107 
be able to detect effects in the short time frames available to tissue culture experiments.  108 
We also combine our current analysis with previously published data to focus on a shared, 109 
much smaller set of candidate genes and pathways.   110 
Material and Methods 111 
133
 5 
Cell culture and reagents 112 
CKI (total alkaloids concentration of 25 mg/mL) in 5 ml ampoules was provided by Zhendong 113 
Pharmaceutical Co. Ltd. (Beijing, China). Chemotherapeutic agent, Fluorouracil (5-FU) was 114 
purchased from Sigma-Aldrich (MO, USA). A human breast adenocarcinoma cell line, MDA-115 
MB-231 and a hepatocellular carcinoma cell line HEPG2 were purchased from American 116 
Type Culture Collection (ATCC, Manassas, VA). The cells were cultured in Dulbecco's 117 
Modified Eagle Medium (DMEM; Thermo Fisher Scientific, MA, USA) supplemented with 118 
10% foetal bovine serum (Thermo Fisher Scientific). Both cell lines were cultured at 37℃ 119 
with 5% CO2.  120 
For all in vitro assays, 4x105 cells were seeded in 6-well trays and cultured overnight before 121 
being treated with either CKI (at 1 mg/mL and 2 mg/mL of total alkaloids) or 5-FU (150 μ122 
g/ml for HEPG2 and 20 μg/ml for MDA-MB-231. As a negative control, cells were treated 123 
with medium only and labelled as “untreated”. After 24 and 48 hours of treatment, cells 124 
were harvested and subjected to the downstream experiments. 125 
Cell cycle and apoptosis assay  126 
The assay was performed as previously described (Qu et al., 2016). For each cell line, three 127 
operators replicated the assay twice in order to ensure reproducibility of the observations. 128 
The results were obtained by flow cytometry using either FACScanto or LSRII (BD 129 
Biosciences, NJ, US).  130 
RNA isolation and sequencing 131 
The treated cells were harvested and the cell pellets were snap frozen with liquid nitrogen 132 
and stored at −80 °C. Total RNA was isolated with PureLink™ RNA Mini Kit (Thermo Fisher 133 
Scientific) according to the manufacturer’s protocol. After quantified using a NanoDrop 134 
Spectrophotometer ND-1000 (Thermo Fisher Scientific), the quality of the total RNA was 135 
verified on a Bioanalyzer by Cancer Genome Facility (SA, Australia) ensuring all samples had 136 
RINs >7.0. 137 
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 For both cell lines, the sequencing was performed in Ramaciotti Centre for Genomics (NSW, 138 
Australia). The sample preparation for each cell line was TruSeq Stranded mRNA-seq with 139 
dual indexed, on the NextSeq500 v2 platform. The parameter was 75bp paired-end High 140 
Output. The fastq files were generated and trimmed through Basespace with application 141 
“FASTQ Generation v1.0.0”.  142 
Bioinformatics analysis of RNA sequencing 143 
The clean HEPG2 reads were aligned to reference genome (hg38) using STAR v2.5.1 with 144 
following parameters: --outFilterMultimapNmax 20 --outFilterMismatchNmax 10 --145 
outSAMtype BAM SortedByCoordinate --outSAMstrandField intronMotif (Dobin et al., 146 
2013). The clean MDA-MB-231 reads were aligned to reference genome (hg19) using 147 
TopHat2 v2.1.1 with following parameters: --read-gap-length 2 --read-edit-dist 2 (Kim et al., 148 
2013). Differential expression analysis for reference genes was performed with edgeR and 149 
differentially expressed (DE) genes were selected with a False Discovery Rate (FDR) < 0.05 150 
(Robinson et al., 2010). 151 
The DE genes in common for both HEPG2 and MDA-MB-231 cell lines at 24 hours and 48 152 
hours after CKI treatment were selected as “shared” genes. These shared genes were 153 
utilized to describe the major anti-cancer functions and principal mechanisms of CKI. 154 
Gene Ontology (GO), and Kyoto Encyclopedia of Gene and Genomes (KEGG) over-155 
representation analyses of both cell lines were carried out using the online database system 156 
ConsensusPathDB (Kamburov et al., 2008) with the following settings: “Biological process” 157 
(BP) at third level (for GO); q values (<0.01) were corrected for multiple testing with the 158 
system default settings. Disease ontology (DO) over-representation analyses of both cell 159 
lines were performed by using the Bioconductor R package clusterProfiler v3.5.1 (Yu et al., 160 
2012). For the function analyses of shared/core genes, the method was as similar as our 161 
previous study (Qu et al., 2016) using ClueGO app 2.2.5 in Cytoscape v3.6.0. We enriched 162 
our GO terms in the biological process category level 3 and KEGG pathways, showing only 163 
terms/pathways with p values less than 0.01. Specific Over-represented terms/pathways 164 
and gene expression status mapping in KEGG pathways were visualised with the R package 165 
“Pathview” (Luo and Brouwer, 2013).  166 
Gene expression-based investigation of bioactive components in CKI 167 
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To integrate with previous data from MCF-7 cells (Qu et al., 2016), all the shared DE genes 168 
regulated by CKI identified in all three cell lines using edgeR were mapped to the BATMAN-169 
TCM database (Liu et al., 2016). The pharmacophore modelling method (Li et al., 2012) was 170 
used to generate the interaction network between the key genes and TCM components 171 
using R package igraph (Csardi and Nepusz, 2006). 172 
Reverse transcription quantitative polymerase chain reaction (RT-qPCR) 173 
RT-qPCR was performed as previously described (Qu et al., 2016). The list of target genes 174 
selected for this study and the sequences of all primers are shown in Additional file 1: Table 175 
S1. 176 
Results 177 
Effect of CKI on the cell cycle and apoptosis 178 
In our previous study, CKI significantly perturbed/suppressed cancer cell target 179 
genes/networks. In the current study we present results that confirm and generalise our 180 
previous work. We observed in the MCF-7 study, low concentrations of CKI in our short-181 
term cell assay showed no/little phenotypic effect within 48 hours, and very high doses 182 
resulted in excessive cell death at 48 hours precluding the isolation of sufficient RNA for 183 
transcriptome analysis (Qu et al., 2016). Therefore, in our current study with the two 184 
additional cell lines, to ensure consistency, we also selected 1 mg/ml and 2 mg/ml total 185 
alkaloid concentrations of CKI for our assays because they generated reproducible and 186 
significant phenotypic effects in our cell culture assay. 187 
We used flow cytometric analysis of propidium iodide (PI) stained cells to assess both CKI 188 
induced alterations to the cell cycle and apoptosis. In HEPG2 cells, CKI treatment resulted in 189 
an overall increase in the proportion of cells in G1 phase and decrease in S phase (Fig. 1a 190 
and b). Similarly in MDA-MB-231 cells, although a consistent increase in G1 phase was not 191 
observed, CKI caused a decrease in S phase particularly at the 24-hour time point (Fig. 1a 192 
and b) indicating possible incidence of cell cycle arrest at G1 phase.  Furthermore, at 2 193 
mg/ml of total alkaloids, CKI consistently induced significantly higher level of apoptosis in 194 
both cell lines at both time points compared to untreated controls (Fig. 1c). These data 195 
together suggest that CKI has effects on the cell cycle by interfering with the transition 196 
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between G1 to S phase as well as by acting on the apoptosis pathway and promoting cell 197 
death. 198 
CKI perturbation of gene expression 199 
In order to elucidate the molecular mechanisms of action of CKI on these cancer cells, 200 
transcriptome analysis of CKI treated cells was performed. As mentioned above, RNA 201 
samples from two cell lines were sequenced with 2x75 bp paired-end reads. We had 202 
previously sequenced transcriptomes from CKI treated MCF-7 cells (Qu et al., 2016) and 203 
have included those results for comparison below. The samples from each cell line 204 
contained 7 groups at 3 time points (Fig. 2a), in triplicate for every group. In the 205 
multidimensional scaling (MDS) analysis, each cell line clustered independently and 206 
generally, within the cell line clusters, untreated cells clustered apart from treated cells 207 
(Additional file 2: Fig. S1). 208 
With the mapping rate were around 90% (Additional file 3: Table S2), a P-value based 209 
ranked list of DE genes (compared to untreated from each time point) was generated for 210 
both cell lines (Additional file 4: Table S3, sheet 1-4). This list was used to select the shared 211 
DE genes. This analysis generated thousands of DE genes (Additional file 4: Table S3, sheet 212 
5) across two cell lines.  213 
Because for each cell line the respective treatment groups clustered together on the MDS 214 
plot, there were large numbers of shared genes between them. As a result, we identified a 215 
set of 6852 shared DE genes by identifying common DE genes from HEPG2 and MDA-MB-216 
231 cell lines, at 24hours and 48 hours (Fig. 2b). These shared genes might predict a 217 
common molecular signature for CKI’s activity. However, there were still a large number of 218 
DE genes that were not shared by both cell lines, as seen in the heatmap in Fig. 2c. The 219 
expression of the shared gene set in both HEPG2 and MDA-MB-231 is highly consistent.  220 
Interestingly, this consistency is with respect to treatment time, rather than with respect to 221 
cell line.  222 
RT-qPCR validation and dose response of gene expression to CKI 223 
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Based on our previous results (Qu et al., 2016), and analysis below, we selected the 4 top 224 
ranked DE genes expressed in G1-S phase of the cell cycle (TP53 and CCND1 for expression 225 
level validation and E2F2and PCNA for low dose response), as well as the proliferation and 226 
differentiation relevant ras subfamily encoding gene (RAP1GAP1) for low dose response. We 227 
also selected a prominently expressed gene (CYP1A1) for validation because of its sensitivity 228 
to CKI treatment. CYP1A1, TP53 and CCND1 expression changes were validated with RT-229 
qPCR with all three genes showing similar patterns of expression in the transcriptome data 230 
and RT-qPCR (Fig. 3a). 231 
Because low dose treatment with CKI did not cause significant gross phenotypic effects in 232 
either cell line, we decided to use gene expression as a more sensitive measure of 233 
phenotype to look at the effect of lower doses of CKI. We used 0.125 mg/ml, 0.25 mg/ml, 234 
0.5 mg/ml and 1mg/ml concentrations to look for dose dependency of gene expression.  235 
Our results showed an obvious dose-dependent expression trend (Fig. 3b) in both cell lines. 236 
Because the 0.125mg/ml concentration of CKI is equivalent to what cancer patients are 237 
treated with, our results are potentially clinically relevant.  238 
Function enrichment analysis 239 
To identify candidate mechanisms of action of CKI, we carried out functional enrichment 240 
analysis. We used ConsensusPathDB(Kamburov et al., 2008) and Clusterprofiler (Li et al., 241 
2012) along with GO and KEGG pathways for over-representation analysis, along with 242 
disease ontology (DO) (Schriml et al., 2011) enrichment.  243 
GO over-representation test was determined based on Biological Process level 3 and q value 244 
0.01. The results for both cell lines at both time points were summarised and visualized 245 
based on semantic analysis of terms in Fig. 4a. From this result, it was obvious that there 246 
were a large proportion of enriched GO terms relating to cell cycle, such as “cell cycle 247 
checkpoint”, “negative/positive regulation of cell cycle process” and so on prominently 248 
featured for all data sets (Additional file 5: Fig. S2, Additional file 6: Table S4, sheet 1-4).  249 
We then used KEGG pathways to determine the specific pathways altered by CKI in cancer. 250 
The most regulated over-representative KEGG pathways are summarized according to KEGG 251 
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Orthology (KO) (Fig. 4b). Cell cycle related pathways such as “cell cycle”, “DNA replication”, 252 
and “apoptosis” were also consistently seen in the KEGG enrichment results (Additional file 253 
6: Table S4, sheet5-8) at both 24 and 48 hours. Moreover, in addition to the cell cycle 254 
relevant pathways, some cancer related pathways were also observed, such as “prostate 255 
cancer” and “chronic myeloid leukaemia”, and a large number of DE genes (283) from the 256 
two cell lines were relevant in “pathways in cancer”. 257 
Because the KEGG enrichment revealed many pathways relating to diseases, most of which 258 
were cancers, we decided to explore the enrichment of DE genes with respect to DO terms 259 
(Fig. 4c). In the DO list (Additional file 6: Table S4, sheet 9-12), all top ranked terms listed are 260 
cancers. Interestingly, most cancer types listed are from the lower abdomen, for example 261 
“ovarian cancer”, “urinary bladder cancer “and “prostate cancer” etc. occurring in 262 
genitourinary organs (Additional file 6: Table S4, sheet 9-12). For both KEGG pathway and 263 
DO enrichment, the effects of CKI on both cell lines were similar.   264 
In addition to cell line specific functional enrichment of DE genes, we also analysed the over-265 
represented GO terms for shared DE genes (Fig. 5a). The most significant clusters were 266 
highly relevant to metabolic process, such as “cellular macromolecule metabolic process”, 267 
as well as the corresponding positive/negative regulatory biological process (Additional file 268 
6: Table S4, sheet 13). Moreover, various signalling pathways, though not forming a large 269 
cluster, were also significant, for example, “regulation of signal transduction” and 270 
“intracellular receptor signalling pathway”. Finally, some “cell cycle” related terms 271 
constituted relatively large sub-clusters, including “cell division” and “mitotic cell cycle 272 
process”. The enriched GO analysis was consistent with the cell line specific enriched 273 
results, and with our previous analysis of MCF-7 cells (Qu et al., 2016). It is worth noting that 274 
for “cell cycle” related terms, most of the participating genes were down-regulated by CKI. 275 
Similar results were observed from KEGG analysis (Fig. 5b, and Additional file 6: Table S4， 276 
sheet 14) of shared genes. Various pathways related to cancer, formed a large cluster. 277 
Pathways such as “DNA replication”, “Ribosome” and “cell cycle” were mostly down-278 
regulated, while up-regulated pathways included “inositol phosphate metabolism” and 279 
“protein processing in endoplasmic reticulum”.  280 
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We also carried out over-representation analysis of DO terms (Fig. 5c) for all shared DE  281 
genes. The analysis results were consistent with the single cell line DO term analysis with 282 
mostly cancer related terms; in particular genitourinary or breast cancer terms.  While this 283 
was also partially similar to the KEGG results for shared DE genes, there were some 284 
differences in the KEGG results for disease pathways compared to the DO results, such as 285 
“bacterial invasion of epithelial cells”, “Fanconi anemia pathway” and “AGE-RAGE pathway 286 
in diabetic complications”.  287 
Regulation of specific pathways related to cancer 288 
Specific to the therapeutic potential of CKI for cancer treatment, we applied our data set 289 
mapping to KEGG cancer pathways: pathways in cancer- homo sapiens (Additional file 7: Fig. 290 
S3). The R package Pathview (Luo and Brouwer, 2013) was used to integrate log fold change 291 
values of all the genes expression patterns into these target pathways. Within the 21 292 
pathways in cancer, the “cell cycle” still featured prominently (Fig. 6a). The expression of 293 
almost every gene in the cell cycle pathway was affected by CKI, with most of them 294 
suppressed. We did not observe this kind of overall pathway suppression in any of the other 295 
pathways. We have displayed the summaries for the remaining 20 pathways in the heatmap 296 
in Fig. 6b. Although all the pathways were all perturbed by CKI, they include both over and 297 
under expressed genes in roughly equal proportions.  298 
Collectively, these results suggest a direct anticancer effect of CKI, and implicate specific 299 
candidate mechanisms of action based on the perturbed molecular networks. The most 300 
obvious example is the cell cycle, where G1-S phase is significantly altered, resulting in the 301 
induction of apoptosis. The downstream process triggered by CKI is the suppression of gene 302 
expression of cell cycle regulators, including P53 and CCND1. The other perturbed cancer 303 
pathways provide additional candidate mechanisms of action for CKI. In the following 304 
section we integrate these results with previous results reported in the literature to refine 305 
the core set of genes and pathways perturbed by CKI.   306 
Discussion  307 
Although HEPG2 (liver cancer – mesodermal tissue origin) and MDA-MB-231 (mammary 308 
epithelial adenocarcinoma – ectodermal tissue origin) are different cancer types, they 309 
shared a large number of CKI DE genes with similar expression profiles, presumably these 310 
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shared genes include CKI response genes that are essential to the apoptotic response 311 
triggered by CKI. However, the number of shared CKI DE genes is too high to allow straight 312 
forward identification of genes critical to the CKI response.  We therefore decided to 313 
combine these data with previously reported CKI DE genes from MCF-7 cells (Qu et al., 314 
2016) in order to reduce the number of core CKI response genes.  The intersection of MCF-7 315 
CKI DE genes with the shared CKI DE genes yielded 363 core CKI DE genes (Additional file 8: 316 
Fig. S4).  317 
Among the 363 core CKI DE genes, cytochrome P450 family 1 subfamily A member 1 318 
(CYP1A1) gene is the most over-expressed. This gene is consistently up-regulated by CKI in 319 
all three cell lines, and showed significant dose response. In liver cancer cells, over-320 
expression of CYP1A1 induced by plant natural products has been associated with Aryl-321 
hydrocarbon Receptor transformation  (Anwar-Mohamed and El-Kadi, 2009; Zhou et al., 322 
2016).   Furthermore, as a steroid-metabolizing enzyme, CYP1A1 is part of cancer metabolic 323 
processes relevant to steroid hormone responsive tumours, such as breast cancer, ovarian 324 
cancer and prostate cancer (Mitsui et al., 2016; Nandekar et al., 2016; Ou et al., 2016; 325 
Piotrowska-Kempisty et al., 2017). Therefore, CYP1A1 may be of particular interest for 326 
understanding the mechanism of action of CKI on cancer cells.  327 
Comparison of the 363 core genes to the 135 Tumour Alterations Relevant for Genomics-328 
driven Therapy (TARGET) genes (version 3) from The Broad Institute 329 
(https://www.broadinstitute.org/ cancer/cga/target) identified 7 DE genes that were shared 330 
across the three cell lines and two time points (Fig. 7a). Of these seven genes, six (TP53, 331 
CCND1, MYD88 (Myeloid differentiation primary response gene 88) , EWSR1, TMPRSS2 and 332 
IDH1 (isocitrate dehydrogenase 1)) were similarly regulated (either always over-expressed 333 
or under-expressed), while CCND3 was over-expressed in all three cell lines at both time 334 
points except at 48 hours in MCF-7 cells, where it was under-expressed.  335 
The TP53 gene encodes a tumor suppressor protein, that can induce apoptosis (Harris and 336 
Levine, 2005). However, in all cell lines TP53 was down-regulated, and all cell lines showed 337 
increased apoptosis. This suggests that CKI induced apoptosis was not TP53-dependent. 338 
Support for this comes from the fact that transcripts for PCNA (proliferating cell nuclear 339 
antigen), and a group of transcription factors: MCM (mini-chromosome maintenance) 340 
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complex and the E2F family are down-regulated. The E2F transcription factors regulate the 341 
cell cycle and TP53-dependent and -independent apoptosis (Hollern et al., 2014; Sun et al., 342 
2013; Woods et al., 2007; Zaldua et al., 2016). In addition, other core genes present in the 343 
TARGET database have also been shown to induce apoptosis. For example, inhibition of 344 
MYD88 induces apoptosis in both triple negative breast cancer and bladder cancer 345 
(Christensen et al., 2017; Zhang et al., 2016).  The increased expression of IDH1  may be 346 
important, as IDH1 is frequently mutated in cancers (Li et al., 2012) and when mutated, it 347 
causes loss of −ketoglutarate production and may be important for the Warburg effect. 348 
TMPRSS2 (transmembrane protease, serine 2) has also been shown to regulate apoptosis in 349 
cancer (Afar et al., 2001). Therefore, CKI may induce apoptosis through a variety of means. 350 
In the GO (Fig. 7b) and KEGG (Fig. 7c) over-representation analysis of the 363 core genes 351 
yielded enrichment for cell cycle and cancer pathways. In the GO enriched genes, cell cycle 352 
and related pathways accounted for the majority of functional sub-clusters. In the KEGG 353 
enriched pathways, cell cycle and cancer pathways predominated in a single cluster. Most of 354 
the core genes in GO and KEGG clusters were down-regulated by CKI.  355 
In addition to the cell cycle, CKI treatment also caused enrichment for terms or pathways 356 
related to cancer progression, such as “focal adhesion” and “blood vessel development”. 357 
(Additional file 6: Table S4, sheet 5-8). These developmental processes contribute to 358 
tumorigenesis and metastasis(Luo and Guan, 2010; Warren et al., 1995). It is tempting to 359 
speculate that CKI may alter these functions in vivo, possibly altering angiogenesis which is 360 
critical for tumours (Hanahan and Folkman, 1996). In addition, there were metabolic 361 
pathways and terms that were also identified as perturbed by CKI. Effects on many 362 
targets/pathways is one of the expected features of TCM drugs which likely hit multiple 363 
targets (Efferth et al., 2007). 364 
We have examined the effect of a complex mixture of plant natural products (CKI) on 365 
different cancer cell lines and have identified specific, consistent effects on gene expression 366 
resulting from this mixture. However, the complexity of CKI makes it difficult to determine 367 
the mechanism of action of individual components, and often testing of individual 368 
components has resulted in either no effect or contradictory results in the research 369 
literature. In spite of this complexity, it is possible to map our results on to a pre-existing 370 
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corpus of work that links individual natural compounds to changes in gene expression. We 371 
have used BATMAN (Liu et al., 2016), an online TCM database of curated links between 372 
compounds and gene expression. Based on this resource, we have identified 14 components 373 
of CKI that have been linked to the regulation of 52 of our core genes (Fig. 7d). We can see 374 
from the network diagram in Fig. 7d that one to one, one to many and many to many 375 
relationships exist between CKI components and genes which is consistent with previous 376 
studies (Liu et al., 2014; Wu et al., 2015; Zhang and Yu, 2016). As more information becomes 377 
available for individual components, we will be able to construct a more comprehensive 378 
model of CKI mechanism based on network analysis. 379 
Conclusions 380 
 Our systematic analysis of gene expression changes in cancer cells caused by a complex 381 
herbal extract used in TCM has proven to be effective at identifying candidate molecular 382 
pathways. CKI has consistent and specific effects on gene expression across multiple cancer 383 
cell lines and it also consistently induces apoptosis in vitro. These effects show that CKI can 384 
suppress the expression of cell cycle regulatory genes and other well characterized cancer 385 
related genes and pathways. Validation of a subset of DE genes at lower doses of CKI has 386 
shown a dose-response relationship that suggests that CKI may have similar effects in vivo 387 
at clinically relevant concentrations. Our results provide a molecular basis for further 388 
investigation of the mechanism of action of CKI.  389 
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Figure legends 561 
Fig. 1 562 
Effects of different treatment on cell cycle and apoptosis of HEPG2 and MDA-MB-231 cells. 563 
A) The apoptosis and cell cycle distribution of each cell line after 24- and 48-hour 564 
treatments with CKI or 5-Fu assessed PI staining. B) Percentages of cells in different phases 565 
of cell cycle resulting from treatment. c Percentage of apoptotic cells after treatment. 566 
Results shown are mean ±SEM (n=6). Statistically significant differences from untreated 567 
control were identified using two-way ANOVA (*p<0.05, **p<0.01, ****p<0.0001).  568 
Fig. 2  569 
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DE genes shared in both cell lines at both time points. A) Work flow diagram showing 570 
experimental design and sample collection. B) Venn diagram showing the number of shared 571 
DE genes between HEPG2 and MDA-MB-231. C) Heatmap presenting the overall gene 572 
expression pattern in both cell lines treated with CKI. Heatmap is split into four parts based 573 
on gene content and expression pattern: 5442 differentially regulated genes with 574 
expression not shared between the two cell lines, 3157 upregulated genes shared between 575 
both cell lines, 3522 down-regulated genes shared between both cell lines, and 173 576 
discordantly regulated genes with differential expression shared between both cell lines. 577 
Fig. 3  578 
Validation of gene expression and effects of low dose CKI using RT-qPCR. A) Comparison of 579 
DE genes between RNA-seq results (left) and RT-qPCR validation (right) for each cell line at 2 580 
time-points. Three DE genes (CYP1A1, TP53 and CCND1) were chosen for validation. Gene 581 
expression was generally consistent between transcriptome data and qPCR data. B) Dose 582 
response of CKI using a subset of genes with conserved expression in HEPG2 (left), and 583 
MDA-MB-231 (right) from 0 mg/ml to 1 mg/ml of total alkaloids. Six genes (CYP1A1, TP53, 584 
CCND1, Rap2GAP1, E2F2 and PCNA) were selected based on their relevance to important 585 
pathways perturbed by CKI. RT-qPCR results are presented as expression relative to RPS13. 586 
Data are represented as mean ±SEM (n>3). A t-test was used to compare CKI doses with 587 
“untreated” (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).  588 
Fig. 4  589 
Functional annotation of DE genes for each cell line as a result of CKI treatment. Summary of 590 
over-represented A) GO terms for Biological Process, B) KEGG pathways and C) DO terms for 591 
DE genes as a result of CKI treatment in each cell line at two time points. For GO semantic 592 
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and enrichment analysis, Lin’s algorithm was applied to cluster and summarize similar 593 
functions based on GO terms found in every treatment. Similarly, by back-tracing the 594 
upstream categories in the KEGG Ontology, we were able to obtain a more generalized 595 
summary of KEGG pathways for each treatment. The size of each bubble represents the 596 
number of GO terms/pathways, and the colour shows the statistical significance of the 597 
relevant function or pathways. The DO summary for each treatment was determined by 598 
back-tracing to parent terms. 599 
Fig. 5 600 
Functional annotation of DE genes with shared expression in both cell lines as a result of CKI 601 
treatment. Over-representation analysis was performed to determine A) GO terms for 602 
Biological Process, B) KEGG pathways, and C) DO terms for DE genes shared in both cell 603 
lines. In nodes for both GO terms and KEGG pathways, node size is proportional to the 604 
statistical significance of over-representation. For DO terms, all the enriched terms are 605 
statistically significant (p<1x10-5) in each category, and the bar length represents the 606 
number of expressed genes that map to the term. 607 
Fig. 6 608 
Comparison of shared genes expression in specific pathways across two cell lines. A) Cell 609 
cycle pathways, where each coloured box is separated into 4 parts, from left to right 610 
representing 24h CKI treated HEPG2, 48h CKI treated HEPG2, 24h CKI treated MDA-MB-231 611 
as well as 48h CKI treated MDA-MB-231. B) Heatmap of pathways in cancer. The top two 612 
heatmaps summarise the effects of CKI on HEPG2 cells for two time-points, and the bottom 613 
two heatmaps show the effects of CKI on MDA-MB-231 cells. In addition to the cell cycle 614 
pathway, there were 21 associated pathways in cancer that were perturbed by CKI. The 615 
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effects of CKI on both cell lines were similar, with changes in TARGET database genes 616 
indicated by arrows. Compared to other pathways in cancer, the effects of CKI on the cell 617 
cycle pathway showed overall down-regulation. 618 
Fig. 7. 619 
Analysis of CKI regulated core genes from this report combined with previous available data. 620 
A) Fold changes of TARGET and cell cycle regulatory gene expression in MDA-MB-231, 621 
HEPG2 and MCF-7(Qu et al., 2016) cell lines 24 and 48 hours after CKI treatment. Only seven 622 
TARGET genes are affected by CKI in all three cell lines. Most of the 14 cell cycle regulatory 623 
genes differentially expressed in all three cell lines are down-regulated.  B) GO term 624 
enrichment analysis of 363 core genes from MDA-MB-231, HEPG2 and MCF-7 cell lines. C) 625 
KEGG pathway enrichment of 363 core genes from MDA-MB-231, HEPG2 and MCF-7 cell 626 
lines. D) Some individual compounds present in CKI linked to genes they regulate that are 627 
also found in this report and our previous study (add citation number Qu et al, 2016).  Node 628 
size is proportional to the number of related components/genes. 629 
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Cell Cycle, Glycolysis and DNA Repair Pathways in
Cancer Cells are Suppressed by Compound Kushen
Injection
Previous work identified the cell cycle, energy metabolism and DNA replication/repair
as candidate target pathways and they were selected for validation experiments. We
carried out a series of experiments to validate the effects of CKI on energy charge, lactate
production, glucose consumption, DNA double strand breaks (DSB) and the ku70/ku80
protein complex in DNA repair in MDA-MB-231 and HEPG2 cell lines. Decreased
reduction in energy charge, increased lactate production and reduced glucose consumption
along with decreased levels of proteins responsible for cell cycle regulation and DNA
repair and increased levels of DSB were observed after treatment with CKI. This chapter
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In this report, we examine candidate pathways perturbed by Compound Kushen Injection (CKI) a
Traditional Chinese Medicine (TCM) that we have previously shown to alter the gene expression
patterns of multiple pathways and induce apoptosis in cancer cells. We have measured protein levels
in Hep G2 and MDA-MB-231 cells for genes in the cell cycle pathway, DNA repair pathway and
DNA double strand breaks (DSBs) previously shown to have altered expression by CKI. We have
also examined energy metabolism by measuring [ADP]/[ATP] ratio (cell energy charge), lactate
production and glucose consumption. Our results demonstrate that CKI can suppress protein levels
for cell cycle regulatory proteins and DNA repair while increasing the level of DSBs. We also show
that energy metabolism is reduced based on reduced glucose consumption and reduced cellular
energy charge. Our results validate these pathways as important targets for CKI. We also examined
the e↵ect of the major alkaloid component of CKI, oxymatrine and determined that it had no e↵ect
on DSBs, a small e↵ect on the cell cycle and increased the cell energy charge. Our results indicate
that CKI likely acts through the e↵ect of multiple compounds on multiple targets where the
observed phenotype is the integration of these e↵ects and synergistic interactions.
Keywords:
alkaloid, matrine, cyclin, Ku70, Ku80, cell-cycle
Abbreviations
DSBs, double strand breaks; Ku70/Ku80,the Ku heterodimer proteins 1
Introduction 2
Compound Kushen Injection (CKI) is a complex mixture of plant bioactives extracted from Kushen 3
(Sophora flavescens) and Baituling (Smilax Glabra) that has been approved for use in China since 4
1995 by the State Food and Drug Administration (SFDA) of China (State medical license no. 5
Z14021231). CKI is widely used in China as an adjunct for both radiotherapy and chemotherapy in 6
cancer. While most of the data supporting its use have been anecdotal and there is little clinical trial 7
data demonstrating its e cacy, it has been shown to be e↵ective at reducing sarcoma growth and 8
cancer pain in an animal model[1] and cancer pain in patients [2]. 9
164
CKI contains over 200 chemical compounds including alkaloids and flavonoids such as matrine, 10
oxymatrine and kurarinol, and has previously been shown to a↵ect the cell cycle and induce 11
apoptosis in cancer cells[1, 2, 3, 4, 5, 6, 7]. Furthermore, functional genomic characterization of the 12
e↵ect of CKI on cancer cells using transcriptome data indicated that multiple pathways were most 13
likely a↵ected by CKI [4]. These observations support a model wherein many/all of the individual 14
compounds present in CKI can act on many single targets or on multiple targets to induce apoptosis. 15
Based on previously reported work [4] and our currently unpublished work (Cui et al)[8], specific 16
pathways were selected for follow up experiments to validate their response to CKI in order to 17
formulate more specific hypotheses regarding the mechanism of action of CKI on cancer cells. We 18
had previously shown that CKI altered the cell cycle and induced apoptosis while altering the 19
expression of many cell cycle genes in three cancer cell lines [4, 8]. We had also shown that DNA 20
repair pathway genes were significantly down-regulated by CKI and that energy production related 21
to NAD(P)H synthesis from glycolysis and oxidative phosphorylation was reduced by CKI. As a 22
result, we focused on the following candidate pathways: cell cycle, DNA repair and glucose 23
metabolism to validate their alteration by CKI. We used two cell lines for these validation 24
experiments, one relatively insensitive to CKI (MDA-MB-231) and one sensitive to CKI (Hep G2). 25
Furthermore, while the literature shows varying e↵ects for major compounds present in CKI on 26
cancer cells [9, 10], we also tested oxymatrine, the major alkaloid found in CKI and widely believed 27
to be very important for the e↵ects of CKI, on our selected pathways. 28
Materials and methods 29
Cell culture and chemicals 30
CKI with a total alkaloid concentration of 26.5 mg/ml in 5 ml ampoules was provided by Zhendong 31
Pharmaceutical Co. Ltd. (Beijing, China). Cell culture methods have been previously described [4]. 32
A human breast adenocarcinoma cell line, MDA-MB-231 and a hepatocellular carcinoma cell line 33
Hep G2 were purchased from American Type Culture Collection (ATCC, Manassas, VA). The cells 34
were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Thermo Fisher Scientific, MA, USA) 35
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supplemented with 10% fetal bovine serum (Thermo Fisher Scientific). Both cell lines were cultured 36
at 37￿ with 5% CO2. For all in vitro assays, cells were cultured overnight before being treated with 37
either CKI (at 1 mg/ml and 2 mg/ml of total alkaloids). As a negative control, cells were treated 38
with medium only and labeled as “untreated”. After 24 and 48 hours of treatment, cells were 39
harvested and subjected to the downstream experiments. 40
All the in vitro assays employed either 6-well plates or 96-well plates. The seeding density for 41
6-well plates for both cell lines was 4⇥105 cells and treatment methods were as previously described 42
[4]. The seeding density of Hep G2 cells for 96 well plates was 4⇥103 cells per well and for 43
MDA-MB-231 cells was 8⇥104 cells per well, and used the same treatment method as above: after 44
seeding and culturing overnight, cells were treated with 2 mg/ml CKI diluted with complete medium 45
for the specified time. 46
Glucose consumption assay 47
Glucose consumption was determined by using a glucose oxidase test kit (GAGO-20, Sigma, St. 48
Louis, MO). After culturing for di↵erent durations (3, 6, 12, 24 and 48 hours), 50 µl of culture 49
medium was collected from untreated groups and treated groups. The cells were trypsinized for cell 50
number determination using trypan blue exclusion assay and the number of bright, viable cells were 51
counted using a hemocytometer. Collected suspension, blank medium and 2 mg/ml CKI, were all 52
filtered and diluted 100 fold with MilliQ water. The absorbance at 560 nm was converted to glucose 53
concentration using a 5µg/ml glucose standard from the kit as a single standard. Glucose 54
consumption was calculated by subtracting the blank medium value from treated/collected medium 55
values. Glucose consumption per cell was calculated from the number of cells determined above. 56
Measurement of [ADP]/[ATP] ratio 57
Cells were cultured in white 96-well plates with clear bottoms. The [ADP]/[ATP] ratio of both cell 58
lines was determined immediately after the incubation period (24 and 48 hours) using an assay kit 59
(MAK135; Sigma Aldrich, USA) according to the manufacturer’s instructions. Levels of luminescence 60
from the luciferase-mediated reaction were measured using a plate luminometer (PerkinElmer 2030 61
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multilabel reader, USA for CKI experiments or Promega, USA for oxymatrine experiments). The 62
[ADP]/[ATP] ratio was calculated from the luminescence values using a formula provided by the kit 63
manufacturer. 64
Lactate content assay 65
The concentration of lactate, the end product of glycolysis, was determined using a lactate 66
colorimetric assay kit (Abcam, Cambridge, MA, USA). Cells were cultured in 6-well plates, and then 67
harvested and deproteinized according to the manufacturer’s protocol. The optical density was 68
measured at 450 nm and a standard curve plot (nmol/well vs. OD 450 nm) was generated using 69
serial dilutions of lactate. Lactate concentrations were calculated with the formula provided by the 70
kit manufacturer. 71
Cell cycle assay 72
Cells were cultured in 6-well plates and treated with 2 mg/ml CKI or 0.5 mg/ml oxymatrine. After 73
culturing for 3, 6, 12, 24 and 48 hours, cells were harvested and subjected to cell cycle analysis by 74
Propidium Iodide staining as previously reported [4]. Data were obtained by flow cytometry using 75
Accrui (BD Biosciences, NJ, US) and analysed using FlowJo software (Tree Star Inc, Ashland, 76
Oregon, USA). 77
Microscopy 78
After culturing for 48 hours on 8 well chamber slides, control and treated cells were fixed in 1% 79
paraformaldehyde for 10 minutes at room temperature, washed with Phosphate Bu↵ered Saline three 80
times and permeabilized with 0.5% Triton X-100 for 10 minutes. After fixation and permeabilization, 81
cells were blocked with 5% Fetal Bovine Serum for 30 minutes. Permeabilized cells were stained with 82
5µg/ml of Alexa Fluor®594 conjugated anti-H2AX.X Phospho (red) (Biolegend, Ser139) in 5% 83
Fetal Bovine Serum overnight followed with Alexa Fluor®488 conjugated Phalloidin (green) 84
(Biolegend) staining for 20 minutes at 4￿. 85
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Stained cells were mounted with 4’,6-diamidino-2-phenylindole (DAPI) and visualized with an 86
Olympus FV3000 (Olympus Corporation, Tokyo, Japan) confocal microscope using a 60× oil 87
objective. Fluorescence intensity was quantified using Imaris software (Bitplane, Saint Paul, MN) 88
and averaged using at least 10 cells in each experiment. 89
Flow-cytometry quantification of protein expression 90
Cells were cultured in 6-well plates and treated with CKI. After 24 and 48 hours, cells were 91
harvested to detect intranuclear/intracellular levels of proteins involved in cell cycle and DNA DSBs 92
pathways using the following antibodies; (cell cycle primary antibodies: (Cell Signaling Technologies, 93
Danvers, MA, USA: P53 Rabbit mono-Ab, CCND1 Rabbit mono-Ab, CDK2 Rabbit mono-Ab) 94
(Abcam, Cambridge, UK:CDK1 Rabbit mono-Ab), for these primaries, cell cycle isotype control: 95
Cell Signaling Technologies: Rabbit igG, cell cycle secondary antibody Anti-rabbit (PE conjugated), 96
additional primary antibody: CTNNB1 Rabbit mono-Ab (Alexa Fluor®647 conjugated) and isotype 97
control: Rabbit IgG (Alexa Fluor®647 conjugated), both from Abcam)(DSBs antibody: Anti-H2AX 98
(PE conjugated) primary antibody and isotype control: Mouse IgG1 (PE conjugated) both from 99
BioLegend, San Diego, CA, USA) (DNA repair antibodies: primary antibodies - KU70 Rabbit 100
mono-Ab (Alexa Fluor®647 conjugated) and KU80 Rabbit mono-Ab (Alexa Fluor®647 101
conjugated), Isotype control: Rabbit IgG (Alexa Fluor®647 conjugated), all from Abcam) Cells 102
were sorted and the data acquired on a FACS Canto (BD Biosciences, NJ, US) or Accrui (BD 103
Biosciences, NJ, US), and the data were analysed using FlowJo (Tree Star Inc.) software. 104
Cell cycle functional enrichment re-analysis 105
In order to identify the phases of the cell cycle a↵ected by CKI, di↵erentially expressed gene data 106




All measurements above were performed in triplicate and repeated at least three times. Statistical 110
significance was determined by two-way ANOVA test; error bars represent standard deviation. 111
Results 112
Pathway validation 113
Based on our previous results indicating that CKI could suppress NAD(P)H synthesis [4] and 114
(Supplementary Material, Figure S1), we examined the e↵ect of CKI on energy metabolism by 115
measuring glucose uptake, [ADP]/[ATP] ratio and lactate production. We measured glucose uptake 116
in both CKI treated and untreated cells from 0 to 48 hrs after treatment and observed a reduction in 117
glucose uptake (Fig. 1A). The growth curves for both cell lines were relatively flat after CKI 118
treatment, in contrast to untreated cells. MDA-MB-231 cells, which are less sensitive to CKI in 119
terms of apoptosis, had a higher level of glucose uptake than Hep G2 cells, which are more sensitive 120
to CKI. Because the overall glucose uptake was consistent with the cell growth curves, the glucose 121
consumption per million cells for each cell line under treatment was di↵erent. Untreated Hep G2 122
cells maintained a relatively flat rate of glucose consumption per million cells, while for CKI treated 123
Hep G2 cells the rate of glucose consumption per million cells decreased with time, becoming 124
significantly less towards 48 hrs. The glucose consumption variance for both untreated and treated 125
MDA-MB-231 cells was high, but both overall glucose consumption and glucose consumption per 126
million cells appeared to decrease over time. 127
Because changes in glucose consumption are mirrored by other aspects of energy metabolism, we 128
assessed the energy charge of both CKI treated and untreated cells by measuring the [ADP]/[ATP] 129
ratio at 24 and 48 hours after treatment (Fig. 1B). Hep G2 cells had a lower energy charge (higher 130
[ADP]/[ATP] ratio) compared to MDA-MB-231 cells and after CKI treatment both cell lines showed 131
a decrease in energy charge, consistent with our previous measurements using a 132
2,3-Bis(2-methoxy-4-nitro-5-sulfonyl)-2H-tetrazolium-5-carboxanilideinner salt (XTT) assay 133
(Supplementary Material, Figure S1). However, the decrease in energy charge was earlier and much 134
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more pronounced for Hep G2 cells compared to MDA-MB-231 cells. 135
The flip side of glucose consumption is the production of lactate via glycolysis, which is the initial 136
pathway for glucose metabolism. We, therefore, measured lactate production in order to determine if 137
the observed decreases in energy charge and glucose consumption were directly attributable to 138
reduced glycolytic activity. We measured intracellular lactate concentration in both CKI treated and 139
untreated cells at 24 and 48 hours after treatment (Fig. 1C) and found that lactate concentrations 140
increased as a function of CKI treatment in both cell lines. This result is consistent with a build up 141
of lactate due to an inhibition of the Tricarboxylic Acid (TCA) cycle leading to decreased oxidative 142
phosphorylation and lower cellular energy charge. CKI must, therefore, inhibit cellular energy 143
metabolism downstream of glycolysis, most likely at the level of the TCA cycle. Decreased energy 144
charge can have widespread e↵ects on a number of energy-hungry cellular processes involved in the 145
cell cycle, such as DNA replication. 146
Having validated the e↵ect of CKI on cellular energy metabolism, we proceeded to examine the 147
perturbation of cell cycle and the expression of cell cycle proteins, as these are energy intensive 148
processes. We had previously identified the cell cycle as a target for CKI based on transcriptome 149
data from CKI treated cells [4, 8]. We carried out cell cycle profiling on CKI treated and untreated 150
cells using Propidium Iodide staining and FACS (Fig. 2A) as described in Materials and Methods. 151
The two cell lines displayed slightly di↵erent profiles to each other, but their response to CKI was 152
similar in terms of an increase in the proportion of cells in G1-phase. For Hep G2 cells, CKI caused 153
consistent reductions in the proportion of cells in S-phase accompanied by corresponding increases in 154
the proportion of cells in G1-phase. This is indicative of a block in S-phase leading to accumulation 155
of cells in G1-phase. For MDA-MB-231 cells, CKI did not promote a significant decrease in the 156
proportion of cells in S-phase, but did cause an increase in the percentage of cells in G1 phase at 157
24hrs and a pronounced decrease in cells in G2/M phase at 12 hours. 158
We also examined the levels of key proteins involved in the cell cycle pathway (Cyclin 159
D1:CCND1,Cyclin Dependent Kinase 1:CDK1, Cyclin Dependent Kinase 2:CDK2, Tumor Protein 160
p53:TP53 and Catenin Beta 1:CTNNB1) at 24 and 48 hours after CKI treatment previously shown 161
to have altered transcript expression by CKI (Fig. 2B). Both cell lines showed similar results for all 162
five proteins, with decreased levels caused by CKI, and validated previous RNAseq data [4, 8]. 163
CCND1 regulates the cell-cycle during G1/S transition. CDK-1 promotes G2-M transition, and 164
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regulates G1 progress and G1-S transition. CDK-2 acts at the G1-S transition to promote the E2F 165
transcriptional program and the initiation of DNA synthesis, and modulates G2 progression. TP53 166
acts to negatively regulate cell division. CTNNB1 acts as a negative regulator of centrosome 167
cohesion. Down-regulation of these proteins is therefore consistent with cell cycle 168
arrest/dysregulation and the cell cycle result in Fig. 2A. These results indicate that CKI alters cell 169
cycle regulation consistent with cell cycle arrest. Cell cycle arrest is also an outcome that can result 170
from DNA damage such as DSBs [12]. 171
We had previously observed that DNA repair genes had lower transcript levels in CKI treated 172
cells [4, 8], so hypothesised that this might result in increased numbers of DSBs. We measured the 173
expression of  -H2AX in both cell lines (Fig. 3A) and found that it was only over-expressed at 48 174
hours in CKI treated Hep G2 cells. We also carried out localization of  -H2AX using quantitative 175
immunofluorescence microscopy and determined that the level of  -H2AX increased in nuclei of CKI 176
treated cells in both cell lines (Fig. 3B). These results indicated an increase in DSBs as a result of 177
CKI treatment. In order to confirm if reduced expression of DNA repair proteins was correlated with 178
the increase in DSBs, we measured levels of Ku70/Ku80 proteins in CKI treated cells (Fig. 3C). In 179
Hep G2 cells, Ku80, a critical component of the Non-Homologous End Joining (NHEJ) DNA repair 180
pathway was significantly down regulated at both 24 and 48 hours after CKI treatment. In 181
MDA-MB-231 cells, Ku70 expression was down-regulated at both 24 and 48 hours after CKI 182
treatment, and Ku80 was down-regulated at 24 hours. Because Ku70/Ku80 are subunits of a 183
required DNA repair complex, reduced expression of either subunit will result in decreased DNA 184
repair. Our results, therefore, support a suppressive e↵ect of CKI on DNA repair, likely resulting in 185
an increased level of DSBs. 186
E↵ect of Oxymatrine, the principal alkaloid in CKI 187
Because CKI is a complex mixture of many plant secondary metabolites that may have many targets 188
and there is little known about its molecular mode of action, we examined the e↵ects of the most 189
abundant single compound found in CKI, oxymatrine, on the most sensitive cell line, Hep G2. 190
Oxymatrine is an alkaloid that has previously been reported to have e↵ects similar to CKI, so we 191
expected it might have an e↵ect on one or more of our three validated pathways. 192
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Oxymatrine, at 0.5 mg/ml which is equivalent to the concentration of oxymatrine in 2mg/ml CKI, 193
did not have an equivalent e↵ect on the cell cycle compared to CKI (Fig. 4A vs Fig. 2A). 194
Oxymatrine caused only minor changes to the cell cycle with small but significant increases in the 195
proportion of cells in G1-phase at 3 and 48 hours and a small but significant decrease in the 196
proportion of cells in S1-phase at 48 hours. Oxymatrine also caused a significant increase in the 197
proportion of cells undergoing apoptosis in Hep G2 cells, albeit at a lower level than CKI 198
(Supplementary Material, Figure 2). 199
Oxymatrine had no e↵ect on H2AX levels in Hep G2 cells (Fig. 4B). This was in stark contrast to 200
the e↵ect of CKI (Fig. 3A) at 48 hours and indicated that oxymatrine alone had no e↵ect on the 201
level of DSBs. 202
Surprisingly, oxymatrine had the opposite e↵ect on energy metabolism compared to CKI, causing 203
a decrease in [ADP]/[ATP] ratio indicating a large increase in the energy charge of the cells (Fig. 204
4C). 205
Integration of results 206
The e↵ect of CKI on cancer cells was validated in all three of our candidate pathways: cell cycle, 207
energy metabolism and DNA repair. Because these pathways are not isolated, but instead are 208
integrated aspects of cell physiology CKI may act through targets in some or all of these three 209
pathways or may act through other targets that either directly or indirectly suppress these pathways. 210
CKI may also act through the synergistic e↵ects of multiple compounds on multiple targets in our 211
candidate pathways. This possibility is consistent with the partial and minor e↵ects of oxymatrine 212
on our candidate pathways. 213
Discussion 214
We have validated three pathways (cell cycle, energy metabolism and DNA repair) that are 215
perturbed by CKI and that can be used as the focus for further investigations to identify specific 216
molecular targets that mediate the perturbations. 217
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Cell cycle perturbation by CKI 218
Our results show that CKI can perturb the cell cycle by altering the proportions of cells in G1-phase, 219
S-phase and G2/M-phase. This result is similar to what we have observed before [4, 8], but has not 220
been widely reported in the literature. The alkaloid oxymatrine, the most abundant compound 221
present in CKI, has also been shown previously to perturb a number of signaling pathways [13] and 222
alter/arrest the cell cycle in a variety of cancer cells [14, 15, 16, 17, 18] and we have confirmed this 223
observation (Fig. 4A) in Hep G2 cells. Our results permit direct comparison with CKI because our 224
experiments have been done using equivalent concentrations of oxymatrine alone or in CKI. While 225
oxymatrine has an e↵ect on the cell cycle, it is not as e↵ective at perturbing the cell cycle as is CKI. 226
This indicates that oxymatrine must interact with other compounds in CKI to have a stronger e↵ect 227
on the cell cycle. 228
Energy metabolism suppression by CKI 229
We have shown for the first time that CKI can inhibit energy metabolism as demonstrated by lower 230
levels of NADH/NADPH and a higher [ADP]/[ATP] ratio. These results, combined with lower 231
glucose utilisation and higher lactate levels indicate that this suppression was likely due to inhibition 232
of the TCA cycle or oxidative phosphorylation. Previously, Gao et al [3] have reported that CKI 233
significantly increased the concentration of pyruvate in the medium and this observation in 234
combination with our results supports a decrease in metabolic flux through the TCA cycle as the 235
likely cause of the reported suppression of energy metabolism. Interestingly, oxymatrine on its own 236
had the opposite e↵ect on [ADP]/[ATP] ratio compared to CKI, indicating that it can enhance 237
energy metabolism and increase the energy charge of the cell. 238
DNA repair suppression by CKI 239
There is only one report in the literature of oxymatrine inducing DSBs [19] and no reports with 240
respect to CKI. Our results show for the first time that not only does CKI induce DSBs, but that is 241
also likely inhibits DNA repair by decreasing the expression of the Ku70/Ku80 complex required for 242
NHEJ mediated DNA repair. It is worth noting, however, that the reported e↵ect of oxymatrine on 243
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DSBs [19] uses significantly higher (4-8 fold) concentrations of oxymatrine compared to our 244
experiments. In our hands oxymatrine alone at 0.5mg/ml showed no e↵ect on DSBs as judged by the 245
level of  -H2AX after 24 or 48 hours. 246
Conclusions 247
CKI causes suppression of energy metabolism and DNA repair along with altered cell cycle 248
(summarized in Fig. 5). CKI has also previously been reported to induce apoptosis in cancer cells [4]. 249
The overarching question is if CKI has independent e↵ects on these three pathways or if the primary 250
e↵ect of CKI is through a single pathway that propagates e↵ects to other, physiologically linked 251
pathways. It may be that CKI suppresses energy metabolism thus disrupting downstream, 252
energy-hungry processes such as DNA replication and DNA repair. Alternatively, there could be 253
independent e↵ects on DNA repair leading to checkpoint-induced cell cycle perturbation/arrest. Our 254
results based on oxymatrine treatment of Hep G2 cells indicate that the cell-cycle is likely directly 255
a↵ected by oxymatrine and thus CKI. However, oxymatrine alone had no e↵ect on DNA repair and 256
boosted, rather than reduced the energy charge of the cell. Taken together, these results support a 257
model of many compounds/many targets [20] for the mode of action of CKI, where multiple 258
compounds a↵ect multiple targets and the synergistic, observed e↵ect is significantly di↵erent to that 259
seen with individual components. 260
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Figure 1. The energy metabolism determination assays in the two cell lines. A. Compar-
ison of glucose consumption analysis between the two cell lines at 3, 6, 12, 24 and 48 hours. Overall
glucose consumption is divided by cell number to calculate the consumption of glucose per million
cells. B. [ATP]/[ADP] ratio assay result for the two cell lines at 24 and 48 hours. C. Lactate content
detection for the two cell lines at 24 and 48 hours. Statistical analyses were performed using two-way
ANOVA comparing treated with untreated (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001); bars
show 1 standard deviation from the mean.
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Figure 2. Cell cycle shift by CKI and undulating expression of the key proteins . A.
Cell cycle shift regulated by CKI over 48 hours. In both cell lines, the earliest shifted cell cycle
phase was S phase 6 hours after treatment. Compared to Hep G2, MDA-MB-231 showed delayed
responses. B. Expression levels for 5 proteins (ccnd1, cdk1, cdk2, p53 and catenin   1) as a result of
CKI treatment at both 24 hours and 48 hours. Statistical analyses were performed using two-way
ANOVA comparing with untreated (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001); bars show 1
standard deviation from the mean.
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Figure 3. DSBs were increased by CKI treatment. A.  -H2AX expression from 3 hours to 48
hours after treatment with 2 mg/ml CKI in two cell lines. B. Localization of  -H2AX in two cell lines
after CKI treatment for 48 hours. Green shows the cytoskeleton stained with an antibody to F-actin,
blue is DAPI staining of nuclei, pink/red is staining of DSBs with antibody to  -H2AX. The bar graph
shows a quantification of the average number of  -H2AX foci per cell detected in immunofluorescence
images of 2 mg/ml CKI treated and untreated groups. At least 10 images of 3 independent replicate
experiments were analyzed. C.Expression of DSBs repair proteins, Ku70 and Ku80, as a result of
treatment with 2 mg/ml CKI in two cell lines. Statistical analyses were performed using two-way
ANOVA comparing treated with untreated (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001); bars
show 1 standard deviation from the mean.
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Figure 4. E↵ect of oxymatrine alone on validated pathways. Oxymatrine was tested at
0.5mg/mL which is equivalent to its concentration in CKI. A. E↵ect of oxymatrine on cell cycle
in Hep G2 cells over 48 hours. B. E↵ect of oxymatrine on  -H2AX (DSBs) levels after 24 and 48
hours. C. E↵ect of oxymatrine on [ADP]/[ATP] ratio after 24 and 48 hours. Statistical analyses were
performed using two-way ANOVA comparing treated with untreated (*p<0.05, **p<0.01, ***p<0.001,
****p<0.0001); bars show 1 standard deviation from the mean.
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Figure 5. Integration of the three pathways altered by CKI. A. General presentation of
energy metabolism a↵ected by CKI. Glucose utilization is down-regulated by CKI. This is accompanied
by increased lactate in the cytoplasm as CKI inhibits glucose metabolism downstream of glycolysis,
leading to an increase in [ADP]/[ATP] and decrease in NADH/NADPH. B. E↵ects on DNA repair in
cancer cells by CKI. CKI may be able to directly induce DSBs, but CKI may also indirectly induce
DSBs by arresting checkpoint functions during the cell cycle. In addition, CKI may also inhibit
NHEJ, the major repair mechanism for DSBs. C. Reactome functional enrichment of cell cycle genes
based on shared di↵erentially expressed (DE) genes from previous studies. From M/G1 to S phase,




Conclusions and Future Directions
For this dissertation, I have characterised the effects of CKI using various approaches. I
have developed a novel research strategy for dissecting the molecular mode of action of
components within CKI by associating phenotypic and global gene expression changes.
The strategy is based on three approaches: 1) analytical chemistry approach to fractionate
the components into different groups, 2) cellular approach that determines the phenotypic
changes triggered by these fractionated mixtures, and 3) systems biology approach to
identify their underlying molecular modes of action. In this study, oxymatrine and
oxysophocarpine (Omt and Ospc) were the only two compounds that when depleted,
caused measurable changes in the effects of CKI. Specifically, removal of N-OmtOspc
paradoxically caused a significant increase in the ability of CKI to reduce viability and
kill cells. It is worth noting that although compounds were well resolved using HPLC
in this study, its detector has limited sensitivity for quantifying the molecular mass of
the compounds, particularly when separating a compound mixture such as CKI which
contains some structurally similar compounds that might potentially have isomers. On
the other hand, MS determines the mass of each ion quantitatively and it is a relatively
sensitive detection approach to detect the molecular mass of the compounds. The flip
side of MS for analysing components from CKI is that multiple components in CKI not
only are structurally similar but have same molecular mass and hence are difficulty to
detect. Therefore, a combination of LC-MS technique would significantly enhance the
detection and separation of CKI for future experiments. If it had been applied to this
research, it would have provided more sensitivity and accuracy of the fractional deletion
of the compounds from CKI. In this study, I have only applied LC-MS/MS to identify
the nine known standard compounds in both original and fractionated mixtures and it has
provided significant benefits for understanding the fractionated mixtures as compared
to the original. Should further experiments be conducted using this fractional deletion
approach, application of LC-MS/MS is highly recommended. By linking transcriptome
analysis from different fractionated mixtures, changes of gene expression were mapped
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with respect to changes in the phenotypes of the cells. In follow on work, the inhibition of
cell migration/invasion by CKI was investigated in six cancer cell lines. By using HPLC
separated major and minor components compared with CKI in cell migration/invasion
assays, CKI was shown to be more inhibitory than either of the two fractions and that
the minor peak fraction was more inhibitory than the major peak fraction. This suggests
that the major and minor peaks/compounds may be synergistic in their contribution to
the activity of CKI. Additional experiments showed that inhibition of migration and
invasion probably occur through perturbation of the actin cytoskeleton, and impairment of
lamellipodial extension via downregulation of gene products..
A prevailing view of TCM is that multiple components act on many targets in a
many to many fashion, however, no hard evidence for this view has been published.
Studies in this dissertation identify the complex and unpredictable interactions between
components that make up CKI and support the notion that single compounds in TCM
may often have no obvious effects but that combinations of such compounds can
have significant effects on cancer cells. One possible effective mechanism that was
beyond of the scope of this thesis was the possible effect of CKI treatment on tumor
microenvironment (TME) which comprises various immune cells, fibroblasts, signaling
molecules and ECM in the surrounding cellular environment of the tumor. TCM has been
claimed to affect tumor microenvironment in several ways including inhibition of ECM
degradation and angiogenesis and reversing immunosuppression. In our signaling pathway
analyses, significant perturbation of ECM-receptor interaction, cytokine-cytokine receptor
interaction and chemokine signaling pathways were observed as a result of CKI treatment
suggesting its potential impact on the tumor microenvironment. The multiple in vitro
cancer cell lines that we have examined in this study provided critical information of the
mechanistic changes of the genes and signalling pathways as a result of CKI treatment
in various cancers. The experiment conducted with the cell models was originally for
the purpose of drug development and testing of developed anticancer drugs. Despite the
fundamental data provided by the use of cancer cell lines, there is still an uncertainty on
the fact whether or not these findings can be extrapolated to and translated into medical
practice. As it has been stated above, an important fact when applying the herbal drug
mixture to consider is the impurities of the extracted herbal medicine that have their own
biological activities which may provide false positive signals of the molecules during drug
screening. As a result, the observed effects of in vitro studies might have been associated
with both anti-cancer activities and the on-target and off-target effects of CKI. Therefore,
futher work on CKI to ensure better outcomes in cancer treatment will need appropriate
preclinical in vivo models in follow-on experiments.
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The major contribution of this study is the identification of a novel model for compound
specific target gene identification that uses a subtractive fractionation approach. However,
the specific protein targets for these compounds remain unknown. As future work,
characterisation of the specific proteins that bind to compounds in CKI needs to be carried
out. In order for a protein to have the potential as a drug target it must be druggable, i.e.
have a conformation that favours interactions with small molecules. One approach to use
for identifying these interactions could be the use of yeast two-hybrid screening, which is
the most commonly used screening method to identify novel protein interactions, in the
presence and absence of CKI in order to characterize specific protein-protein interactions
that are perturbed by CKI. By comparing the interactions of tumor suppressors with
oncoproteins as a result of CKI treatment, we might better characterise the genetic
pathways leading to apoptosis and/or inhibition of metastasis. These interactions could be
further explored by using subtractive fractions of CKI and individual compounds to map
them to specific compounds or compound families. The yeast three-hybrid assay, where
interactions between proteins and small molecules can be detected, which was developed
based on the yeast two-hybrid method can be used to support the identification of specific
compounds of CKI and their activities for drug screening.
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Appendix A
Supplementary Tables, Data and Video
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All the supplementary tables and
data for chapters 2, 3, 4 and 5 can be obtained online: https://drive.google.
com/open?id=1I9nQy4GzcALD3flYqgFHL9lJEm1C7a5w.
1. For chapter 2, there are one supplementary Data and one supplementary Table:
a) Data 1. Calibration curve for the concentrations of known compounds in CKI and
reconstituted subtractive fractions.
b) Table 1. Summary of shared, differentially expressed (DE) genes across treatments.
Similarity percentage calculated from total number of shared DE genes from all
listed comparisons. To find the number of DE genes, CKI treatment was used as a
baseline to compare all other fractionated treatments in order to emphasize the effect
of depleted compounds and UT (untreated) was used as a base to calculate the DE
genes for CKI treatment.
2. For chapter 3, there are three supplementary Data, one supplementary table and one
supplementary video including:
a) Data 1: Significantly over-represented functional GO terms, as determined by GO
analysis of the transcriptome from CKI treated MDA-MB-231 cells. (P < 0.05).
b) Data 2: Significantly perturbed pathways, as determined by SPIA analysis of the
transcriptome from CKI treated MDA-MB-231 cells. (pG < 0.05).
c) Data 3: Matching of genes in two strongly affected pathways (‚Äúfocal adhesion‚Äù
and ‚Äúactin cytoskeleton‚Äù) against three independent gene datasets containing: (i)
a set TARGET gene and (ii) migration related genes from published articles.
d) Video: Live-cell imaging of the migration blocking effect of CKI in MDA-MB-231
cells in the wound closure migration assay. Videos show cell motility and wound
closure rate in CKI at 2 mg/ml was reduced as compared to untreated control. Images
were captured at 10-minute intervals for 20 hours.
e) Table 1: Concentrations of Matrigel and number of cells used for each cell line in
transwell invasion assay.
f) Table 2: Fourteen clinically relevant DE genes from three independent gene datasets
(see methods).
3. For chapter 4, there are six supplementary tables including:
a) Table S1: Summary of RNA-seq datasets used in this study
b) Table S2: Summary of significantly differentially expressed genes for different
comparisons
c) Table S3: Significantly perturbed KEGG pathways based on SPIA analysis
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d) Table S4: Numbers of transcripts in 53 co-expression modules
e) Table S5: Significantly over-represented GO and KEGG terms in protein-coding
genes from three CKI-5FU co-expression modules (count > 4 and P-value < 0.05)
f) Table S6: Primers used for qPCR
4. For chapter 5, there are four supplementary tables including:
a) Table S1. RT-qPCR target genes and their primer sequences.
b) Table S2. Mapping rate of each cell line.
c) Table S3. List of DE genes in each cell line at each time point.
d) Table S4. The summary of the functional analysis of both separate datasets and shared
datasets.
i. Sheet 1-4: GO enrichment of each cell line at two time points. Selection standard:
cut off p value<0.01, cut off q value<0.01.
ii. Sheet 5-8: KEGG enrichment of each cell line at two time points. Selection
standard: cut off p value<0.01, cut off q value<0.01.
iii. Sheet 10-12: GO enrichment of each cell line at two time points. Selection
standard: cut off p value<0.01, cut off q value<0.01.
iv. Sheet 13: GO enrichment of shared genes by both cell lines. Selection standard:
cut off p value<0.01.
v. Sheet 14: KEGG enrichment of shared genes by both cell lines. Selection
standard: cut off p value<0.01.
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Supplementary Figures for Chapter 2
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Sup. Fig. 1: HPLC profiles of 25 mixtures including CKI, MJ, MN, 9 (N-1), 4 (N-3), and 6 (N-2). 
Numbers represent compounds 1: Mac, 2: Ade, 3: Nme, 4: Spr, 5: Mt, 6: Spc, 7: Ospc, 8: Omt and 9: 
Tri. 50 µl of the samples at 1 mg/ml concentration was injected through the semi-preparative column 














































































































































































Sup. Fig. 2: XTT Cell viability assays of subtractive fractions in MDA-MB-231 cells at 24- and 48-
hour timepoints treated with 1 mg/ml or 2 mg/ml of CKI and 2 mg/ml equivalent concentrations of all 




































































































































































































































































































































































































































































































































































































































































































































































































































































B (whole reconstituted CKI in buffer/vehicle control), and WRCKI-H (whole reconstituted CKI in 
milliQ H2O) (B) assessment of the interaction effects of single MJ compounds by the addition to the 
MN subtractive fraction. Single major compounds were dissolved in either MilliQ H2O or Dimethyl 
sulfoxide. Effect of subtractive fractions (C) N-OmtOspcSpc, (D) N-MacAdeTri, (E) N-MtNmeSpr, 
(F) N-MtNme, (G) N-OmtSpc, (H) N-OspcSpc, (I) N-MacTri, (J) N-AdeTri, (K) N-MacAde, (L) N- 
MtSpr, (M) NmeSpr. Statistically significant results shown as p < 0.05 (*) or p < 0.01 (**) p < 0.001 




Sup. Fig. 3: XTT Cell viability assays of subtractive fractions N-OmtOspc and N-MacOmtOspc in 
MDA-MB-231 cells at 24- and 48-hour timepoints treated 4 different concentrations ranging from 0.25 
mg/ml to 2 mg/ml of CKI and equivalent concentrations of two other agents. Statistically significant 
results shown as p < 0.05 (*) or p < 0.01 (**) p < 0.001 (***), or p < 0.0001 (****); ns (not significant). 















































































Sup. Fig. 4: Representative plots of Annexin V and PI staining in (A) MDA-MB-231, (B) HEK-293, 




UT MDA-MB-231 24hr CKI (2mg/mL) MDA-MB-231 24hr
N-OmtOspc (2mg/mL) MDA-MB-231 24hr N-MacOmtOspc (2mg/mL) MDA-MB-231 24hr
OmtOspc (2mg/mL) MDA-MB-231 24hr MacOmtOspc (2mg/mL) MDA-MB-231 24hr
UT HEK-293 24hr CKI (2mg/mL) HEK-293 24hr
 N-OmtOspc (2mg/mL) HEK-293 24hr  N-MacOmtOspc (2mg/mL) HEK-293 24hr
 OmtOspc (2mg/mL) HEK-293 24hr  MacOmtOspc (2mg/mL) HEK-293 24hr
 UT HFF 24hr  CKI (2mg/mL) HFF 24hr
 N-OmtOspc (2mg/mL) HFF 24hr  N-MacOmtOspc (2mg/mL) HFF 24hr
 OmtOspc (2mg/mL) HFF 24hr  MacOmtOspc (2mg/mL) HFF 24hr
UT HEK-293 48hr CKI (2mg/mL) HEK-293 48hr
 N-OmtOspc (2mg/mL) HEK-293 48hr  N-MacOmtOspc (2mg/mL) HEK-293 48hr
 OmtOspc (2mg/mL) HEK-293 48hr  MacOmtOspc (2mg/mL) HEK-293 48hr
 UT HFF 48hr  CKI (2mg/mL) HFF 48hr
 N-OmtOspc (2mg/mL) HFF 48hr  N-MacOmtOspc (2mg/mL) HFF 48hr
 OmtOspc (2mg/mL) HFF 48hr  MacOmtOspc (2mg/mL) HFF 48hr
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Sup. Fig. 5: Multiple dimensional scaling (MDS) plot for samples based on expression profiles of all 
genes before the removal of unwanted variance (RUVs) in R package.  
 




Sup. Fig. 7: Box plot for samples based on expression profiles of all genes before the application of 
RUVs.  
 




Sup. Fig. 9: Venn diagrams showing the number of overlaping DE genes between treatments at 24-























































































































































































































































































































































































































































































































































































































Sup. Fig. 10: Identification of significantly perturbed pathways using SPIA (pG< 0.05) analysis. 
Eighty-six significantly perturbed pathways from twenty-two comparisons were found. 
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Sup. Fig. 11: DE genes from the following comparisons (CKI vs UT, CKI vs N-Mac, CKI vs N-Nme, 
CKI vs N-Omt and CKI vs N-Tri) shown in the "Cytokine-Cytokine Receptor Interaction pathway at 
48-hours. Significantly up- and down-regulated DE genes were coloured red and green respectively. 
Each coloured box was separated into five parts according to treatments in this order: CKI vs UT, CKI 
vs N-Mac, CKI vs N-Nme, CKI vs N-Omt and CKI vs N-Tri. White or grey colours represented 
gene(s) that were not significantly differentially expressed by the treatments. 
Treatments (48hrs, from left to right) : CKI vs UT, CKI vs N-Mac, CKI vs N-Nme, CKI vs N-Omt, CKI vs N-Tri 
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Sup. Fig. 12: DE genes from the following comparisons (CKI vs UT, CKI vs N-OmtOspc, CKI vs N-
MacOmtOspc, CKI vs OmtOspc and CKI vs MacOmtOspc) shown in the Cytokine-Cytokine Receptor 
Interaction pathway at 48-hours. Significantly up- and down-regulated DE genes were coloured red 
and green respectively. Each coloured box was separated into five parts according to this order: CKI 
vs UT, CKI vs N-OmtOspc, CKI vs N-MacOmtOspc, CKI vs OmtOspc and CKI vs MacOmtOspc. 
White or grey colours represented gene(s) that were not significantly differentially expressed by the 
treatments. 
Treatments (48hrs, from left to right) : CKI vs UT, CKI vs N-OmtOspc, N-MacOmtOspc, CKI vs OmtOspc, CKI vs MacOmtOspc
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Sup. Fig. 13: DE genes from the following comparisons (CKI vs UT, CKI vs N-OmtOspc, CKI vs N-
MacOmtOspc, CKI vs OmtOspc and CKI vs MacOmtOspc) shown in the Cytokine-Cytokine Receptor 
Interaction pathway at 24-hours. Significantly up- and down-regulated DE genes were coloured red 
and green respectively. Each coloured box was separated into five parts according to this order: CKI 
vs UT, CKI vs N-OmtOspc, CKI vs N-MacOmtOspc, CKI vs OmtOspc and CKI vs MacOmtOspc. 
White or grey colours represented gene(s) that were not significantly differentially expressed by the 
treatments. 
Treatments (24hrs, from left to right) : CKI vs UT, CKI vs N-OmtOspc, N-MacOmtOspc, CKI vs OmtOspc, CKI vs MacOmtOspc
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Sup. Fig. 14: DE genes from the following comparisons (CKI vs UT, CKI vs N-Mac, CKI vs N-Nme, 
CKI vs N-Omt and CKI vs N-Tri) shown in the Cell Cycle pathway at 48-hours. Significantly up- and 
down-regulated DE genes were coloured with red and green respectively. Each coloured box was 
separated into five parts according to this order: CKI vs UT, CKI vs N-Mac, CKI vs N-Nme, CKI vs 
N-Omt and CKI vs N-Tri. White or grey colours represented gene(s) that were not significantly 
differentially expressed by the treatments. 
Treatments (48hrs, from left to right) : CKI vs UT, CKI vs N-Mac, CKI vs N-Nme, CKI vs N-Omt, CKI vs N-Tri 
202
 
Sup. Fig. 15: DE genes from the following comparisons (CKI vs UT, CKI vs N-OmtOspc, CKI vs N-
MacOmtOspc, CKI vs OmtOspc and CKI vs MacOmtOspc) shown in the Cell Cycle pathway at 48-
hour treatments. Significantly up- and down-regulated DE genes were coloured red and green 
respectively. Each coloured box was separated into five parts according to this order: CKI vs UT, CKI 
vs N-OmtOspc, CKI vs N-MacOmtOspc, CKI vs OmtOspc and CKI vs MacOmtOspc. White or grey 
colours represented gene(s) that were not significantly differentially expressed by the treatments. 
Treatments (48hrs, from left to right) : CKI vs UT, CKI vs N-OmtOspc, N-MacOmtOspc, CKI vs OmtOspc, CKI vs MacOmtOspc
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Sup. Fig. 16: DE genes from the following comparisons (CKI vs UT, CKI vs N-OmtOspc, CKI vs N-
MacOmtOspc, CKI vs OmtOspc and CKI vs MacOmtOspc) shown in the Cell Cycle pathway at 24-
hours. Significantly up- and down-regulated DE genes were coloured red and green respectively. Each 
coloured box was separated into five parts according to this order: CKI vs UT, CKI vs N-OmtOspc, 
CKI vs N-MacOmtOspc, CKI vs OmtOspc and CKI vs MacOmtOspc. White or grey colours 
represented gene(s) that were not significantly differentially expressed by the treatments. 
Treatments (24hrs, from left to right) : CKI vs UT, CKI vs N-OmtOspc, N-MacOmtOspc, CKI vs OmtOspc, CKI vs MacOmtOspc
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Sup. Fig. 17: Differential gene expression profiles of all treatments for TGF-ß signalling pathway: the 
left panel shows comparison of subtractive fraction treated cells against CKI treatment and the right 
panel shows comparison of single compound subtractive fraction treated cells against the treatments 
for two and three compound subtractive fractions.  
























































































































































































































































































































































































Sup. Fig. 18: DE genes from the following comparisons (CKI vs UT, CKI vs N-Mac, CKI vs N-Nme, 
CKI vs N-Omt and CKI vs N-Tri) shown in the TGF-ß signalling pathway at 48-hours. Significantly 
up- and down-regulated DE genes were coloured red and green respectively. Each coloured box was 
separated into five parts according to this order: CKI vs UT, CKI vs N-Mac, CKI vs N-Nme, CKI vs 
N-Omt and CKI vs N-Tri. White or grey colours represented gene(s) that were not significantly 
differentially expressed by the treatments. 
Treatments (48hrs, from left to right) : CKI vs UT, CKI vs N-Mac, CKI vs N-Nme, CKI vs N-Omt, CKI vs N-Tri 
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Sup. Fig. 19: DE genes from the following comparisons (CKI vs UT, CKI vs N-OmtOspc, CKI vs N-
MacOmtOspc, CKI vs OmtOspc and CKI vs MacOmtOspc) shown in the TGF-ß signalling pathway 
at 48-hour treatments. Significantly up- and down-regulated DE genes were coloured red and green 
respectively. Each coloured box was separated into five parts according to this order: CKI vs UT, CKI 
vs N-OmtOspc, CKI vs N-MacOmtOspc, CKI vs OmtOspc and CKI vs MacOmtOspc. White or grey 
colours represented gene(s) that were not significantly differentially expressed by the treatments. 
Treatments (48hrs, from left to right) : CKI vs UT, CKI vs N-OmtOspc, N-MacOmtOspc, CKI vs OmtOspc, CKI vs MacOmtOspc
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Sup. Fig. 20: DE genes from the following comparisons (CKI vs UT, CKI vs N-OmtOspc, CKI vs N-
MacOmtOspc, CKI vs OmtOspc and CKI vs MacOmtOspc) shown in the TGF-ß signalling pathway 
at 24-hours. Significantly up- and down-regulated DE genes were coloured red and green respectively. 
Each coloured box was separated into five parts according to this order: CKI vs UT, CKI vs N-
OmtOspc, CKI vs N-MacOmtOspc, CKI vs OmtOspc and CKI vs MacOmtOspc. White or grey 






Treatments (24hrs, from left to right) : CKI vs UT, CKI vs N-OmtOspc, N-MacOmtOspc, CKI vs OmtOspc, CKI vs MacOmtOspc
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Sup Table 1: Summary of shared, differentially expressed (DE) genes across treatments. Similarity 
(%) calculated from total number of shared DE genes from all listed comparisons. To find the number 
of DE genes, CKI treatment was used as a baseline to compare all other fractionated treatments in 
order to emphasize the effect of depleted compounds and UT (untreated) was used as a base to calculate 
the DE genes for CKI treatment. 
 
Sup Data 1: Calibration curve for the concentrations of known compounds in CKI and reconstituted 




Supplementary Figures for Chapter 3
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Additional file 1: FigureS1: (a) Total ion chromatogram (TIC) for CKI in 1 in 100 dilution 
from 25 mg/ml of stock concentration. Single peaks were extracted based on the molecular 
mass. (b) cytisine (spike in control), (c) macrozamin, (d) adenine, (e) n-methylcytisine, (f) 
sophoridine and matrine (similar molecular mass with different retention time) (g) 
oxysophocarpine, (h) oxymatrine, (i) sophocarpine and (j) trifolirhizin. 
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Additional file 2: FigureS2: (a) Total ion chromatogram (TIC) for MJ in 1 in 100 dilution 
from 25 mg/ml of stock concentration. Single peaks were extracted based on the molecular 
mass. (b) adenine, (c) cytisine (spike in control), (d) macrozamin, (e) n-methylcytisine, (f) 
sophoridine and matrine (similar molecular mass with different retention time) (g) 
oxysophocarpine, (h) oxymatrine, (i) sophocarpine and (j) trifolirhizin. 
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Additional file 3: FigureS3: Combinatorial analysis of the effects of MN with each of the nine 
major individual compounds, analyzed in eight cell lines with wound closure assays. Data were 
normalized to results with 0.5 mg/ml minor (MN) alone. Significantly increased or decreased 
percent block of migration resulting from the addition of major compounds is shown as p < 
0.05 (*), p < 0.01 (**), p < 0.001 (***) and not significant (ns). Data are mean ± SD. 
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Additional file 4: FigureS4: Functional classification of genes by GO over-representation 
analyses. Over-represented GO terms (Biological Process, BP=3) for differentially expressed 
(DE) genes were identified from MDA-MB-231 cells treated by CKI. Upregulated and 
downregulated genes contained in each term were shown in red and green respectively. GO 
terms shown above the blue line were significant terms related to migration.  
 
Additional file 5: VideoS1: Live-cell imaging of the migration blocking effect of CKI in 
MDA-MB-231 cells in the wound closure migration assay. Videos show cell motility and 
wound closure rate in CKI at 2 mg/ml was reduced as compared to untreated control. Images 
were captured at 10-minute intervals for 20 hours.   
 
Additional file 6: DataS1: Significantly over-represented functional GO terms, as determined 
by GO analysis of the transcriptome from CKI treated MDA-MB-231 cells. (P < 0.05).  
 
Additional file 7: DataS2: Significantly perturbed pathways, as determined by SPIA analysis 
of the transcriptome from CKI treated MDA-MB-231 cells.  (pG < 0.05).  
 
Additional file 8: DataS3: Matching of genes in two strongly affected pathways (“focal 
adhesion” and “actin cytoskeleton”) against three independent gene datasets containing: (i) a 
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set TARGET gene and (ii) migration related genes from published articles. 14 core DE genes 
from three datasets including CTNNB1, CDH1, AKT1, AKT2, AKT3, CCND1, MAPK1, JAK2, 
APC, CDK4, RB1, PIK3CA, and PTEN, are known to have effects on cell migration.  
 
Additional file 9: TableS1: Concentrations of Matrigel and number of cells used for each cell 
line in transwell invasion assay.  
 
Additional file 10: TableS2: Fourteen clinically relevant DE genes from three independent 
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Identification of candidate anti-cancer molecular mechanisms of 
compound kushen injection using functional genomics
SUPPLEMENTARY FIGURES AND TABLES
Supplementary Figure 1: CKI inhibited MCF-7 cell growth in a dose-dependent fashion and increased caspase-3/7 
activity. A. The level of viability of cells after different treatments were measured using XTT:PMS. Data are represented as mean ±SEM 
(n=9). X-axis is log2 scaled. B. The level of caspase-3/7 activity in cells was measured with Caspase-3/7 Colorimetric Assay Kit. Data are 
represented as mean ±SEM (n=3). Statistical analyses were performed using two-way ANOVA (**p<0.01, ***p<0.001).
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Supplementary Figure 2: Multiple dimensional scaling (MDS) plot for samples based on expression profiles of all 
genes.
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Supplementary Figure 3: Venn diagrams showing the overlap of DE genes in cells treated with CKI (2 mg/mL) or 5-FU 
for A. 24 hours or B. 48 hours.
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www.impactjournals.com/oncotarget/  Oncotarget, Supplementary Materials 2016
Supplementary Figure 4: Normalised expression values of the top10 significantly differentially expressed genes in cells 
treated with CKI (2 mg/mL) or 5-FU for 24 hours A. and B. or 48 hours C. and D.
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Supplementary Figure 5: Effect of CKI on cell cycle and apoptosis in MCF-7 cells. Proportions of cells in either apoptosis, G1, 
S or G2/M phase were determined by measuring the DNA contents of permeabilised cells stained with Propidium Iodide. A. Percentages 
of cells in each cell cycle phase. B. Representative histograms of PI staining with gating designation. Data are represented as mean ±SEM 
(n=9). Statistical analyses were performed using t-test comparing with “Untreated” (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).
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Supplementary Figure 6: Flowchart of de novo identification of lncRNAs from RNA-seq dataset. Digits in red colour 
represent the numbers of transcripts after corresponding data processing.
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Supplementary Figure 7: Clustering dendrogram of genes, with dissimilarity based on topological overlap, together 
with co-expression module colors. Merged dynamic modules (lower color band) mean highly co-expressed modules are merged based 
on eigengene correlations in original clustered modules (upper color band).
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Supplementary Figure 8: Expression patterns of transcripts in CKI-specific modules “indianred2” and 
“mediumpurple2” are shown in the top panels A. and C. and the barplot in the bottom panels (A and C) shows the eigengene 
values for different samples. Green represents “under-expressed” and red represents “over-expressed” in the heatmap. The “eigengene 
value” is defined as the first principal component of this module, so it can be considered as representative of the gene expression profiles in 
this module. Visualization of CKI-specific modules “indianred2” and “mediumpurple2” B. and D. The black labels represent refGenes and 
gold labels represent lncRNAs. The size of the node/label and edge weight is proportional to betweenness centrality.
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Supplementary Figure 9, Representative CKI-5FU co-expression modules. Expression patterns of transcripts in CKI-5FU 
modules A. “green3”, B. “indianred4” and C. “magenta2” are shown in the top panels, and the barplot in the bottom panels show the 
eigengene values in different samples. Green represents “under-expressed” and red represents “over-expressed” in the heatmap. The 
“eigengene value” is defined as the first principal component of this module, so it can be considered as representative of the gene expression 
profiles in this module.
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Supplementary Table 1: Summary of RNA-seq datasets used in this study
See Supplementary File 1
Supplementary Table 2: Summary of significantly differentially expressed genes for different comparisons
See Supplementary File 2
Supplementary Table 3: Significantly perturbed KEGG pathways based on SPIA analysis
See Supplementary File 3
Supplementary Table S4: Numbers of transcripts in 53 co-expression modules
See Supplementary File 4
Supplementary Table 5: Significantly over-represented GO and KEGG terms in protein-coding genes from three 
CKI-5FU co-expression modules (count > 4 and P-value < 0.05)
See Supplementary File 5
Supplementary Table 6: Primers used for qPCR
See Supplementary File 6
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Supplementary Material:
Cell Cycle, Energy Metabolism and DNA Repair
Pathways in Cancer Cells are Suppressed by
Compound Kushen Injection
Jian Cui, Zhipeng Qu, Yuka Harata-Lee, Thazin Nwe Aung, Hanyuan Shen and David L Adelson
The University of Adelaide, School of Biological Sciences, Dept of Molecular and Biomedical Sciences
1 SUPPLEMENTARY DATA
1.1 Methods
XTT assay: The wells of 96-well tray were seeded with 4×103 cells per well for HEPG2 cells and
8×104 cells per well for MDA-MB-231 cells in 50 µL of medium and cultured overnight. On the following
day, 50 µL of either medium, CKI or 5-FU were added to the cells. Viability of the cells was measured at 0,
24 and 48 hours after the treatment by adding XTT:PMS (50:1; Sigma-Aldrich). After 4-hour incubation at
37C optical density (OD) of each well was read at 490nm. The background OD was also measured and the
average was subtracted from the OD readings of appropriate wells.
1.2 Figures
Figure S1. XTT assay result of HEPG2 and MDA-MB-231 cell lines. The XTT assay measures levels
of NADH and NADPH by producing a formazan dye product that can be detected at 490nm. A. XTT assay
result for HEPG2 cells. The assay was carried out at three time points: 0, 24, and 48 hours. 5 treatment
groups were used and compared, 150 µg/ml 5-FU as a positive control for a cytotoxic agent, 1 mg/ml and
2 mg/ml CKI as well as the corresponding concentration of vehicle control (VC). CKI has a clear effect on
the amount of formazan dye produced indicating a significant and marked suppression in the production
of NADH and NADPH. B. XTT result of MDA-MB-231 cells. This test is with a low concentration of
5-FU (20 µg/ml). CKI has a clear and marked effect on the level of formazan dye produced indicating a
significant and marked suppression in the production of NADH and NADPH. Statistical analyses were
performed using two-way ANOVA comparing with untreated (****p<0.0001); bars show 1 standard
deviation from the mean.
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Figure S2. Cell apoptosis assay. A. Cell apoptosis in HEPG2 cells treated with CKI. The assay was
carried out at 5 time points to detect apoptosis levels between untreated and 2 mg/ml CKI treated groups.
From 3 to 12 hours, both groups maintained a baseline level of apoptosis. After 24 hour, apoptosis of CKI
treated cells increased, with the difference attaining statistical significance at 48 hours. B. Cell apoptosis in
MDA-MB-231 cells treated with CKI. From 3 to 24 hours, both groups show similar, if noisy results. By 48
hours apoptosis has increased and was statistically significantly different to the control. C. Cell apoptosis
in HEPG2 cells treated with oxymatrine. We compare apoptosis levels between an untreated group and a
group treated with 0.5 mg/ml oxymatrine. From 3 to 24 hours we observed a baseline level of apoptosis.
By 48 hours apoptosis in the oxymatrine treated group is significantly greater than in the control group.
Statistical analyses were performed using two-way ANOVA comparing with untreated (****p<0.0001);
bars show 1 standard deviation from the mean.
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